TW546295B - Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists - Google Patents
Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists Download PDFInfo
- Publication number
- TW546295B TW546295B TW087114595A TW87114595A TW546295B TW 546295 B TW546295 B TW 546295B TW 087114595 A TW087114595 A TW 087114595A TW 87114595 A TW87114595 A TW 87114595A TW 546295 B TW546295 B TW 546295B
- Authority
- TW
- Taiwan
- Prior art keywords
- ffi
- alkyl
- phenyl
- group
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
546295 A7 _________— B7 五、發明説明(,) 本發明係關於新穎的瘦酸衍生物,其製備及其用途。 (誚先閱讀背面之·注意事嗔再填寫本頁) 内皮考是由22種胺基酸所組成的肽,其由血管内皮合成 釋放出來的。内皮素共有三種異構物,分別爲Επ,et_2 及ET-3,本專利説明書所指的,’内皮素,,或” ET,,係指其中一 種内皮素兴構物或是所有的内皮素異構物。内皮素具有血 管收縮的能力,對於血管張力有強烈的影響。咸已知此血 管收縮能力是因内皮素鍵結至其受體後所造成的(自然, 112_(1988) 41 1_415 ; FEBS文獻,211 (1988) 440-444及生物 化學與生物物理研究文獻.,(1988) 868-875)。 增加内皮素的釋放量或是内皮素不正常的釋放量會造成 週邊血管,腎血管及腦血管持續的血管收縮。文獻中曾報 告指出内皮素與一些疾病有關,這些疾病包括高血壓,急 性心肌梗塞,肺高血壓,雷諾氏疾病,腦血管痙攣,中 風,良性前列腺肥大,動脈硬化症及氣喘(血管醫學生物 雜誌Z (1990) 207,美國醫學協會雜誌2M (0990) 2868,自 然 Ml (1990) 1 14,N_ eg··醫學雜誌 HI (1 989) 205, N. eg.. 醫學雜誌12! (1993) 1732, Nephron 赵(1994) 373,中風ϋ546295 A7 _________— B7 V. Description of the Invention (,) The present invention relates to novel leptin derivatives, their preparation and uses. (诮 Read the notes on the back of the page before filling in this page) Endothelial test is a peptide composed of 22 kinds of amino acids, which are released by vascular endothelial synthesis. Endothelin has three kinds of isomers, namely Eπ, et_2 and ET-3. The term “endothelin,” or “ET,” as used in this patent specification refers to one of the endothelin constructs or all of the endothelium. Isomers of endothelin. Endothelin has the ability of vasoconstriction, which has a strong effect on vascular tone. It is known that this vasoconstriction ability is caused by endothelin binding to its receptor (Nature, 112_ (1988) 41 1_415; FEBS literature, 211 (1988) 440-444 and biochemical and biophysical research literature, (1988) 868-875). Increasing the release of endothelin or abnormal release of endothelin will cause peripheral blood vessels, Continuous vasoconstriction of renal and cerebral blood vessels. Endothelin has been reported in the literature to be associated with a number of diseases, including hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's disease, cerebral vasospasm, stroke, benign prostatic hypertrophy, Arteriosclerosis and Asthma (Journal of Biology of Vascular Medicine Z (1990) 207, Journal of the American Medical Association 2M (0990) 2868, Natural Ml (1990) 1 14, N_ eg · Medical Journal HI (1 989) 205, N. eg : Medical Academic Journal 12! (1993) 1732, Nephron Zhao (1994) 373, Stroke
(1994) 904,自然(1993) 759,分子心肌細胞雜誌H (1995) A234 ;癌症研究丛(1996) 663)。 現今文獻中發現至少具有兩種亞型的内皮素受體,分別 爲ETA及ETB受體(自然(1990) 730及732)。根據此一敘 述,能抑制内皮素鍵結至此兩種受體上的物質應該可以拮 抗内皮素在生理上的效應,因此這些物質是具有價値的藥 劑。 -4- 本紙張尺度適州中國國家標緙1 CNS ) Λ4規梅(210X 297公釐) 546295 A7 B7 五、發明説明( ^而’ WO 9 6/U914揭示對ETa受體有高親和力键結的瘦 鉍何生物對ETB受體的親和力相當的低(此稱爲ETf專一性 插抗劑)。(1994) 904, Nature (1993) 759, Journal of Molecular Cardiomyocytes H (1995) A234; Cancer Research Series (1996) 663). There are at least two subtypes of endothelin receptors found in the literature today, namely ETA and ETB receptors (Nature (1990) 730 and 732). According to this description, substances that can inhibit endothelin binding to these two receptors should be able to antagonize the physiological effects of endothelin, so these substances are valuable drugs. -4- The size of this paper is China National Standard 适 1 CNS) Λ4 gauge plum (210X 297 mm) 546295 A7 B7 V. Description of the invention (^ and 'WO 9 6 / U914 reveals high affinity binding to ETa receptors The bioavailability of slender bismuth to the ETB receptor is quite low (this is called ETf specific insertion resistance).
^專利况明書中所指的eTa.專―性括抗劑係指其對A 文的親和力至少高於對ΕΤΒ受體的親和力i 〇倍以上。 本發明主旨是提供内皮素受體拮抗劑,其對A及EL受 體的鍵結親和力概略相同(稱之爲混合拮抗刊)。 對受體的親和力概略相同意指親和力的;例大於〇ι小於 10° 本發明係關於㈣衍生物,爲式⑴或式晴酸衍生物: (誚先閲讀背面之注意事务再填寫本頁) 喷. R4 R6__ 2 _q—CH. B R I R5 〇·^ The eTa. Specific-specific antagonist in the patent statement means that its affinity for A-text is at least higher than its affinity for ETB receptor by more than 0 times. The main purpose of the present invention is to provide an endothelin receptor antagonist, which has roughly the same binding affinity for A and EL receptors (referred to as a mixed antagonist). The affinity for the receptor is roughly the same meaning the affinity; for example, greater than 〇ι and less than 10 °. The present invention is about a hydrazone derivative, which is a formula ⑴ or a formula acid derivative: (诮 Please read the attention on the back before filling this page) Spray. R4 R6__ 2 _q—CH. BRI R5 〇 ·
Het 其中取代基的意義如下: R是四唑[sic]或 R1 是 OR7 其中R7是 氫,驗金屬陽離子,驗土金屬陽離子或生程學上可 機銨離子; 〇 •C—R1 訂 ·丨 烷基 C3-C8 -環 基,(^-匕- 5- Λ4規格(210X 297公釐) 本紙張尺度適用中國國家標嘩(rNs ) 546295 A7 B7 1、發明説明(3 ) 未經取代或經取代之CH2-苯基, ---------- (請先閱讀背面之注意事货再填寫本頁) 未每取代或經取代之C3 - C6 -晞基或c 3 - c 6 -块基,或 未經取代或經取代之苯基, R2 是氫,# 基,NH2,NHCCVCV燒基),n(Ci-c4_、虎基, 鹵素,CVC4-烷基,c2-c4·烯基,c2_c4_炔基,Ci-C4^ 素烷基,CVC4-烷氧基,cvc4-自素烷氧基,或Cl-c4-烷基硫,或CR2與CR1G(定義如下)聯結成5 _或6 _員環, 或,假若Het是5 _員環,CR2可與CR3聯結成未經取代或 經取代之5 -或6 -貝婦基或環綿·基環; X是氮或次甲基; γ是氮或次甲基; w是氮或CR1G,其中R1G是氫或Cn-烷基,或CR10與CR2或 CR3共同形成未經取代或經取代之5 -或6 -員晞基或環烯 基環,其中每個情形中的一個或多個亞甲基可被氧, 硫,-NH或-NCCVCV烷基)取代; »丨 R3 是氫,羥基,NH2,NHCCVCf 烷基),烷基)2, 鹵素,(^-(34-烷基,C2-C4-烯基,C2-C4-炔基,鹵 素烷基,CVC4-烷氧基,Ci-CV鹵素烷氧基,CVCV烷 基硫;或CR3與前定義的CR1G聯結成5-或6 -員環; R4及R5(可相同或不相同)是: 未經取代或經取代之苯基或蓁基,或 鄰位上直接聯結亞甲基,伸乙基,或ethenylene,氧或 硫或S02,NH或N-烷基之苯基或莕基; 未經取代或經取代之C3-C8-環烷基; -6- 本紙張尺度述州中國國家標缚((、NS ) Λ4規格(210 X 297公釐) ' — °^295 五、發明説明(4 ) —--- --------着农— (讀先閱讀背面之注意事赞再填寫本頁) Μ是氫’ Cl_c8H C3_c㈣基或c3_c8_块基,這每個 基團可能經—個或多個下列基圏取代:南素,經基, 親基,竣基,硝基,胺基,氰基,cvc4-垸氧基,C3-C6-晞氧基,c3_c6-炔氧基,Ci_C4i基硫,Ci_C4峭素 烷氧基,cvcv燒基羰基,Ci_C4-燒氧基窥基,CA-烷基班幾基燒基,NH(Cl々燒基),n(Ci_c4_燒基)2,C3_ cs %烷基含有一致二個氮原子及/或一個硫元子或氧 原子的5或6貝之雜方香氧基或雜芳香基,芳香基上依 次被一個或多個(如一至三個)南素或羥基,巯基,羧 基’确基,氰基,CA-燒基,Cl_C4__素烷基,Ci_ c4-烷氧基,Cl_c4_ ή素烷氧基,胺基,NH(C「C4_烷 基)’ Nd-CV烷基)2,或Ci_c4_烷基硫取代之苯氧基或 苯基; 可經一個或多個下列的基團取代之苯基或莕基:鹵 素’硝基’氰基,羥基,胺基,Cl_c4_烷基,Ci_c4^ 素淀基,cvcv烷氧基,Cl_c4_鹵素烷氧基,苯氧基, CVCVfe基硫,Cl_c4-烷基胺基,Cl_c4_二烷基胺基, 二氧亞甲基或二氧伸乙基; 含有一至二個氮原子及/或一個硫或氧原子的5 _或6 -員 雜芳香系統,其可攜帶一至四個鹵素原子及/或一至二 個下列的基團:Cl_C4_烷基,Cl-C4- ή素烷基,Ci-CV 坑氧基’ CpCU- _素燒氧基,CVC4-燒基硫,苯基,苯 氧基或苯基羰基,苯基上可依次攜帶一至五個I[素原 子及/或1至3個下列基團:CrCV烷基,d-Cr鹵素燒Het The meaning of the substituents is as follows: R is tetrazol [sic] or R1 is OR7 where R7 is hydrogen, metal cation test, earth metal cation test, or biochemically organic ammonium ion; 〇 • C—R1 Order · 丨Alkyl C3-C8-cyclic group, (^ -dagger- 5- Λ4 size (210X 297 mm) This paper size applies to Chinese national standard (rNs) 546295 A7 B7 1. Description of the invention (3) Substituted CH2-phenyl, ---------- (Please read the note on the back before filling this page) Not every substituted or substituted C3-C6 -fluorenyl or c 3-c 6 -Block group, or unsubstituted or substituted phenyl, R2 is hydrogen, # group, NH2, NHCCVCV alkyl), n (Ci-c4_, tigeryl, halogen, CVC4-alkyl, c2-c4 · ene Group, c2_c4_alkynyl, Ci-C4 ^ alkyl, CVC4-alkoxy, cvc4-self-alkoxy, or Cl-c4-alkylsulfur, or CR2 and CR1G (defined below) are combined to form 5 _ Or 6 _member ring, or, if Het is 5 _member ring, CR2 can be combined with CR3 to form an unsubstituted or substituted 5-or 6 -befyl or ring cotton ring; X is nitrogen or methine Γ is nitrogen or methine; w is nitrogen or CR1G, where R1G is Or Cn-alkyl, or CR10 and CR2 or CR3 together to form an unsubstituted or substituted 5- or 6-membered fluorenyl or cycloalkenyl ring in which one or more methylene groups in each case can be replaced by Oxygen, sulfur, -NH or -NCCVCV alkyl) substitution; »丨 R3 is hydrogen, hydroxyl, NH2, NHCCVCf alkyl), alkyl) 2, halogen, (^-(34-alkyl, C2-C4-ene Group, C2-C4-alkynyl, haloalkyl, CVC4-alkoxy, Ci-CV haloalkoxy, CVCV alkylsulfide; or CR3 and CR1G previously defined to form a 5- or 6-membered ring; R4 And R5 (which may be the same or different) are: unsubstituted or substituted phenyl or fluorenyl, or directly linked to methylene, ethylene, or ethenylene, oxygen or sulfur, or S02, NH, or N -Phenyl or fluorenyl group of alkyl group; Unsubstituted or substituted C3-C8-cycloalkyl group; -6- Size of this paper states China National Standard ((, NS) Λ4 size (210 X 297 mm) ) — ° ^ 295 V. Description of the invention (4) —--- -------- Zong Nong— (Read the notes on the back and read the praise page before filling out this page) Μ is hydrogen 'Cl_c8H C3_c ㈣ group or c3_c8_ block group, each group may be Substituted by sulfonium: Southernin, via group, parent group, end group, nitro group, amine group, cyano group, cvc4-fluorenyloxy group, C3-C6-fluorenyloxy group, c3_c6-alkynyloxy group, Ci_C4i group sulfur group, Ci_C4 Ankylosyl alkoxy, cvcv alkoxycarbonyl, Ci_C4- alkoxycarbonyl, CA-alkylbankiyl, NH (Cl々alkyl), n (Ci_c4_alkyl) 2, C3_cs% alkane A 5 or 6 shell aromatic aryloxy or heteroaryl group containing two nitrogen atoms and / or one sulfur atom or oxygen atom, one or more (such as one to three) nans Or hydroxyl, mercapto, carboxyl ', cyano, CA-alkyl, Cl_C4__alkyl, Ci_c4-alkoxy, Cl_c4_valentin alkoxy, amine, NH (C "C4_alkyl" 'Nd-CV alkyl) 2, or Ci_c4-alkylthio substituted phenoxy or phenyl groups; phenyl or fluorenyl groups which may be substituted with one or more of the following groups: halogen' nitro 'cyano, Hydroxyl, amine, Cl_c4_alkyl, Ci_c4 ^ sulfonyl, cvcv alkoxy, Cl_c4_haloalkoxy, phenoxy, CVCVfe sulfide, Cl_c4-alkylamino, Cl_c4_dialkylamino , Dioxymethylene or dioxyethylene; containing one A 5- or 6-membered heteroaromatic system with two nitrogen atoms and / or one sulfur or oxygen atom, which can carry one to four halogen atoms and / or one to two of the following groups: Cl_C4_alkyl, Cl-C4 -valentin alkyl, Ci-CV pitoxy 'CpCU- _sulfinyloxy, CVC4-sulfanylsulfur, phenyl, phenoxy or phenylcarbonyl, phenyl can carry one to five I [素Atoms and / or 1 to 3 of the following groups: CrCV alkyl, d-Cr halogen
耒紙張尺度適用中國) ( 21 ox 297^tT 546295 A7 ________B7 五、發明説明(5 ) — 基,CVC4·统氧基’ C!-(V鹵素烷氧基及/或Ci_C4_烷基 硫; 可經下列的基團取代一次或多次的C3_C8_環烷基:鹵 素,羥基,毓,羧基,硝基,氰基,Ci_C4_烷基,c2_ C4-烯基,C2-C4-炔基,氧基,Ci_Czr烷氧基, Ci-C4-乾基石見’ Ci-Czp鹵素燒氧基; Z 是硫或氧; B sc2-c4-烯基耒 The paper size is applicable to China) (21 ox 297 ^ tT 546295 A7 ________B7 V. Description of the invention (5) — radical, CVC4 · unoxy 'C!-(Vhaloalkoxy and / or Ci_C4_ alkyl sulfur; can C3_C8_cycloalkyl substituted one or more times by the following groups: halogen, hydroxy, cyano, carboxy, nitro, cyano, Ci_C4_alkyl, c2_C4-alkenyl, C2-C4-alkynyl, oxygen Group, Ci_Czr alkoxy group, Ci-C4- dry base stone see 'Ci-Czp halooxy group; Z is sulfur or oxygen; B sc2-c4-alkenyl
Het是式(la)或(lb)的雜環基團,其中丁=〇,s,nr8 --------着衣-- (讀先閱讀背面之注意事境再填寫本頁)Het is a heterocyclic group of the formula (la) or (lb), where d = 0, s, nr8 -------- clothing-(read the cautionary matter on the back before filling in this page)
R3 訂 R 疋 Ci-Ce-fe 基 # 及醫藥學上可耐受鹽類與鏡像異構物學上的純物質。 關於此説明書及後文所用的名詞定義如下: 鹼金屬是,例如,鋰,鈉,鉀;鹼土金屬是,例如, #5,鍰,鋇;R3 has R 疋 Ci-Ce-fe group # and is pharmacologically tolerant to salts and mirror image isomers. The terms used in this description and the following are defined as follows: Alkali metals are, for example, lithium, sodium, and potassium; Alkaline earth metals are, for example, # 5, thorium, barium;
Cs-Cs-環烷基是,例如,環丙基,環丁基,環戊基,環 己基,環庚基或環辛基; 、Cs-Cs-cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
Ci Cf鹵素^元基可爲直鍵或具支鍵,諸如氟曱基,二氟 甲基’三氟甲基,氯二氟甲基,二氯氟甲基,三氯甲基, -8- 本紙張尺度14心_家料((TNS ) ^^7210 X 297公ΪΊ --- 546295 ΑΊ Β7 五、發明説明( 1 ·氟乙基’孓氟乙基,2,2-二氟乙基,2,2,2-三氟乙基, ---------- (請先閱讀背面之注意事壻再填寫本頁) 2、氯-2士 一氟乙基,2,2-二氯·2_氟甲基,2,2,2-三氯乙基 或五氟乙基; 匕々函素烷氧基可爲直鏈或具支鏈,諸如二氟曱氧 基’三氟曱氧基’氯二氟曱氧基,r氟甲氧基,2,2_二氟 乙氧基’ U’2’2-四氟乙氧基’,2,2,2_三氟乙氧基,2_氣_ 1,1,2-三氟乙氧基,2_氟乙氧基或五氟乙氧基; q-C4-烷基可爲直鏈或具支鏈,諸如曱基,乙基,丨_丙 基,2-丙基,2-曱基_2_丙基,2_曱基]•丙基,卜丁基或 2- 丁基; c2-c4-稀基可爲直鏈或具支鏈,諸如乙稀,卜丙缔_3_ 基,1-丙烯-2-基,1-丙晞基,2_甲基小丙烯基,^丁 晞基或2 _ 丁綿基; G-C4-炔基可爲直鏈或具支鏈,諸如乙炔基,丨_丙炔-^ 基,1-丙炔-3-基,1-丁決_4_基或2•丁炔_心基; #- 烷氧基可爲直鏈或具支鏈,諸如甲氧基,乙氧 基,丙氧基,i-甲基乙氧基,丁氧基,^甲基丙氧基,2_ 甲基丙氧基或1,1-二甲基乙氧基; C3_C0-烯氧基可爲直鏈或具支鏈,諸如烯丙氧基,2_丁 晞-1-基氧基或3-丁烯-2-基氧基; CVCV块氧基可爲直鏈或具支鏈,諸如2_丙炔小基氧 基,2-丁炔-1-基氧基或3-丁炔基氧基;、 C〗_C4-燒基硫可爲直鏈或具支鏈,諸如甲基硫,乙基 硫,丙基硫,1-甲基乙基硫,丁基硫,丨_甲基丙基硫,2_ 9 - 本紙张尺度適用中國國家標蜂.(ΓΝ$ ) Λ4規格(210X 297公釐) 546295 A7 _______B7 五、發明説明(7 ) 甲基丙基硫或1,1 -二甲基乙基硫; C ! - C 4 - 基疑基可爲直鏈或具支鏈,諸如乙醯基,乙基 羰基或2 -丙基藏基; C ! - C4 - 乳基談基可爲直鍵或具支鍵,諸如甲氧基幾 基’乙氧基複基’正-丙氧基裂基,異-丙氧基羰基或正_ 丁氧基羰基; 基疑基基可爲直鍵或具支鏈,諸如2_氧_1_丙 基,3-氧-1-丁基或3-氧-2-丁基;Ci Cf halogen radicals may be straight or branched, such as fluorofluorenyl, difluoromethyl'trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, -8- This paper is 14 hearts _ house materials ((TNS) ^^ 7210 X 297 male ΪΊ --- 546295 ΑΊ Β7) 5. Description of the invention (1. Fluoroethyl 'fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, ---------- (Please read the cautions on the back before filling this page) 2. Chloro-2 ± monofluoroethyl, 2,2- Dichloro · 2-fluoromethyl, 2,2,2-trichloroethyl or pentafluoroethyl; dagger functional alkoxy may be straight or branched, such as difluorofluorenyloxy'trifluoro Ethyloxy'chlorodifluoroamyloxy, rfluoromethoxy, 2,2-difluoroethoxy 'U'2'2-tetrafluoroethoxy', 2,2,2_trifluoroethoxy Group, 2_gas_1,1,2-trifluoroethoxy, 2-fluoroethoxy or pentafluoroethoxy; q-C4-alkyl may be straight or branched, such as fluorenyl, Ethyl, __propyl, 2-propyl, 2-fluorenyl_2_propyl, 2-fluorenyl] • propyl, butyl or 2-butyl; c2-c4-diluted may be straight-chain or Branched, such as ethylene, bupropion_3_, 1-propen-2-yl, 1-propene Fluorenyl, 2-methacryl, butyl butynyl or 2-butynyl; G-C4-alkynyl may be straight or branched, such as ethynyl, _propynyl- ^ yl, 1-propynyl- 3-yl, 1-butdecyl_4_yl or 2 • butyne_cardiyl; # -alkoxy may be straight or branched, such as methoxy, ethoxy, propoxy, i- Methylethoxy, butoxy, ^ methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy; C3_C0-alkenyloxy can be straight or branched, such as Allyloxy, 2-buten-1-yloxy or 3-buten-2-yloxy; CVCV block oxygen can be straight or branched, such as 2-propynyl small oxy, 2-butyn-1-yloxy or 3-butynyloxy ;, C〗 -C4-alkylthio may be straight or branched, such as methylsulfide, ethylsulfide, propylsulfide, 1 -Methyl ethyl sulfide, butyl sulfide, 丨 _ methyl propyl sulfide, 2_ 9-This paper size applies to the Chinese national standard bee. (ΓΝ $) Λ4 size (210X 297 mm) 546295 A7 _______B7 V. Description of the invention (7) Methylpropylsulfide or 1,1-dimethylethylsulfide; C! -C4- group may be linear or branched, such as ethylamyl, ethylcarbonyl Or C-C4-lactyl may be straight or branched, such as methoxyisopropyl'ethoxy complex, n-propoxy cleaved, iso- Propoxycarbonyl or n-butoxycarbonyl; the radical may be straight or branched, such as 2-oxo_1-propyl, 3-oxo-1-butyl or 3-oxo-2- Butyl
Ci-cvfe基可爲直鏈或具支鏈,諸如燒基,戊基, 己基,庚基,或辛基; 鹵素是,例如,氟,氯,溴,破。 除此之外,本發明亦關於可釋放出式⑴化合物的化合物 (稱之爲前藥)。 較佳的前藥是其在某種條件下釋放出而廣泛的存於身體 的某些部位(諸如胃,腸,血流,肝)的前藥。 這些化合物及製備這些化合物的中間物質(諸如式π,ΙΠ 及IV化合物)具有一個或多個不對稱的取代碳原子,此種 類型的化合物可以純鏡像異構物或純非鏡像異構物或此兩 種混合物的形式存在。較佳的是用鏡像異構物的純化合物 作爲活性成分。 另外本發明是利用前述的羧酸衍生物製藥劑,特別是製 備eta及etb受體的抑制劑。根據本發明的化合物特別適人 作爲最初定義的混合拮抗劑。 如W0 96/11914中所揭示,可製備式IV化合物,亦爲鏡 -10- 本紙張尺度ill则,_:料(Fns ) Λ4規格(2丨0? 297公釐) _ — (讀先閱讀背面之注意事赞再填寫本頁) 訂 546295 A7 B7 五、發明説明( 像異構物純物贺,其中z爲硫或氧 R4 〇 广/V/ +The Ci-cvfe group may be linear or branched, such as alkyl, pentyl, hexyl, heptyl, or octyl; halogen is, for example, fluorine, chlorine, bromine, or oxo. In addition to this, the present invention also relates to compounds (referred to as prodrugs) that can release compounds of formula VII. Preferred prodrugs are those that are released under certain conditions and are widely stored in certain parts of the body (such as the stomach, intestines, bloodstream, liver). These compounds and intermediates (such as compounds of formulae π, ΙΠ, and IV) have one or more asymmetrically substituted carbon atoms. These types of compounds can be pure mirror isomers or pure non-image isomers or These two mixtures exist. It is preferable to use a pure compound of the image isomer as an active ingredient. In addition, the present invention uses the aforementioned carboxylic acid derivative pharmaceutical agent, particularly to prepare inhibitors of the eta and etb receptors. The compounds according to the invention are particularly suitable as mixed antagonists as originally defined. As disclosed in WO 96/11914, a compound of formula IV can be prepared, which is also a mirror -10- this paper scale ill, _: material (Fns) Λ4 specification (2 丨 0? 297 mm) _ — (read first read Note on the back, please fill in this page) Order 546295 A7 B7 V. Description of the invention (like isomers of pure materials, where z is sulfur or oxygen R4 〇 广 / V / +
,R R4 C- R6- 2·, R R4 C- R6- 2 ·
•H R6-2• H R6-2
BB
IIII
III C~CH— 〇H B R IV is 或 式III化合物是已知的,或將對岸卷酴 曰 〜町玎I鈸敎或其酯類還原, 疋用其他一般已知的方法合成式m化合物。 可製備式1彳匕合物定義取代基之根據本發明化人物, 如,將式之羧酸衍生物(其取代基如所述的定義盥式 化合物反應。 ;^ IV + R1 -Het ^ !III C ~ CH—OH B R IV is or a compound of formula III is known, or the other side is reduced to 玎 玎 I 玎 or its esters, and 化合物 compounds of formula m are synthesized by other generally known methods. The compound of the present invention can be prepared according to the definition of the substituents of Formula 1 by, for example, reacting a carboxylic acid derivative of the formula (whose substituents are as defined in the formula.) ^ IV + R1-Het ^!
VV
式V中的R1是自素或R12_s〇2_,其中烷基, q-c:4- ή素燒基或苯基。除此之外,環結構中至少一個X 或Y或Z爲氮。添加適當鹼時,如將J v中間物質去質子的 鹼。反應較佳在惰性溶劑或稀釋劑中進行,反應溫度範圍 是自室溫至溶劑的沸點。 當中間物負I V中R爲COOH ’經兩當量的適當驗去質子 後,並與式V化合物反應,可直接製得r=c〇〇h的式I化合 物。此反應亦於惰性溶劑中進行,而反應溫度範圍是自室 溫至溶劑的沸點。 1 - 本紙張尺度適用中國國家標蜂(rNS ) Λ4規格(210X297公釐) ^46295 五 '發明説明( A7 可購買或是以 a此種溶劑及稀釋劑的範例包括脂肪族,脂肪環族及芳香 族的碳早化合物,每個化合物可經氣化’諸如己烷,環己 ,,石f醚’蕃油,苯,甲苯,二甲苯,二氯:烷Γ氯 万’四虱化碳’氣乙烷及三氯乙烯,醚類,諸如二異丙基 醚’二丁醚,T基第三_ 丁基醚,環氧丙烷,二氧烷及四 氧呋喃,腈類,諸如乙腈及丙腈,醯胺類,諸如二曱基甲 醯胺,二甲基乙醯胺及N_甲基吡咯啶酮,亞砜及颯二 諸如二甲基亞颯及四氫嘧吩h二氧化物。 式v化合物是已知的,或在某些情形下 —般已知的方法製備之。 所用的鹼可爲鹼金屬或鹼土金屬的氫化物,諸如氫化 鈉,氫化鉀或氫化鈣,鹼金屬之碳酸化物,諸如碳酸^或 碳酸鉀,鹼金屬或鹼土金屬的氫氧化物,諸如氫氧化鈉或 氫氧化鉀,有機金屬化合物,諸如丁基鋰,或鹼金屬醯 胺’諸如二異丙基醯胺化鋰或醯胺化鋰。 亦可自對應的羧酸開始製備化合物,如Rl爲C00H的 式I化合物,初期是以傳統的方法將其轉換成活化形式, 诸如酸的卣化物,酐或咪唑化合物,而後再與適當的羥基 化合物HOR7反應。此反應可在傳統的溶劑中進行,且常 需添加驗,合適的驗如前所述。這兩個步驟亦可簡化,例 如在脱水劑存在下(如碳二亞胺),將羧酸與羥基化合物反 應。 另一種方法由適當的羧酸之鹽類製備式I化合物,如Rl 爲COR基團的式I化合物,其中r*0m,而M是鹼金屬陽 12- 本紙張尺度適用中國國家標嘩((、NS ) Λ4規格(210X 297公釐) --------—I (讀先閱讀背面之•注意事香再填寫本頁) 、11 •Ί 546295 A7 B7 五、發明説明( —-— 10 ^•'"''部十^^^^员二消赘合竹^印1々 離子,或是等當量的鹼土金屬陽離子。這些鹽類可與許多 式R-A化合物反應,其中A是傳統核脱離基,例如鹵素, 諸如氯,溴,破或未經取代或鹵素-,烷基-或鹵素燒基· 取代芳香基或烷基磺醯基,諸如甲苯磺醯基及甲基續醯 基,或其他相當的脱離基。具反應取代基A的式R-a化合 物是已知的,或爲一般專家的基本知識。此反應可在傳統 的落劑中進行’而其好處是添加驗冗成的,如前所述的情 形是合適的。 鑒於生物效應,較佳的式I羧酸衍生物(包括純鏡像異構 物及純非鏡像兴構物及其兩者混合物)的取代基意義如 下: R1 COOR7,其中 R7是 氫,驗金屬的陽離子,驗土金屬的陽離子或生理學上可耐 受的有機銨離子; C3-C8-環烷基,cvcv烷基, 未經取代或經取代之CH2-苯基, 未經取代或經取代之C3-C6-烯基或c3-c6-炔基,或 未經取代或經取代之苯基。 R2氫,羥基,鹵素,n(cvc4-烷基)2,Ci_C4-烷基,Cl_ c4-:fe 氧基 ’ C^-Czr:)%* 基石荒,CVCV _ 素燒基,CVC4-卣 素烷氧基,或CR2與CR1G(意義如下)聯結成5-員或6_員 環,或,假若Het是5 -員環,CR2與CR3共同形成未經取 代或經取代的5 -員或6 -員烯基或環埽基環; X 氮或次甲基; -13- 本紙張尺度適用中國^標__ ( (、NS ) Λ4規格(210X 297公釐) ----- --------脅衣_丨 (讀先閱讀背面之注意事臂再填寫本頁} 、11 ^46295 A7 B7 Λ、發明説明(H ) Y 氮或次甲基; W氮或CR1G,其中R1G是氫或Ci-CV烷基,或CR10與CR2或 CR3共同形成未經取代或經一個甲基或兩個甲基取代之 5 -員或6 -員alkylene或alkenylene環,其中每種情形中 的亞甲基可被氧或硫置換,諸如-CH2-CH2-0-, C Η 2 - C Η 2 - 〇 -,_ C Η = C Η Ο -,_ C Η 二 C Η - C Η 2 Ο _,_ C Η ( C Η 3)-ch(ch3)-o-,-CH二c(ch3)-o-,-C(CH3)=C(CH3)-〇_,或 -C(CH3)二C(CH3)-S ; 至少一個環組成物X,Y或w爲氮。 R3氫,羥基,鹵素,N(cvc4-烷基)2,CVC4-烷基,Ci-C4-烷氧基,CVCV烷基硫,Ci-CVi^素烷基,CpCVi^ 素烷氧基,或CR3連結至前述CR1G上形成5 -員或6_員 環,或,假若Het是5 -員環,CR2可與CR3共同形成未經 取代或經取代之5 -員或6 -員烯基或環晞基環; R4及R5(可相同或不相同): 可經一個或多個下列的基團取代之苯基或萘基:自 素,硝基,氰基,經基,窥基,胺基,C^C:4-燒基, Ci-cv鹵素烷基,Cl_c4_烷氧基,Cl_Czr鹵素烷氧基, 苯氧基,CrCV烷基硫,NHCCVCV烷基)或N(CVc4-户 基)2或經氫,硝基,氰基,Cl_C4_烷基,Ci_C4__素燒 基’ 氧基,CVC4·鹵素燒氧基或CVC4-燒基辟 取代一至多次(如一至三次)的苯基;或' 鄰位直接連結亞甲基,伸乙基或ethenylene或氧或硫原 子或S02,NH或N-烷基之苯基或莕基; _ _ - 14- i、紙張尺度“中關家料((ϋ~Λ4規格(21GX297公釐) "_ ^—__ ------訂------ (請先閲讀背面之注意事货再填寫本頁) 546295 A7 B7 Λ '發明説明(12) C3-C8-環燒基; R6 CyCp環烷基,其可經鹵素,羥基,巯基,羧基,硝 基’氣基’ Ci_C4-fe氧基,C1-C4-板基’ C2-C4 -缔基’ C2-C4-块基’ C3-C6 -缔基氧基,C3-C6-块基氧基’ C1-C4-虼基硫,Ci-CV鹵素烷氧基,crC4-烷基羰基,CVC4-垸氧基羰基,NH((VC4·烷基),NXCVCV烷基)2取代^ 至多次,或是經鹵素,硝基,氰基’ C^-Czp燒基,Ci· C4-鹵素燒基,cvcv燒氧基,C1-C4-鹵素燒氧基或CV C 4 - fe基硫取代一至多次(如一至三次)之苯基; 可經一個或多個下列的基團取代之苯基或蕃基:鹵 素,硝基,巯,羧基,氰基,羥基,胺基,CVC4-烷 基,C2-C4-稀基,C2-C4-炔基,c3-c6-烯基氧基,crCr 鹵素烷基,C3-C6-炔基氧基,Ci-CV烷基羰基,Ci-Cr 鹵素燒基’ C3-C6 -块基氧基,C1-C4 -燒基談基,C1-C4-fe氧基羰基,Ci-Czr烷氧基CrC4-鹵素烷氧基,苯氧 基,CVC4·烷基硫,NHKCVCV 烷基),NKi-Cr 烷基)2, 二氧甲基,二氧乙基[sic]或經鹵素,硝基,氰基,Cr c4-烷基,CrC4-鹵素烷基,q-CV烷氧基,Ci-CV鹵素 燒氧基或C i -Cr烷基硫取代一至多次(如一至三次)的苳 基; 含有一至二個氮原子及/或一個硫或氧原子的5 _員或$ -員雜芳香族系統,其可含有一至四個自、素原子及/或/ 至二個下列的基團:Ci_C4_烷基,鹵素烷基,Ci_ C4-燒氧基,CVCV鹵素烷氧基,cvcv烷基硫,苯基, __ -15- 本紙張尺度適A中國(、NS 規格(210X 297公釐) '-- ----- (讀先閱讀背面之注意事艰存填寫本頁) 1 - · 訂 #丨 546295 A7 —_____ B7 五、發明説明(13) — 苯氧基’或苯基談基,苯基可依次帶有一至五個南$ 原子;及/或一至三個下列的基團:cKc4-烷基,c 。 素A元基’ 氧基’ C1-C4-卣素fe氧基及/或c 烷基硫; ~ 1_cv z 硫或氧; B c2-c4-烯基R1 in formula V is a self-prime or R12_s0_2_, wherein alkyl, q-c: 4-valenyl or phenyl. In addition, at least one of X or Y or Z in the ring structure is nitrogen. When an appropriate base is added, such as a base that has been deprotonated by J v intermediates. The reaction is preferably carried out in an inert solvent or a diluent, and the reaction temperature ranges from room temperature to the boiling point of the solvent. When R is COOH 'in the intermediate negative IV, the protons of two equivalents are appropriately removed and reacted with the compound of formula V to directly prepare the compound of formula I with r = c00h. This reaction is also performed in an inert solvent, and the reaction temperature ranges from room temperature to the boiling point of the solvent. 1-This paper size applies to the Chinese National Standard Bee (rNS) Λ4 specification (210X297 mm) ^ 46295 Five 'invention description (A7 Examples of such solvents and diluents that can be purchased or a) include aliphatic, cycloaliphatic and Aromatic early carbon compounds, each of which can be gasified 'such as hexane, cyclohexyl, sulfide, ether, benzene, toluene, xylene, dichloro: alkane, chloro, and chlorotetrafluorocarbon' Gas ethane and trichloroethylene, ethers such as diisopropyl ether 'dibutyl ether, T-based tertiary butyl ether, propylene oxide, dioxane and tetraoxofuran, nitriles such as acetonitrile and propane Nitriles, amidines, such as dimethylamidoxamine, dimethylacetamide and N-methylpyrrolidone, sulfoxides and amidines such as dimethylsulfinium and tetrahydropyrimidine h dioxide. Compounds of formula V are known or, in some cases, generally known methods. The bases used may be alkali metal or alkaline earth metal hydrides such as sodium hydride, potassium hydride or calcium hydride, Carbonates, such as ^ or potassium carbonate, hydroxides of alkali or alkaline earth metals, such as sodium hydroxide Potassium hydroxide, organometallic compounds, such as butyllithium, or alkali metal amidamine 'such as diisopropylammonium lithium or amido lithium. Compounds can also be prepared starting from the corresponding carboxylic acid, such as Rl C00H The compound of formula I is initially converted into an activated form by conventional methods, such as acid halides, anhydrides or imidazole compounds, and then reacted with the appropriate hydroxy compound HOR7. This reaction can be carried out in traditional solvents, and often An additional test is required, and the appropriate test is described previously. These two steps can also be simplified, for example, by reacting a carboxylic acid with a hydroxy compound in the presence of a dehydrating agent (such as a carbodiimide). Another method consists of an appropriate carboxylic acid. The compound of formula I, such as the compound of formula I in which Rl is a COR group, wherein r * 0m, and M is an alkali metal cation 12- This paper is applicable to Chinese national standard ((, NS) Λ4 specification (210X 297) (Mm) --------— I (Read the first note on the back and fill in this page first), 11 • Ί 546295 A7 B7 V. Description of the invention (—-— 10 ^ • '"' '部 十 ^^^^ member 2 eliminates superfluous bamboo ^ India 1々 ions, or equivalent Alkaline earth metal cations. These salts can react with many compounds of formula RA, where A is a traditional nuclear leaving group, such as halogen, such as chlorine, bromine, broken or unsubstituted or halogen-, alkyl-, or halogen-substituted. Aromatic or alkylsulfonyl groups, such as tosylsulfonyl and methylcontinyl, or other equivalent leaving groups. Compounds of the formula Ra with reactive substituent A are known, or are the basic knowledge of general experts This reaction can be carried out in traditional formulations, and its benefit is that it is redundant and suitable for the conditions described above. In view of biological effects, preferred carboxylic acid derivatives of formula I (including pure mirror image The meanings of the substituents are: R1 COOR7, where R7 is hydrogen, metal cation, earth metal cation, or physiologically tolerable organic ammonium ion. ; C3-C8-cycloalkyl, cvcv alkyl, unsubstituted or substituted CH2-phenyl, unsubstituted or substituted C3-C6-alkenyl or c3-c6-alkynyl, or unsubstituted Or substituted phenyl. R2 hydrogen, hydroxy, halogen, n (cvc4-alkyl) 2, Ci_C4-alkyl, Cl_c4-: fe oxygen 'C ^ -Czr:)% * Cornerstone shortage, CVCV_ sulfenyl, CVC4-fluorene Alkoxy, or CR2 and CR1G (meaning as follows) are combined to form a 5-membered or 6-membered ring, or, if Het is a 5-membered ring, CR2 and CR3 together form an unsubstituted or substituted 5-membered or 6 -Member alkenyl or cyclofluorenyl ring; X nitrogen or methine; -13- This paper size is applicable to Chinese standard __ ((, NS) Λ4 specification (210X 297 mm) ----- --- ----- 衣衣 _ 丨 (Read the cautions on the back before filling this page}, 11 ^ 46295 A7 B7 Λ, invention description (H) Y nitrogen or methine; W nitrogen or CR1G, where R1G Is hydrogen or Ci-CV alkyl, or CR10 and CR2 or CR3 together form a 5- or 6-membered alkylene or alkenylene ring that is unsubstituted or substituted with one or two methyl groups, where in each case Methylene can be replaced by oxygen or sulfur, such as -CH2-CH2-0-, C Η 2-C Η 2-〇-, _ C Η = C Η Ο-, _ C Η two C Η-C Η 2 〇 _, _ C Η (C Η 3) -ch (ch3) -o-, -CH di c (ch3) -o-, -C (CH3) = C (CH3) -〇_, or -C (CH3) C (CH3) -S; At least one ring component X, Y or w is nitrogen. R3 hydrogen, hydroxyl, halogen, N (cvc4-alkyl) 2, CVC4-alkyl, Ci-C4-alkoxy, CVCV alkyl sulfur, Ci-CVi ^ Alkyl, CpCVi ^ alkoxy, or CR3 is linked to the aforementioned CR1G to form a 5-membered or 6-membered ring, or, if Het is a 5-membered ring, CR2 and CR3 can form an unsubstituted or Substituted 5-membered or 6-membered alkenyl or cyclofluorenyl rings; R4 and R5 (which may be the same or different): phenyl or naphthyl which may be substituted by one or more of the following groups: autogen, nitrate Cyl, cyano, mesyl, peptyl, amine, C ^ C: 4-alkyl, Ci-cv haloalkyl, Cl_c4-alkoxy, Cl_Czr haloalkoxy, phenoxy, CrCV alkylsulfur , NHCCVCV alkyl) or N (CVc4-housed) 2 or via hydrogen, nitro, cyano, Cl_C4_alkyl, Ci_C4__sulfanyl'oxy, CVC4 · haloalkyloxy or CVC4-alkyl Phenyl substituted one or more times (such as one to three times); or phenyl or fluorenyl group directly linked to methylene, ethylene or ethylen or oxygen or sulfur atom or S02, NH or N-alkyl in ortho position; _-14- i. Paper size "Zhongguan Household Materials ((ϋ ~ Λ4 size (21GX 297 mm) " _ ^ —__ ------ Order ------ (Please read the notice on the back before filling in this page) 546295 A7 B7 Λ 'Invention Note (12) C3-C8 -Cycloalkyl; R6 CyCp cycloalkyl, which can be passed through halogen, hydroxyl, thiol, carboxyl, nitro's Ci_C4-feoxy, C1-C4-plateyl 'C2-C4-allyl' C2- C4-Block 'C3-C6-alkenyloxy, C3-C6-Blockyloxy' C1-C4-fluorenylsulfur, Ci-CV haloalkoxy, crC4-alkylcarbonyl, CVC4-fluorenyloxy Carbonyl, NH ((VC4 · alkyl), NXCVCV alkyl) 2 substituted ^ many times, or through halogen, nitro, cyano 'C ^ -Czp alkyl, Ci · C4-halo alkyl, cvcv oxygen Phenyl, C1-C4-halohaloxy or CV C 4-fe-based thio substituted phenyl for one or more times (such as one to three times); phenyl or phenyl which may be substituted with one or more of the following groups: halogen , Nitro, thiol, carboxyl, cyano, hydroxy, amine, CVC4-alkyl, C2-C4-diluted, C2-C4-alkynyl, c3-c6-alkenyloxy, crCr haloalkyl, C3 -C6-alkynyloxy, Ci-CV alkylcarbonyl, Ci-Cr haloalkyl, C3-C6-blockyloxy, C1-C4-alkylphenyl, C1-C4-feoxy Group, Ci-Czr alkoxy, CrC4-haloalkoxy, phenoxy, CVC4 · alkylsulfur, NHKCVCV alkyl), NKi-Cr alkyl) 2, dioxomethyl, dioxoethyl [sic] Or substituted one or more times with halogen, nitro, cyano, Cr c4-alkyl, CrC4-haloalkyl, q-CV alkoxy, Ci-CV halooxy or Ci-Cr alkylsulfur (such as 1 to 3) fluorenyl groups; 5-membered or $ -membered heteroaromatic systems containing one to two nitrogen atoms and / or one sulfur or oxygen atom, which may contain one to four self, prime atoms, and / or two The following groups: Ci_C4_alkyl, haloalkyl, Ci_C4-carboxy, CVCV haloalkoxy, cvcv alkylsulfur, phenyl, __ 15- This paper is suitable for A China (, NS specifications (210X 297mm) '------ (Read the first page and read the cautions on the back and fill out this page) 1-· Order # 丨 546295 A7 —_____ B7 V. Description of the invention (13) — Phenoxy 'Or phenyl, phenyl, which may in turn carry one to five atoms; and / or one to three of the following groups: cKc4-alkyl, c. Element A-membered group'oxy 'C1-C4-fluorenin-feoxy and / or c alkylsulfur; ~ 1_cv z sulfur or oxygen; B c2-c4-alkenyl
Het是T二0,S之式la或lb雜環基團。 特別佳的式(I)化合物(包括純鏡像異構物及純非鏡像異 構物與其混合物)的取代基意義如下: R’ C00H ; X,Y N ; W CR10 ; R2,R3 氫,輕基,ΝΗ2,ΝΗ(<^_ίν 燒基),N(C广C4_ 燒 基)2,ή 素 ’ C1_C4-院基,C2-C4-晞基,C2-C4-块基, C^-C4·鹵素抗基’ 氧基’ Ci-C4·鹵素:1 完氧基或 C^C:4-烷基硫,或CR2連結至下述定義之CR1G而形成5-員或6 -員環’或’假若Het是5 -員環,CR2可與CR3共同 形成未經取代或經取代之5 -貝或6 -貝稀基或環烯基 環; R4經下列一個或多個基團取代之苯基:ή素,硝基,氰 基,#i基,統基,胺基,cvcv規基,c〗-c4- _素燒 基,CKC4-烷氧基,C「C4-鹵素烷氧基、,苯氧基,Cl-C4-坑基硫 ’ NH(Ci-C4_'J%* 基)或 N(Ci_C4_:fe 基)2或經鹵 素’硝基’戴基’ Ci-Cf燒基’ Ci-Cf鹵素燒基, -16- 4*〔紙張^度適州中國C、NS ) Λ4規格(210X 297公釐) 546295 A7 B7 五、發明説明(14) CV烷氧基,CVCzr自素烷氧基或CrCV烷基硫取代—至 多次(如~ —至二次)的苯基;或 R5苯基或3,4-二曱氧基苯基 R6可經下列基團取代一至多次之c5_c7-環烷基:cvc4_燒 氧基’ Ci-cv燒基,cvc^ -燒基硫,鹵素,經基,幾 基,氰基,三氟甲基,乙醯基,或經鹵素,氰基, 11 · c4-烷基,Crcv鹵素烷基,cvcv烷氧基,cvcv卣素 Ί乳基或C 1 - C4 -坑基硫取代一至多次(如一至三次)的笨 基; 經下列一個至多個基團取代之苯基或萘基:鹵素,石肖 基,毓基,羧基,氰基,羥基,胺基,Ci_C4_烷基, Ci-CV鹵素烷基,乙醯基,Ci_c4_烷氧基羰基, 燒氧基,C^CV鹵素烷氧基,苯氧基,Ci_c4_烷基硫, NHiCVCV烷基),Ν((ν<:4-烷基)2,二氧甲基,二氧乙 基或經卣素,硝基,氰基,Ci_C4_烷基,Ci_C4_ _素烷 基,cvc:4-烷氧基,c^-cv鹵素烷氧基或Ci_Czr烷基硫 取代一至多次(如一至三次)的苯基; 含有一至二個氮原子及/或一個硫或氧原子的5 -員或k 員雜芳香環系統,其可帶有一至四個齒素原子及/或— 至二個下列基團:Cl_C4_虎基,Ci-C41素燒基, C4_烷氧基,三氟甲氧基,Ci_c^烷基硫,苯基或笨氧 基,苯基可依次帶有一至五個_素原子及/或至三個下 列基團· cvcvfe基,Cl-C4- _素境基,境 基,G-c:4-鹵素烷氧基及/或Ci_c^烷基硫; 氧 讀 閱 讀 背 3' 1 頁 訂 -17- 546295 A7 * ~~〜---------- Β7 五、發明説明(15) — 〜--- z 硫或氧; B C^-a'kyleneHet is a heterocyclic group of the formula T or 0, S of la or lb. The meanings of the substituents of particularly preferred compounds of formula (I) (including pure mirror isomers and pure non-mirro isomers and mixtures thereof) are as follows: R 'C00H; X, YN; W CR10; R 2, R 3 hydrogen, light group, ΝΗ2, ΝΗ (< ^ _ ίν alkyl), N (C2C4_ alkyl) 2, price 'C1_C4-Cycyl, C2-C4-Cycyl, C2-C4-Block, C ^ -C4 · halogen Anti-radical 'oxy' Ci-C4 · halogen: 1 complete oxygen or C ^ C: 4-alkyl sulfur, or CR2 linked to CR1G as defined below to form a 5-membered or 6-membered ring 'or' if Het is a 5-membered ring. CR2 and CR3 can jointly form an unsubstituted or substituted 5- or 6-belenyl or cycloalkenyl ring; R4 is a phenyl substituted with one or more of the following groups: Element, nitro group, cyano group, #i group, system group, amine group, cvcv gauge group, c〗 -c4- _ group group, CKC4-alkoxy group, C, C4-haloalkoxy group, phenoxy group Group, Cl-C4- pit-based sulfur 'NH (Ci-C4_'J% * group) or N (Ci_C4_: fe group) 2 or via a halogen' nitro'-daiyl 'Ci-Cf alkyl group' Ci-Cf halogen Burning base, -16- 4 * [paper ^ degrees of Shizhou China C, NS) Λ4 size (210X 297 mm) 546295 A7 B7 V. Description of the invention (14) CV alkoxy, CVCzr is substituted by prime alkoxy or CrCV alkyl sulphur-phenyl that has been substituted to several times (such as ~ to two times); or R5 phenyl or 3,4-dimethoxyphenyl R6 may be substituted by one or more of c5_c7-cycloalkyl with the following groups: cvc4_alkyloxy 'Ci-cv alkyl, cvc ^ -alkylthio, halogen, mesityl, alkyl, cyano, trifluoromethyl Group, ethenyl, or substituted with halogen, cyano, 11 · c4-alkyl, Crcv haloalkyl, cvcv alkoxy, cvcv sulfonyl lactyl, or C 1 -C4-pit sulfur. (Such as one to three times) phenyl; phenyl or naphthyl substituted by one or more of the following groups: halogen, schottyl, fluorenyl, carboxyl, cyano, hydroxyl, amine, Ci_C4_alkyl, Ci-CV haloalkane Group, ethenyl, Ci_c4-alkoxycarbonyl, carboxy, C ^ CV haloalkoxy, phenoxy, Ci_c4-alkylsulfur, NHiCVCV alkyl), N ((ν <: 4-alkyl ) 2, Dioxomethyl, Dioxoethyl or Viadin, Nitro, Cyano, Ci_C4_alkyl, Ci_C4__alkyl, cvc: 4-alkoxy, c ^ -cv haloalkoxy Or Ci_Czr alkyl sulfur substituted one or more times (such as one to three times) Phenyl; a 5- or k-membered heteroaromatic ring system containing one to two nitrogen atoms and / or one sulfur or oxygen atom, which may carry one to four halo atoms and / or — to two of the following groups: Cl_C4_Tigeryl, Ci-C41 sulfenyl, C4_alkoxy, trifluoromethoxy, Ci_c ^ alkylsulfur, phenyl or phenyloxy, phenyl may have one to five _ prime atoms in sequence and / Or to three of the following groups: cvcvfe group, Cl-C4- _environment group, enclosing group, Gc: 4-haloalkoxy and / or Ci_c ^ alkyl sulfur; oxygen read read back 3 '1 page order -17- 546295 A7 * ~~~ ---------- Β7 V. Description of the invention (15) — ~ --- z Sulfur or oxygen; BC ^ -a'kylene
HetR2及R3爲甲基,而T=〇,_Ia。 本發明提供對高血壓,肺高血壓,心肌梗塞,狹心症, 急性/慢性腎衰竭,腎功能不全,腦血管痙攣,腦缺血, 蛛=膜下出血,偏頭痛,氣喘,動脈硬化,内毒素休克, 内母素#發(器官衰竭,血管内凝血,血管術後再狹窄, 良性可列腺發育不全,間葉腫瘤的轉移及生長,對比劑謗 發的腎衰竭,胰臟炎,腸胃潰瘍具療效之化合物。 除此之外,本發明係關於含有式τ内皮素受體拮抗劑及 腎酵素-血管收縮素系統的抑制劑之組合產物。腎酵素-血 管收縮素系統的抑制劑是腎酵素抑制劑,血管收縮素11拮 抗劑’及特別是血管收縮素轉換酵素(ACE)抑制劑。 這些組合產物特別適合用以治療及預防高血壓與其續發 症,以及治療心臟衰竭。 這些化合物的良好效果可用下列的測試證明: 受體鍵結研究 鍵結研究是採用選殖人類ETA或ETB受體·表現CHO細 胞。 膜的製備 將ETA或ΕΤβ受體-表現CHO細胞生長於内含10%胎牛血清 (PAA實驗室GmbH,Linz,編號A1 5-0220,、1〇〇單位/毫升盤 林西靈及100微克/毫升鏈黴素(吉柏克,西格馬編號P-0781) 之DMEM NUT MUX F12培養基(吉柏克,編號21331-020) -18- 本紙張尺度適W中國國家標嘩(rNS ) Λ4規格(210X 297公釐) 546295 A7 B7 ~----- 五、發明説明(16 ) 中。4 8小時後,用PBS清洗細胞,並用含0.05%胰蛋白酶 之PBS在3 7 °C下處理5分鐘,其後用培養基中和之,以3〇〇 g速度離心收集細胞。 以膜的製備而言,將細胞調整至濃度爲1〇8細胞/亳升緩 衝液(5 0 mM tris · HC1緩衝液,pH 7.4),而後用超音波(布 雷申梭尼佛250,40-70秒/固定/輸出2 0)將細胞分散。 鍵結方析 以ETA及ETB受體鍵結分析而言,將膜懸浮於培養緩衝液 (内含5 mM MnCl,40微克/毫升細菌素(bacitracin)及0.2% BSA之50 mM tris-HCl,pH 7.4)中,使每個分析混合物中含 有蛋白質5 0微克,並於含有待測物或不含待測物下,將膜 製備物與25 PM [1251]^^ (ETA受體分析)或25 pM [1251]-ET3 (ETB受體分析)置於25 °C下培養,用ΐ〇_7 μ ET,j定非 專一性鍵結。3 0分鐘後,以GF/B玻璃纖維濾紙(華特曼, 英國)經斯克雷細胞收集器(斯克雷,來訥,挪威)過濾, 以便將键結配位體與未鍵結的配位體分開,用含有〇.2〇/〇HetR2 and R3 are methyl groups, and T = 0, _Ia. The present invention provides for hypertension, pulmonary hypertension, myocardial infarction, asthma, acute / chronic renal failure, renal insufficiency, cerebral vasospasm, cerebral ischemia, subarachnoid hemorrhage, migraine, asthma, arteriosclerosis, Endotoxin shock, 内 母 素 #fat (organ failure, intravascular coagulation, restenosis after vascular surgery, benign gliosis, metastasis and growth of mesenchymal tumors, renal failure due to contrast agents, pancreatitis, Compounds with gastrointestinal ulcer. In addition, the present invention relates to a combination product containing an endothelin receptor antagonist of formula τ and an inhibitor of the renin-angiotensin system. An inhibitor of the renin-angiotensin system Are renal enzyme inhibitors, angiotensin 11 antagonists' and especially angiotensin-converting enzyme (ACE) inhibitors. These combined products are particularly suitable for the treatment and prevention of hypertension and its secondary symptoms, as well as the treatment of heart failure. These The good effect of the compound can be proved by the following tests: Receptor Bonding Studies Bonding studies are performed using selected human ETA or ETB receptors and expressing CHO cells. Preparation of membranes ETA or ETβ receptor-expressing CHO cells are grown in cells containing 10% fetal bovine serum (PAA Labs GmbH, Linz, No. A1 5-0220, 100 units / ml pancillin and 100 μg / ml streptomyces DMEM NUT MUX F12 Medium (Jibo Ke, Sigma No. P-0781) (Gibo Ke, No. 21331-020) -18- This paper is suitable for China National Standard (rNS) Λ4 Specification (210X 297 (Mm) 546295 A7 B7 ~ ----- 5. In the description of the invention (16). After 48 hours, the cells were washed with PBS and treated with 0.05% trypsin-containing PBS at 37 ° C for 5 minutes. The cells were neutralized with culture medium, and the cells were collected by centrifugation at a speed of 300 g. For the preparation of the membrane, the cells were adjusted to a concentration of 108 cells / liter buffer (50 mM tris · HC1 buffer, pH 7.4), and then disperse the cells with ultrasound (Breshensonifer 250, 40-70 seconds / fixation / output 2 0). Bonding analysis For ETA and ETB receptor bonding analysis, the membrane is suspended in Culture buffer (containing 5 mM MnCl, 40 μg / ml bacitracin and 0.2% BSA in 50 mM tris-HCl, pH 7.4). With 50 micrograms of protein, and with or without the test substance, the membrane preparation was reacted with 25 PM [1251] ^^ (ETA receptor analysis) or 25 pM [1251] -ET3 (ETB receptor (Analyze) incubate at 25 ° C, and bind non-specifically with ΐ0-7 μ ET, j. After 30 minutes, collect with GF / B glass fiber filter paper (Watman, UK) via Scree cells Filter (Skeley, Leine, Norway) to separate the bound ligand from the unbound ligand, using 0.20 / 〇
BSA的冰冷tris-HCl,pH 7.4清洗濾膜,利用派卡22000 CA 液®閃爍計數器定出滤膜上所收集的放射性。 活體内E T拮抗劑的測試 用亞莫巴比脱將250-300克的Sd雄鼠麻醉,進行人工換 氣’切斷迷走神經並去髓,在頸動脈及頸靜脈插入導管。 在控制組的動物中,以靜脈内投藥法施以1微克/公斤的 ET1 ’使其血壓上升一段長時間。 在投樂ET1之前3 〇分鐘,以靜脈注射法注射待測化合物 —— -19- 本紙張尺度ϋι则,_:彳_ (-— ---- ---------着衣—丨 f請先閱讀背面、5'>1意事可再填寫本頁} 丁 546295 A7 B7 五、發明説明(17 至貫驗動物體(1晕克/公斤)中,爲測定ET_拮抗劑的特 性,比較實驗動物血壓的改變結果與控制組動物的血壓改 變結果。 混合ETA及ETB抬抗劑的口服測試 將重f馬250-300克的i常血壓雄鼠(斯瑞克道立,截幅) 先以口服方式施以代測物質,8〇分鐘之後,用胺醋麻醉動 物,在頸動脈(測量血壓)及頸靜脈(施以大内皮素/内皮素 1)插入導管。 一段穩定期之後,靜脈注射方式施以大内皮素(20微克/ 公斤,投藥體積爲0.5毫升/公斤)或ΕΤ1 (〇·3微克/公斤,投 樂體積0.5 *升/公斤),持續紀錄血壓及心跳3 〇分鐘,以 曲線下的面積(AUC)作爲血壓明顯的改變及長期的改變, 比較實驗動物所得之AUC及控制組動物所得之Auc,以測 定這些待測物質的拮抗效果。 可用傳統的方法,以口服或非經腸方式(皮下,靜脈 内,肌肉,腹膜内)投與根據本發明之化合物,亦可經鼻 咽喉處以蒸氣或噴霧方式投與根據本發明之化合物。 投與劑量視病患的年齡,病徵及體重與投藥的方式而 定。通常口服投藥時,活性成分的日劑量約以⑼毫克/公 斤體重,而非經腸投藥時則爲0.M〇亳克/公斤體重。 消 合 11 印 本發明新穎化合物可用於傳統的固態或液態^藥形式, 如未塗覆或(薄膜)塗覆的錠片,膠囊,粉末,顆粒,坐 劑’溶液,軟#,乳液或噴霧劑,這些均可以傳統的方法 製備,可根據目的將活性成分與傳統的醫藥輔劑一起處 本紙張尺度適川中國國家標缚((、NS ) -20- Λ4規招(210X 297公釐 ) 546295 A7 B7 五、發明説明(18 ) 理,諸如錠片鍵結劑,填充劑,保存劑,錠片分散劑,流 素碉節劑,塑型劑,濕潤劑,分散劑,乳化劑,溶劑,遲 緩釋放劑,抗氧化劑及/或推進劑(參考Η .洒克等人.:藥 學技術’太米-凡樂’斯特格,19 9 1)。此法所得的投藥形 式内含0。1至90%重量比的活性成分。 合成範例 範例1 : 2,3-¾氧基-3,6 - —苯基己酸甲酯 將14 · 3克(3 1當莫耳)之5 0 %氫化鋼在8小時内,分批加入 内含4克(17.8毫莫耳)1,心二苯基-1-丁酮及2.7毫升(31毫莫 耳)氯乙酸甲酯之60毫升THF溶液中。酮完全反應之後, 將反應混合物加至冰冷的水中,並以乙_萃取之。利用硫 酸鎂乾燥有機層,並在溶劑蒸發之後,可得55克進一步 反應之油狀物。 範例2 : 2-¾基-3-甲氧基-3,6 -二苯基己酸甲酉旨 將2克(6.75¾莫耳)的2,3-環氧基-3,6-二苯基己酸曱酯加 入0 · 5毫升的甲醇後,再加至2 〇毫升的二氯甲烷中,並加 入5滴的boron trifluoride etherate。2小時之後,濃縮混合 物,並以MPLC純化殘餘物(環己烷/乙酸乙酯爲溶液梯 度),如此可得第一個非鏡像異構物53〇毫克,第二個鏡像 異構物7 2 0耄克及混合物分液8 〇 〇毫克。 範例3 : 2-¾基-3-甲氧基-3,6-二苯基己酸(一個鏡像異構物,立體 -21 - 本紙張尺度ί州中-¾家標绛(('NS ) A4^i77T〇x 297^f ) ----- ---------- (讀先閱讀背面t注意事嘴再填寫本頁) 訂 丨·· 546295 Α7 Β7 五、發明説明(19 ) 一 化學未知) 將第二個鏡像異構物(720毫克,2.2亳莫耳)溶解於9毫升 的二氧甲虎中,並加入4.5毫升1N氫氧化鈉溶液,攪拌混 合物1 6小時,而後添加水,再以乙醚萃取之。用擰檬酸酸 化水層,並以乙醚萃取之。用硫酸鎂乾燥有機層,蒸發溶 劑’如此可分離9 3 6晕克油狀物,再立刻進一步反應。 範例4 : 2-(4-甲氧基-6-甲基-2-嘧啶基氧基)-3 -甲氧基-3,6-二苯基-己酸(一個鏡像異構物) 將195毫克(4.4毫莫耳)50%氫化鈉,465毫克(1.5毫莫 耳)2-羥基-3-甲氧基-3,6-二苯己酸及291毫克(1·5毫莫耳) 的3,4-二甲基-2-甲基砜嘧啶混合於20毫升的DMF中,並在 Α溫下攪拌2小時。將反應混合物加至1 〇 〇毫升冰冷的水 中,以檸檬酸酸化之,並以乙醚萃取。用硫酸鎂乾燥有機 相,蒸發掉溶劑。利用MPLC純化殘餘物(環己烷/乙酸乙 酯爲濃度梯度),如此可分離103毫克的一個鏡像異構物。 1H-NMR (200 MHz? CDC13): 7.1-7.5 ppm (10 H5 m)? 6.2 (1 Η, s),5.6 (1 H,s),3·8 (3 H,s),3·3 (3 H,s),2.5-2.8 (3 H,m), 2.3 (3 H,s),2.0 (1 H,m),1.5-1.8 (2 H,m)。 ESI MS: M+-436 範例5 : 2,3-環氧基-3-苯基-6_(3,4-甲氧基苯基)己酸、甲酯(鏡像異構 物的混合物) 將12.6克(44毫莫耳)的1 -苯基-4-(3,4-二甲氧基)苯基-1- -22- 本紙張尺度適用中-國家摞蟑(('NS ) Λ4ϋ ( 210X 297公ϋ ' ' -- (請先閱讀背面之注意事喷再填寫本頁) 訂 546295 A7 B7 五、發明説明(20 丁酮[sic]與8.3克氯乙酸甲酯一起溶解於5〇毫升的DMF 中,1:溫下,將3.7克50%氫化鈉懸浮液分批在上小時内加 入其中。1·5小時後先驅物的反應完全,將反應溶液加至 3 〇 0耄升冰水中,以檸檬酸酸化水層,並以乙醚萃取數 次,將有機相分開,清洗,並以硫酸鎂乾燥◦蒸發溶劑 後’可分離1 3克的油狀物,其再立刻進一步反應。 範例6 : 2-¾基·3-(2-(3,4-二甲氧基苯基)乙氧基)_3_苯基 二甲氧基苯基)己酸甲酯 擾拌内含3.6克(1〇毫莫耳)2,3-環氧基-3-苯基-6-(3,4-甲氧 基苯基)己酸甲酯,1.8克(10毫莫耳)2-(3,4-二甲氧基)乙醇 及對-甲苯磺酸之5 〇毫升二氯甲烷混合物1小時,期間在 冰中冷部。將反應溶液加至飽和的碳酸氫鈉溶液中,將有 機相分開並以硫酸鎂乾燥。蒸發掉溶劑,利用MPLC純化 所得的4·7克於物(梯度:環己烷/乙酸乙酯),如此可分離 750毫克鏡像異構物的混合物。 範例7 : 二-羥基^-^-㈠^-二甲氧基苯基^乙氧基卜^苯基…气夂心二 甲氧基苯基)己酸 U 準 局 j 消 合 fi ϋ 印 將2.1亳升的1Ν氫氧化鈉溶液加至内含750毫克(1.4毫莫 耳)的2 -經基-3-(2-(3,4-二甲氧基苯基)乙氧基)-3-苯基-6-(3,4-二甲氧基苯基)己酸甲酯之4_2亳升的二氧烷溶液中, 並在室溫下攪拌混合物1 6小時。將丨〇〇毫升的水加至混合 物中,而後用乙醚萃取。接著用氫氯酸中和,用乙醚萃取 23- 本紙張尺度削:;(⑽((、NS ) Λ4規格(fy 546295 A7 B7 21 五、發明説明 水相,用硫酸鎂乾燥乙醚相,蒸發掉溶劑,如此可分離 62〇毫克淖狀物,並立刻進一步利用。 範例8 : 2-(4,6-二甲基-2-嘧啶基氧基)-3-(2_(3,‘二甲氧基苯基)乙 氧基)-3-苯基-6-(3,4-二甲氧基苯基)己酸 知164¾克(3.42¾莫耳)的氫化鋼,6〇〇毫克(1.14毫莫耳) 的2_羥基_3-(2-(3,4_二甲氧基苯基)乙氧基)_3_苯基_6_(3,4_ 二甲氧基苯基)己酸及223毫克(1.2毫莫耳)3,4-二甲基-2-甲 基颯嘧啶[sic]混合於1〇毫升的dmF中,並在室溫下攪拌6 小時,將反應混合物加至1 〇〇亳升的冰水中,以檸檬酸酸 化,並以乙醚萃取,利用硫酸鎂乾燥有機相,蒸發掉溶 劑。利用閃火層析法純化殘餘物(環己烷/乙酸乙酯梯度) 後可分離11 5毫克一種結晶的鏡像異構物。 鏡像異構物I : 熔點:93-96°C ESI MS: M+=630 範例9 : 2_(4,6-二甲基-2-嘧啶基氧基)-3-(3,4-二甲氧基芊基氧基)-3_ 苯基_6_(3,4-二甲氧基苯基)己酸 鏡像異構物I : 熔點:130- 133°C ESI MS: M+-616 範例1 0 : 2-(4,6-二甲基-2-嘧啶基氧基)-3-(4-甲氧基苯氧基)_3_苯基_ -24- 本紙張尺度適州中國國家標碑(rNS ) Μ規格(210X297公釐) 546295 ii 卑 局 消 1V 合 印 A7 Β7 五、發明説明(24 ) 範例1 7 : 2-(4-甲氧基-6-甲基-2-嘧啶基氧基)-3-(3,4-二甲氧基芊基-氧基)-3,6-二苯基己酸 鏡像異構物I : 1H-NMR (200 MHz,CDC13): 7.1-7.5 ppm (10 H,m),6.9 (3 H, m),6·25 (1 H,s),5·75 (1 H,s),4·45 (1 H,d),4·35 (1 H,d), 3.9(3H,s),3.85(6H,s),2.4-2.7(3H,m),2.3(6H,s),2.0-2.2 (1 H,m),1.7-1.9 (2 H,m)。 ESI MS: M+ = 572 範例1 8 : 2-(4-甲氧基-6-甲基基氧基)-3-(2-(2 -硫冬基-乙乳 基)-3,6-二苯基己酸 3 :1鏡像異構物混合物BSA's ice-cold tris-HCl, pH 7.4 was used to clean the filter. The radioactivity collected on the filter was determined using a Picard 22000 CA Liquid® scintillation counter. Test of in vivo E T antagonists 250-300 g of Sd male rats were anesthetized with ambobidine, artificial ventilation was used to cut off the vagus nerve and remove the pulp, and a catheter was inserted into the carotid artery and jugular vein. In the animals of the control group, 1 microgram / kg of ET1 'was administered intravenously to increase blood pressure for a long period of time. 30 minutes before cast ET1, the test compound was injected by intravenous injection. -19- This paper is ϋι 则, _: 彳 _ (-— ---- --------- 衣衣 —丨 f Please read the back, 5 '> 1, you can fill in this page} D 546295 A7 B7 V. Description of the invention (17 to the test animal body (1 ha g / kg), for the determination of ET_ antagonist The results of blood pressure changes in experimental animals were compared with those of control animals. Oral tests with mixed ETA and ETB antagonists will weigh 250-300 grams of normal blood pressure male rats (Sreek Doyle, Clip) The test substance is administered orally. After 80 minutes, the animal is anesthetized with amine vinegar and the catheter is inserted into the carotid artery (measurement of blood pressure) and jugular vein (administrated with endothelin / endothelin 1). After the period, large endothelin (20 μg / kg, 0.5 ml / kg administered volume) or ET1 (0.3 μg / kg, cast volume 0.5 * liter / kg) was administered intravenously to continuously record blood pressure and heartbeat For 30 minutes, the area under the curve (AUC) was used as a significant change in blood pressure and a long-term change. The AUC obtained from the animals and Auc obtained from the animals in the control group were tested to determine the antagonistic effect of these test substances. The traditional method can be administered orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally). The compound of the invention can also be administered by steam or spray through the nasopharynx. The dosage depends on the age, symptoms and weight of the patient and the way of administration. Usually, when administered orally, the day of the active ingredient The dose is approximately ⑼mg / kg body weight, but not 0. 〇 亳 克 / kg body weight when not administered parenterally. Digestion 11 The novel compounds of the present invention can be used in traditional solid or liquid forms, such as uncoated or (Film) Coated tablets, capsules, powders, granules, formulations, solutions, soft #, emulsions or sprays, all of which can be prepared by conventional methods, and the active ingredients can be processed with traditional pharmaceutical adjuvants according to the purpose This paper is suitable for China National Standards ((, NS) -20- Λ4 Regulations (210X 297 mm) 546295 A7 B7 V. Description of the Invention (18) Principles, such as tablet bonding agent, fill Agents, preservatives, tablet dispersants, rhenium tinctures, plasticizers, humectants, dispersants, emulsifiers, solvents, slow-release agents, antioxidants and / or propellants (see 洒. Sack et al. .: Pharmaceutical technology 'Tai Mi-Fan Le' Steger, 19 9 1). The dosage form obtained by this method contains 0.1 to 90% by weight of the active ingredient. Synthesis example 1: 2,3-¾ Oxy-3,6-phenylhexanoic acid methyl ester 14.3 g (31 1 mole) of 50% hydrogenated steel was added in 8 hours in portions containing 4 g (17.8 mmol) 1. Cardiodiphenyl-1-butanone and 2.7 ml (31 mmol) of methyl chloroacetate in 60 ml of THF. After the ketone had completely reacted, the reaction mixture was added to ice-cold water and extracted with ethyl acetate. The organic layer was dried with magnesium sulfate, and after the solvent was evaporated, 55 g of a further reacted oil was obtained. Example 2: Formyl 2-methoxy-3-methoxy-3,6-diphenylhexanoate 2 g (6.75 ¾ mole) of 2,3-epoxy-3,6-diphenyl After adding 0.5 ml of methanol to ethyl hexanoate, it was added to 20 ml of dichloromethane, and 5 drops of boron trifluoride etherate were added. After 2 hours, the mixture was concentrated, and the residue was purified by MPLC (cyclohexane / ethyl acetate as a solution gradient). Thus, the first non-mirromeric isomer was 53 mg, and the second specular isomer 7 2 was obtained. 0 g and the mixture was separated into 800 mg. Example 3: 2-¾yl-3-methoxy-3,6-diphenylhexanoic acid (a mirror image isomer, stereo-21-the paper standard ί 州-¾ house standard 绛 (('NS) A4 ^ i77T〇x 297 ^ f) ----- ---------- (Read the back t note before filling in this page) Order 丨 · 546295 Α7 Β7 V. Description of the invention ( 19) A chemical unknown) Dissolve the second mirror image isomer (720 mg, 2.2 μmol) in 9 ml of dioxolane, and add 4.5 ml of a 1N sodium hydroxide solution, and stir the mixture for 16 hours. Then water was added and extracted with ether. The aqueous layer was acidified with citric acid and extracted with ether. The organic layer was dried over magnesium sulfate, and the solvent was evaporated, so that 9 3 6 g of oil was separated, and further reaction was performed immediately. Example 4: 2- (4-methoxy-6-methyl-2-pyrimidinyloxy) -3 -methoxy-3,6-diphenyl-hexanoic acid (a mirror image isomer) will be 195 Mg (4.4 mmol) 50% sodium hydride, 465 mg (1.5 mmol) 2-hydroxy-3-methoxy-3,6-diphenylhexanoic acid and 291 mg (1.5 mmol) 3,4-Dimethyl-2-methylsulfone pyrimidine was mixed in 20 ml of DMF and stirred at A for 2 hours. The reaction mixture was added to 1000 ml of ice-cold water, acidified with citric acid, and extracted with ether. The organic phase was dried over magnesium sulfate and the solvent was evaporated. Purification of the residue using MPLC (cyclohexane / ethyl acetate as a concentration gradient) allowed 103 mg of a mirror image isomer to be separated. 1H-NMR (200 MHz? CDC13): 7.1-7.5 ppm (10 H5 m)? 6.2 (1 Η, s), 5.6 (1 H, s), 3 · 8 (3 H, s), 3 · 3 ( 3 H, s), 2.5-2.8 (3 H, m), 2.3 (3 H, s), 2.0 (1 H, m), 1.5-1.8 (2 H, m). ESI MS: M + -436 Example 5: 2,3-Epoxy-3-phenyl-6- (3,4-methoxyphenyl) hexanoic acid, methyl ester (a mixture of mirror isomers) (44 millimolar) 1-phenyl-4- (3,4-dimethoxy) phenyl-1- -22- This paper is applicable to the national-national cockroach (('NS) Λ4ϋ (210X 297 Ϋ '-(Please read the precautions on the back before filling this page) Order 546295 A7 B7 V. Description of the invention (20 Butanone [sic] is dissolved in 50 ml of DMF with 8.3 g of methyl chloroacetate At 1: temperature, 3.7 g of 50% sodium hydride suspension was added to it in batches within the last hour. The reaction of the precursor was completed after 1.5 hours. The reaction solution was added to 3,000 liters of ice water to Citric acid acidified the aqueous layer and extracted several times with diethyl ether. The organic phase was separated, washed, and dried over magnesium sulfate. After evaporation of the solvent, 13 grams of oil could be separated, and it was immediately reacted further. Example 6: 2 -¾yl · 3- (2- (3,4-dimethoxyphenyl) ethoxy) _3-phenyldimethoxyphenyl) hexanoic acid methyl ester stirrer contains 3.6 g (10 mmol) Mol) 2,3-epoxy-3-phenyl-6- (3,4-methoxyphenyl) hexanoate Ester, 1.8 g (10 mmol) of 2- (3,4-dimethoxy) ethanol and 50 ml of methylene chloride mixture of p-toluenesulfonic acid for 1 hour, during which time the part was cooled in ice. The reaction solution was Add to a saturated sodium bicarbonate solution, separate the organic phase and dry over magnesium sulfate. Evaporate off the solvent, and use MPLC to purify 4 · 7 g of the obtained substance (gradient: cyclohexane / ethyl acetate). 750 mg of a mixture of mirror isomers. Example 7: Di-hydroxy ^-^-㈠ ^ -dimethoxyphenyl ^ ethoxyb ^ phenyl ... Quasi-stationary j-combination fi ϋ imprint 2.1 liters of 1N sodium hydroxide solution was added to 750 mg (1.4 millimoles) of 2-acyl-3- (2- (3,4-dimethoxy) Phenyl) ethoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoate in 4_2 liters of dioxane solution, and the mixture was stirred at room temperature 1 6 hours. Add 100 ml of water to the mixture, and then extract with ether. Then neutralize with hydrochloric acid and extract with ether. 23-Paper scale: (; ((, NS) Λ4 size (fy 546295 A7 B7 21 V. Invention Clear the water phase, dry the ether phase with magnesium sulfate, and evaporate off the solvent. In this way, 62 mg of amidine can be separated and used immediately. Example 8: 2- (4,6-dimethyl-2-pyrimidinyloxy) ) -3- (2- (3, 'dimethoxyphenyl) ethoxy) -3-phenyl-6- (3,4-dimethoxyphenyl) hexanoic acid Ear) hydrogenated steel, 600 mg (1.14 mmol) of 2-hydroxy_3- (2- (3,4-dimethoxyphenyl) ethoxy) _3_phenyl_6_ (3 , 4-dimethoxyphenyl) hexanoic acid and 223 mg (1.2 mmol) of 3,4-dimethyl-2-methylpyrimidine [sic] were mixed in 10 ml of dmF and kept at room temperature After stirring for 6 hours, the reaction mixture was added to 100 liters of ice water, acidified with citric acid, and extracted with ether. The organic phase was dried over magnesium sulfate, and the solvent was evaporated. After purification of the residue by flash chromatography (cyclohexane / ethyl acetate gradient), 115 mg of a crystalline mirror isomer was isolated. Mirror isomer I: Melting point: 93-96 ° C ESI MS: M + = 630 Example 9: 2_ (4,6-dimethyl-2-pyrimidinyloxy) -3- (3,4-dimethoxy Methylfluorenyloxy) -3_phenyl_6_ (3,4-dimethoxyphenyl) hexanoic acid mirror isomer I: Melting point: 130- 133 ° C ESI MS: M + -616 Example 1 0: 2 -(4,6-dimethyl-2-pyrimidinyloxy) -3- (4-methoxyphenoxy) _3_phenyl_ -24- This paper is the China National Monument of Shizhou (rNS) Μ specifications (210X297 mm) 546295 ii Hummel 1V joint printing A7 B7 V. Description of the invention (24) Example 17 7: 2- (4-methoxy-6-methyl-2-pyrimidinyloxy)- 3- (3,4-dimethoxyfluorenyl-oxy) -3,6-diphenylhexanoic acid mirror isomer I: 1H-NMR (200 MHz, CDC13): 7.1-7.5 ppm (10 H , M), 6.9 (3 H, m), 6.25 (1 H, s), 5.75 (1 H, s), 4.45 (1 H, d), 4.35 (1 H, d ), 3.9 (3H, s), 3.85 (6H, s), 2.4-2.7 (3H, m), 2.3 (6H, s), 2.0-2.2 (1 H, m), 1.7-1.9 (2 H, m ). ESI MS: M + = 572 Example 1 8: 2- (4-methoxy-6-methylyloxy) -3- (2- (2-thiotetyl-ethoxylate) -3,6-di Phenylhexanoic acid 3: 1 mirror image isomer mixture
分解:85°C ESI MS: M+ = 532 範例1 9 : 2-(4,6-二甲基-2-嘧啶基氧基)-3-(2-(3,4,5-三甲氧基苯基)-乙氧基)-3,6-二苯基己酸 鏡像異構物I : 1H-NMR (200 MHz? CDC13): 7.0-7.3 ppm (10 H? m)? 6.65 (1 H,m),6·4 (2 H,s),5·75 (1 H,s),3·9 (3 H,s),3·85 (6 H,s), 3.5-3.7 (2 H,m),2.8-2.9 (2 H,m),2.3-2.5 (3 H,m),2·3 (6 H, s),2.0-2.3 (1 H,m),1.5-1.7 (2 H,m)。 ESI MS: M+二600 -27- 本紙張尺度適用中國國家標埤(ms ) Λ4規招(210X 297公釐) (讀先閱讀背面之注意事f再填寫本頁)Decomposition: 85 ° C ESI MS: M + = 532 Example 19: 2- (4,6-dimethyl-2-pyrimidinyloxy) -3- (2- (3,4,5-trimethoxybenzene Group) -ethoxy) -3,6-diphenylhexanoic acid isomer I: 1H-NMR (200 MHz? CDC13): 7.0-7.3 ppm (10 H? M)? 6.65 (1 H, m ), 6.4 (2 H, s), 5.75 (1 H, s), 3. 9 (3 H, s), 3.85 (6 H, s), 3.5-3.7 (2 H, m ), 2.8-2.9 (2 H, m), 2.3-2.5 (3 H, m), 2.3 (6 H, s), 2.0-2.3 (1 H, m), 1.5-1.7 (2 H, m ). ESI MS: M + II 600 -27- This paper size applies to the Chinese national standard (ms) Λ4 regulations (210X 297 mm) (read the precautions on the back first and then fill out this page)
、1T J·. 546295 A7 __ 五、發明説明(25 ) 範例20 : 2-(4-甲氧基-6-甲基-2-嘧啶基氧基)-3-(2-(3,4,5-三甲氧基-苯基)乙氧基)-3,6-二苯基己酸 鏡像異構物I ·· 熔點:1 53- 1 55°C ESI MS: M+ = 616 範例2 1 : 2-(4,6-二甲基-2-嘧啶基氧基)-3-(2-(4-羥基-3-甲氧基-苯基) 乙氧基)-3,6-二苯基己酸 鏡像異構物I : 1H-NMR (200 MHz,CDC13): 7.0-7.4 ppm (10 H,m),6.9 (1 H, dm),6.6-6.75 (3 H,m),5.8 (1 H,s),5.5 (OH),3.9 (3 H,s), 3.85 (3 H,s),3.5-3.7 (2 H,m),2.8-2.9 (2 H,tr),2.3-2.5 (3 H, m),2.3 (6 H,s),2.0-2.3 (1 H,m),1.5-1.7 (2 H,m)。 ESI MS: M+二556 鏡像異構物II : ESI MS: M+ = 556 範例22 : A 屮 -贞 準 消 f: 合 Vi ϋ 印 (讀先閱讀背面、t注意事t再填寫本頁) 2-(4 -甲氧基-6 -甲基-2 -p密淀基氧基)-3-(2-(4-¾基-4 -甲乳基 苯基)乙氧基)-3,6-二苯基己酸 鏡像異構物I : 熔點:1 54-157°C ' ESI MS: M +二572 範例23 : -28- 本紙張尺度適川中國國家標碑(CNS ) Λ4規桔(210X 297公釐 546295 A7 Β7 五 '發明説明( 26 yf1, 部 十 卑 局 j 消 f: 合 fi 印 $) 2-(4,6-二甲基-2-喊淀基氧基)-3-(4-叛基爷基氧基)-3,6-二苯 基己酸 鏡像異構物I ·· 1H-NMR (200 MHz, CDC13): 8.0 (2 H, d), 7.1-7.5 ppm (12 H5 m),6.8(lH,m),6.8(lH,s),4.6(lH,d),4.5(lH,d),2.5-2.7 (3 H,m),2.3 (6 H,s),2.1-2.25 (1 H,m),1.5-1.7 (2 H, m)。 ESI MS: M+ = 540 鏡像異構物Π ·· 熔點:160-167°C ESI MS: M+ = 540 範例2 4 : 2-(4-甲氧基—6-甲基-2-嘧啶基氧基)-3-(4-羧基苄基氧基)_ 3.6- 二苯基己酸 鏡像異構物I : 1H-NMR (200 MHz? CDC13): 8.0 (2 H? d)? 7.1-7.5 ppm (12 H5 m),6.2 (1 H,m),5.6 (1 H,s),4.55 (1 H,d),4.45 (1 H,d), 3·9 (3 H,s),2.5-2.7 (3 H,m),2.3 (3 H,s),2.1-2.25 (1 H,m), 1.6- 1.8 (2 H,m)。 ESI MS: M+二556 鏡像異構物II : ESI MS: M+-556 範例25 : 2-(4,6-二甲基-2-嘧啶基氧基)-3-(4-甲氧基苯氧基)-3,6-二苯 本紙張尺度適州中國國家標磾((、NS ) Λ4規格(210X297公釐) (諳先閱讀背面之注意事項再填寫本頁}1T J ·. 546295 A7 __ V. Description of the Invention (25) Example 20: 2- (4-methoxy-6-methyl-2-pyrimidinyloxy) -3- (2- (3,4, 5-trimethoxy-phenyl) ethoxy) -3,6-diphenylhexanoic acid isomer I · · Melting point: 1 53-1 55 ° C ESI MS: M + = 616 Example 2 1: 2 -(4,6-dimethyl-2-pyrimidinyloxy) -3- (2- (4-hydroxy-3-methoxy-phenyl) ethoxy) -3,6-diphenylhexyl Acid mirror image isomer I: 1H-NMR (200 MHz, CDC13): 7.0-7.4 ppm (10 H, m), 6.9 (1 H, dm), 6.6-6.75 (3 H, m), 5.8 (1 H , S), 5.5 (OH), 3.9 (3 H, s), 3.85 (3 H, s), 3.5-3.7 (2 H, m), 2.8-2.9 (2 H, tr), 2.3-2.5 (3 H, m), 2.3 (6 H, s), 2.0-2.3 (1 H, m), 1.5-1.7 (2 H, m). ESI MS: M + two 556 mirror image isomers II: ESI MS: M + = 556 Example 22: A 屮-贞 准 消 f: Compatible with Vi ϋ (read the back, read the note, and then fill out this page) 2- (4-methoxy-6-methyl-2 -p denselyloxy) -3- (2- (4-¾yl-4 -methyllactylphenyl) ethoxy) -3,6- Diphenylhexanoic acid image isomer I: Melting point: 1 54-157 ° C 'ESI MS: M + two 572 Example 23: -28- This paper is suitable for Sichuan National National Monument (CNS) Λ4 standard orange (210X 297 mm 546295 A7 B7 Five 'invention description (26 yf1, ministry of ten countries j elimination f: total fi printed $) 2- (4,6-dimethyl-2-ylamino) -3- ( 4-Syridyloxy) -3,6-diphenylhexanoic acid image isomer 1 · 1H-NMR (200 MHz, CDC13): 8.0 (2 H, d), 7.1-7.5 ppm (12 H5 m), 6.8 (lH, m), 6.8 (lH, s), 4.6 (lH, d), 4.5 (lH, d), 2.5-2.7 (3 H, m), 2.3 (6 H, s), 2.1-2.25 (1 H, m), 1.5-1.7 (2 H, m). ESI MS: M + = 540 Mirror isomer Π ·· Melting point: 160-167 ° C ESI MS: M + = 540 Example 2 4: 2- (4-methoxy-6-methyl-2-pyrimidinyloxy) -3- (4-carboxybenzyloxy) _ 3.6- diphenylhexanoic acid mirror Isomer 1: 1H-NMR (200 MHz? CDC13): 8.0 (2 H? D)? 7.1-7.5 ppm (12 H5 m), 6.2 (1 H, m), 5.6 (1 H, s), 4.55 (1 H, d), 4.45 (1 H, d), 3.9 (3 H, s), 2.5-2.7 (3 H, m), 2.3 (3 H, s), 2.1-2.25 (1 H, m), 1.6-1.8 (2 H, m). ESI MS: M + di556 isomers II: ESI MS: M + -556 Example 25: 2- (4,6-dimethyl-2-pyrimidinyloxy) Base) -3- (4-methoxyphenoxy) -3,6-diphenyl paper size Shizhou Chinese national standard 磾 ((, NS) Λ4 size (210X297 mm) (谙 Please read the note on the back first Matters refill this page}
、1T 1#. 546295 A7 B7 五、發明説明(28 ) 4.2 (1 H, m), 3.85 (3 H? s), 3.8 (3 H? s)? 3.75 (3 H? s)? 3.4 (1 H,m),2·4·2·7 (3 H,m),2.3 (6 H,s),2.0-2.1 (1 H,m),1_5_ 1.7 (2 H, m)。 ESI MS: M + = 612 表1中所列的化合物可用相似的方法製備之或用一般所 述之方法製備之。 (請先閱讀背面之注意事項再填寫本頁) Φ今 、11 本紙張尺度適州中國國家標缚(rNS ) Λ4規格(210X 297公釐) 546295 A7 B7 五、發明説明(29) HH 1 Η-* ΗΗ 1 Η-* Ο h-H 1 HH 1 00 HH 1 <1 H-H 1 Os H-H i Ux HH 1 HH 1 U) HH 1 to 1-Η 瞳 2 :1 Ο ο o o o o o n o o Ο Ο ο o O o o o O o o ο ο ο o O o o o O o o ο X X X K K sc K E X X ffi 舛 辦 >ΐ Lh 1 1 4^ 1 1 -a Ch -9 -¾ p p 駟 ο O o o o o o 〇 in ο ο N ο o o o o o o o 〇 ο ο W X to K to ffi to X N) ffi hj X to ffi K) X to ffi K) κ Ν) X Κ) ο o o o o o o o o ο ο W NJ ffi to ffi hJ ffi K) ffi ro ffi K) ffi to K K) ffi K) κ Κ) κ to ο o o o o o o o o ο ο κ κ> X to X K) X to K to X to ffi K) E K) K K) X Κ) κ to 1 1 1 1 -¾ o KH -9 -a NJ LO 1 -¾ 祖 1 1 /-"N o -¾ U) o ffi to o K bo K NJ r\ V J X NJ 〇 1 o K o K 1 1 1 o ffi to o o Ο ίυ η Ε 1 z 2 1 1 1 z 2 2 X 1 Z 1 1 1 2 2 Ζ κ> κ ^ 1 1 H-^ to 1 1 1 I I ffi a * * * r*f -32-、 1T 1 #. 546295 A7 B7 V. Description of the invention (28) 4.2 (1 H, m), 3.85 (3 H? S), 3.8 (3 H? S)? 3.75 (3 H? S)? 3.4 (1 H, m), 2.4 · 2 · 7 (3 H, m), 2.3 (6 H, s), 2.0-2.1 (1 H, m), 1_5_ 1.7 (2 H, m). ESI MS: M + = 612 The compounds listed in Table 1 can be prepared by similar methods or by methods generally described. (Please read the precautions on the back before filling out this page) Φ Today and 11 paper sizes Shizhou China National Standards (rNS) Λ4 size (210X 297 mm) 546295 A7 B7 V. Description of the invention (29) HH 1 Η -* ΗΗ 1 Η- * 〇 hH 1 HH 1 00 HH 1 < 1 HH 1 Os HH i Ux HH 1 HH 1 U) HH 1 to 1-Η Pupil 2: 1 Ο ο ooooonoo Ο ο o O ooo O oo ο ο ο o O ooo O oo ο XXXKK sc KEXX ffi Office > ΐ Lh 1 1 4 ^ 1 1 -a Ch -9 -¾ pp 驷 ο O ooooo 〇in ο ο N ο ooooooo ο ο WX to K to ffi to XN) ffi hj X to ffi K) X to ffi K) κ Ν) X Κ) ο oooooooo ο ο W NJ ffi to ffi hJ ffi K) ffi ro ffi K) ffi to KK) ffi K) κ Κ) κ to ο oooooooo ο κ κ > X to XK) X to K to X to ffi K) EK) KK) X Κ) κ to 1 1 1 1 -¾ o KH -9 -a NJ LO 1 -¾ Zu 1 1 /-" N o -¾ U) o ffi to o K bo K NJ r \ VJX NJ 〇1 o K o K 1 1 1 o ffi to oo ίυ η Ε 1 z 2 1 1 1 z 2 2 X 1 Z 1 1 1 2 2 Z κ > κ ^ 1 1 H- ^ to 1 1 1 II ffi a * * * r * f -32-
Rcn cffi ——Ο ——Hert (讀先閲讀背面之注意事項再填寫本頁) to匁 I iRcn Y—nKIo_ij I X=Rcn cffi ——〇 ——Hert (Read the precautions on the back before filling this page) to 匁 I iRcn Y—nKIo_ij I X =
ROJ /5:ROJ / 5:
Rto 本紙張尺度適用+國國家標缚(CNS ) Λ4規抬(210X 297公釐) 546295 A7 _______________B7 五、發明説明(3〇 ) HH 1 Ι-Η 1 1—( 1 ΗΗ 1 ΗΗ 1 ΚΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 1 t-H 1 Η—( 1 t—< 1 1 乂 K) 〇〇 Κ) <! Κ) Κ) to 仁 Κ) Κ) Κ) to Η—ι to Ο Η—^ οο 5: 1—* Η—k 払 H—^ UJ H—1 to 一5 η Ο η ο η η ο Ο η Ο ο Ο η O Ο O o 〇 ο Ο ο ο ο ο ο Ο ο Ο ο ο o ο O 〇 〇 ο Ο ο ο ο ο ο ο ο ο ο ο o ο o o X κ κ κ κ X κ Ε κ κ κ κ κ ffi κ K 舛 舛 树 ψτ Lh 1 I I 1 1 I I I 4^ I 4^ I ί^ 1 Lk) Lk) L*J Lk) 1 4^ 1 On -¾ -a ρ 声t 声τ ρ -Ρ^ 1 -Ρ^ 1 I 1 -9 -¾ 1 1 1 I I 1 k l· 1 l· 1 l· 1 l· 1 p\ ,\j ,. .Vi , 1 1 pi p 1 1 1 k , 〇 Ο Ο Ο Ο ο ο Ο Ο ο ο ο Ο Ο ο 〇 o N 〇 ο ο η η ο ο ο Ο ο ο Ο Ο η η n n dd K) X Κ) Κ) Κ Κί Κ Κ) κ KJ κ Κ) κ to κ to κ Κ) κ to ffi Κ) ffi Κ) κ to κ Κ) ro K to 〇 η η η ο ο η η Ο Ο ο ο ο η Ο n n ffi to κ to X Κ) κ Κ) ffi Κ) κ to κ to κ to X to ffi Κ) ffi Μ ffi Μ ffi Κ) X Κ) κ Κ) ffi to a to η ο ο ο ο ο ο ο ο ο ο η ο η Ο o o X to κ Κ) Ε κ Κ) κ Κ) κ Κ) X NJ κ to κ KJ κ Μ Ε to κ Κ) ffi κ> Ε to ffi NJ Ki K> 1 1 -θ I 1 -Θ 1 K) ρ ρ ρ ρ ρ p 1 ο r-N 1 -¾ I 1 ο 1 -a ,^s n κ Κ) Ο Ε , κ NJ Γ\ ffi Κ) Γ^\ Π Ϊ3 X to V J X κ> ο to Ο κ NJ V J Κ to η \ J Κ to η K) o ffi ho { J K ro o 1 to ο Ο sw^ 1 η κ η κ κ NJ η I 1 Ο κ ο κ. ffi NJ Ο 1 Ο a n ffi o E to o Β Β 2 I 1 ζ 2 2 1 ζ 2 Z X 1 1 Ζ 1 1 2 ζ 1 2 2 Z 2 to 1 1 Η-^ I I I to Η—^ I I I h—k h—^ * I 1 1 B K a> r-t' •衣II (讀先閲讀背面、5-注意事t再填寫本頁) 、11 -33- 本紙張尺度適用中國國家標埤((、NS ) Λ4規格(210X 297公釐) 546295 A7 __ B7 五、發明説明(31 ) Η—1 ! 〇\ 1-45 |ΐ-44 I - 43 1-42 1-41 ΗΗ 1 ο 1-39 ΗΗ 1 LO οο 1-37 Η-Η 1 LO 〇\ HH 1 U) 1-34 1-33 1-30 HH 1 K) \〇 ζ η Ο Ο Ο Ο η ο Ο ο Ο ο o 〇 Ο o n Ο n ο Ο Ο ο Ο ο ο ο Ο Ο ο o o Ο o o ο o ο ο ο ο ο ο ο ο ο ο ο o o ο o o ο o X κ κ κ κ κ Ε X ffi κ X ffi X X K a K 舛 舛 舛 ψτ 1 1 1 1 1 1 LO U) υο U) OJ 1 1 1 1 I 1 σν 〇 ο 〇 -€ -¾ -¾ V 1 V I V 1 V 1 V 1 V 1 -¾ -¾ -a 〇 〇 ο ο 〇 〇 l· l· l· l· l· l· ρ pi pi ρ ffi 1 κ 1 E 1 一 一 | 1 1 ρ p l 1 1 1 I I 十r Ή ο ο 〇 Ο ο ο ο Ο ο Ο o o ο 〇 〇 〇 o Ο Ν ο ο 〇 ο ο ο η Ο η η o o ο η 〇 η o Ο dd X Κ) Ε NJ X to X to X (Ο X Ν) X Κ) κ Κ) ffi κ> ffi Κ) K K) X to X Κ) Κ Κ) K NJ ffi Κ) X (Ό κ to ο η 〇 ο ο ο η η ο ο o o ο 〇 o ο n ο κ Κ) κ κ> ffi to κ Κ) κ Κ) κ Κ) κ Κ) NJ ffi Κ) κ Κ) ffi K) X to κ to X κ> K K) to ffi NJ X to ο Ο ο ο ο ο ο Ο ο ο o n ο ο o η 〇 Ο ffi Κ) a Κ) κ to X Κ) κ to X to X to X Κ) κ ffi Κ) ffi NJ ffi K) κ to ffi K) ffi K) X to X K) to -a 1 1 1 1 1 -¾ -¾ hO ρ ρ p -θ I 1 1 η I 1 ffi η κ n ffi η X Κ) ο K Ki η X η κ o Κ) ο ffi Κ) ο ffi NJ ο ffi η ο ί ο η 1 1 ο ffi o n 1 B n ffi O η NJ Ο a κ κ X NJ Ο ffi tr to η ffi X ζ 乂 1 ζ ζ 1 1 2 I 1 Z ζ X Ζ 2 1 ζ 1 1 I 1 2 ζ κ; I Β fl 1 b〇 ! 1 1 B to 1—k 1 I 8 S Het (讀先閱讀背面之注意事項再填寫本頁)Rto This paper size applies + National Standard Binding (CNS) Λ4 gauge (210X 297 mm) 546295 A7 _______________B7 V. Description of the invention (3〇) HH 1 Ι-Η 1 1— (1 ΗΗ 1 ΗΗ 1 ΚΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 1 tH 1 Η— (1 t— < 1 1 乂 K) 〇〇Κ) <! Κ) Κ) to 仁 Κ) Κ) Κ) to Η—ι to Ο Η— ^ οο 5: 1— * Η—k 払 H— ^ UJ H—1 to a 5 η Ο η ο η η ο Ο η Ο ο Ο η O Ο O o 〇ο ο ο ο ο ο ο ο ο ο ο Ο ο Ο ο ο o ο O 〇〇ο Ο ο ο ο ο ο ο ο ο ο ο ο oo X κ κ κ κ X κ Ε κ κ κ κ κ ffi κ K 舛 舛 τ Lh 1 II 1 1 III 4 ^ I 4 ^ I ί ^ 1 Lk) Lk) L * J Lk) 1 4 ^ 1 On -¾ -a ρ sound t sound τ ρ -ρ ^ 1 -Ρ ^ 1 I 1 -9 -¾ 1 1 1 II 1 kl · 1 l · 1 l · 1 l · 1 p \, \ j,. .Vi, 1 1 pi p 1 1 1 k, 〇〇 Ο Ο Ο ο ο Ο Ο ο ο ο Ο Ο ο o N 〇ο ο η η ο ο ο Ο ο ο Ο Ο η η nn dd K) X Κ) Κ) Κ ΚίΚΚ) κ KJ κ κ) κ to κ to κ κ) κ to ffi κ) ffi κ ) κ to κ Κ) ro K to 〇η η η ο ο η η Ο Ο ο ο ο η Ο nn ffi to κ to X Κ) κ κ) ffi to κ to κ to X to ffi κ) ffi Μ ffi Μ ffi κ) X Κ) κ κ) ffi to a to η ο ο ο ο ο ο ο ο ο ο η ο η Ο oo X to κ Κ) Ε κ Κ) κ κ) κ κ) X NJ κ to κ KJ κ Μ Ε to κ Κ) ffi κ > Ε to ffi NJ Ki K > 1 1 -θ I 1 -Θ 1 K) ρ ρ ρ ρ ρ p 1 ο rN 1 -¾ I 1 ο 1 -a, ^ sn κ Κ) Ο Ε, κ NJ Γ \ ffi Κ) Γ ^ \ Π Ϊ3 X to VJX κ > ο to Ο κ NJ VJ Κ to η \ J Κ to η K) o ffi ho {JK ro o 1 to ο Ο sw ^ 1 η κ η κ κ NJ η I 1 Ο κ ο κ. ffi NJ Ο 1 〇 an ffi o E to o Β Β 2 I 1 ζ 2 2 1 ζ 2 ZX 1 1 Zn 1 1 2 ζ 1 2 2 Z 2 to 1 1 Η- ^ III to Η— ^ III h—kh— ^ * I 1 1 BK a > rt '• clothing II (Read the back page first, 5-note the matter before filling out this page), 11 -33- This paper size applies to the Chinese national standard ((, NS) Λ4 specifications (210X 297 mm) 546295 A7 __ B7 V. Description of the invention (31) Η—1! 〇 \ 1-45 | ΐ-44 I-43 1-42 1-41 ΗΗ 1 ο 1-39 ΗΗ 1 LO οο 1-37 Η-Η 1 LO 〇 \ HH 1 U) 1 -34 1-33 1-30 HH 1 K) \ 〇ζ η Ο Ο Ο Ο η ο Ο ο Ο ο o 〇〇 on Ο n ο Ο Ο ο Ο ο ο ο ο Ο ο oo ο ο ο ο ο ο ο ο ο ο ο ο ο oo ο oo ο o X κ κ κ κ κ Ε X ffi κ X ffi XXK a K 舛 舛 舛 ψτ 1 1 1 1 1 1 LO U) υο U) OJ 1 1 1 1 I 1 σν 〇ο 〇- € -¾ -¾ V 1 VIV 1 V 1 V 1 V 1 -¾ -¾ -a 〇〇ο ο 〇〇l · l · l · l · l · l · ρ pi pi ρ ffi 1 κ 1 E 1 one one | 1 1 ρ pl 1 1 1 II r ο ο ο 〇〇 ο ο ο ο ο Ο oo ο 〇〇〇〇o Ο Ν ο ο ο ο ο ο η Ο η η oo ο η 〇η o Ο dd X Κ) Ε NJ X to X to X (Ο X Ν) X Κ) κ Κ) ffi κ > ffi κ) KK) X to X KK) Κ Κ) K NJ ffi Κ) X (Ό κ to ο η οο ο ο η η ο ο oo ο οo ο n ο κ Κ) κ κ > ffi to κ κ) κ κ) κ κ) κ κ) NJ ffi κ) κ Κ) ffi K) X to κ to X κ > KK) to ffi NJ X to ο Ο ο ο ο ο ο ο ο ο on ο ο o η 〇〇 ffi κ) a Κ) κ to X Κ ) κ to X to X to X Κ) κ ffi κ) ffi NJ ffi K) κ to ffi K) ffi K) X to XK) to -a 1 1 1 1 1 -¾ -¾ hO ρ ρ p -θ I 1 1 η I 1 ffi η κ n ffi η X Κ) ο K Ki η X η κ o Κ) ο ffi KK) ο ffi NJ ο ffi η ο ί ο η 1 1 ο ffi on 1 B n ffi O η NJ 〇 a κ κ X NJ 〇 ffi tr to η ffi X ζ 乂 1 ζ ζ 1 1 2 I 1 Z ζ X ZO 2 1 ζ 1 1 I 1 2 ζ κ; I Β fl 1 b〇! 1 1 B to 1 —K 1 I 8 S Het Complete this page)
、1T f -34- 本紙張尺度適用中國國家標缚((、NS ) Λ4規招(210X 297公釐) 546295 A7 B7 五、發明説明 32 Ψ 4\ 樣 卑 消 f: A ίΐ 印 HH 1 〇\ 〇\ )—Η 祖 〇\ Lh ΗΗ 1 Η—1 1 〇\ ΗΗ 1 ο\ Κ) ΗΗ 1 Ον ΗΗ 1 ΗΗ 1 U\ Η—( 1 LT\ 00 )-Η 1 Lh ΗΗ 1 U\ ►—I 1 Lh Lh ΗΗ 1 Lh ΗΗ 1 Lh LO ΗΗ 1 U\ to ΚΗ 1 LT\ ΗΗ 1 Lh 1—( 么 VO »—Η ▲ 1—Η 1 4^ ζ 〇 ο η ο ο ο Ο ο ο η η η η ο η Ο η Π ο ο 〇 ο ο ο ο ο ο ο Ο ο ο ο ο ο ο ο ο Ο ο ο 〇 ο ο ο ο ο ο ο Ο ο ο ο ο ο ο ο ο ο ο ο X κ κ κ κ κ X ffi Ε κ κ κ X κ κ X κ X 辦 辦 辦 η 辦 舛 辦 ^J\ 1 1 1 I ι U) 1 U) I 1 1 1 1 1 1 1 ι I ι 〇 ο η π η ο Ο Ο ο Ο ο iVUf -¾ iSUf 1 1 1 Ο ο η 〇 ο ο ο ο ο ο ο ο Ο ο Ο ο ο 〇 ο ο ο ο ο ο ο ο ο ο ψτ Mr "Η ο ο ο Κ 1 κ κ κ X κ κ 1 κ 1 κ 1 κ 1 κ 曹 ffi 1 ffi ι κ 1 UJ 1 υο 1 UJ I U) I UJ I U) 1 LO I LO Ή ~^r Ή : -a -0 4 ρ ρ pi ρ -Η 十r Ο Ο ο Ο ο ο ο Ο ο Ο Ο Ο Ο ο Ο ο Ο Ο Ο Ο Ν 〇 η ο ο ο ο ο Ο ο ο Ο ο 〇 η Ο ο η ο ο Ο W X Κ) Ε ro X Κ) κ Κ) κ ro ffi to Κ) ffi Κ) Ε Κ) X Κ) X Κ) Ε Κ) X to X Κ) to X Κ) ffi κ> X to X Κ) X Κ) 〇 η Ο η ο ο ο ο ο Ο η ο Ο Ο Ο ο ο ο ο ο ffi to κ Κ) ffi to κ hj κ to κ NJ Ε Μ ίϋ Κ) X NJ ffi to ffi NJ κ to κ κ> a to ffi Κ) κ Μ κ ro κ to κ ro ο ο ο ο ο ο Ο Ο ο η ο η η ο ο ο Ο ο ο ο Ε Κ) κ Κ) κ Κ) κ κ> X Κ) κ Κί X Κί Ε κ> ffi ro Ε Κ) ffi ho ro X κ> X Κ) X K) κ ro X κ> X Κ) X ro X ΪΌ -a 1 ο Ητ^ ο 1 -S -€ I -¾ I -a 1 -S -¾ I ι Κ) ρ u> ρ ρ ρ ρ 1 -9 -9 I -¾ -S 1 -a -a 1 -9 -¾ 1 -9 -¾ 1 I 〇 U) ο X Κ) ο κ Ο ο 1 Ο Ο 1 Ο Ο 1 η ο 1 Ο ο Β Ο ο 1 ! ο κ Ε κ ffi ffi κ κ κ Κ κ κ ζ 1 ζ Ζ 1 ζ 1 ζ 1 Ζ ζ 1 ζ 1 1 ζ X Ζ 2 1 ζ 2 1 Ζ ζ 1 乂 ζ 1 乂 ζ 1 Ζ 乂 1 1 乂 1 I I I Κ) I I I I I I I 1 to I—^ 1 κ ο r-^ -35- ** (讀先閱讀背面之注意事項再填寫本頁)、 1T f -34- This paper size is applicable to China National Standards ((, NS) Λ4 Regulations (210X 297 mm) 546295 A7 B7 V. Description of the invention 32 Ψ 4 \ like humble f: A ίΐ 印 HH 1 〇 \ 〇 \) —Η 祖 〇 \ Lh ΗΗ 1 Η—1 1 〇 \ ΗΗ 1 ο \ Κ) ΗΗ 1 Ον ΗΗ 1 ΗΗ 1 U \ Η— (1 LT \ 00) -Η 1 Lh ΗΗ 1 U \ ► —I 1 Lh Lh ΗΗ 1 Lh ΗΗ 1 Lh LO ΗΗ 1 U \ to ΚΗ 1 LT \ ΗΗ 1 Lh 1— (VO »—Η ▲ 1— 1 1 4 ^ ζ ο η ο ο ο ο ο ο η η η η ο η Ο η Π ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο X κ κ κ κ κ X ffi Ε κ κ κ X κ κ X κ X Offices and Offices ^ J \ 1 1 1 I ι U) 1 U) I 1 1 1 1 1 1 1 1 ι I ι 〇 ο η π η ο Ο Ο ο Ο ο iVUf -¾ iSUf 1 1 1 Ο ο η 〇ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ψτ Mr " Η ο ο ο Κ 1 κ κ κ X κ κ 1 κ 1 κ 1 κ 1 κ Cao ffi 1 ffi ι κ 1 UJ 1 υο 1 UJ IU) I UJ IU) 1 LO I LO Ή ~ ^ r Ή: -a -0 4 ρ ρ pi ρ-十 十 r Ο Ο ο Ο ο ο ο Ο ο Ο Ο Ο Ο ο Ο ο Ο Ο Ο Ο Ν 〇η ο ο ο ο ο ο ο ο ο Ο ο 〇η Ο ο η ο ο ο Ο WX Κ) Ε ro X Κ) κ Κ) κ ro ffi to Κ) ffi κ) Ε Κ) X Κ) X Κ) Ε Κ) X to X Κ) to X Κ) ffi κ > X to X Κ) X Κ) 〇η 〇 η ο ο ο ο ο ο ο ο ο ο ο ο ο ο ffi to κ κ) ffi to κ hj κ to κ NJ Ε Μ ίϋ Κ) X NJ ffi to ffi NJ κ to κ κ > a to ffi κ) κ Μ κ ro κ to κ ro ο ο ο ο ο Ο Ο ο η ο η η ο ο ο ο ο ο ο Ε Κ) κ Κ) κ κ) κ κ > X Κ) κ Κί X Κί Ε κ > ffi ro Ε Κ) ffi ho ro X κ > X Κ) XK) κ ro X κ > X Κ) X ro X ΪΌ -a 1 ο Ητ ^ ο 1 -S-€ I -¾ I -a 1 -S- ¾ I ι Κ) ρ u > ρ ρ ρ ρ 1 -9 -9 I -¾ -S 1 -a -a 1 -9 -¾ 1 -9 -¾ 1 I 〇U) ο X Κ) ο κ Ο ο 1 Ο Ο 1 Ο Ο 1 η ο 1 Ο ο Β Ο ο 1! Ο κ Ε κ ffi ffi κ κ κ κ κ κ ζ ζ 1 ζ ZE 1 ζ 1 ζ 1 ζ ζ 1 ζ 1 1 ζ X ZE 2 1 ζ 2 1 ζ ζ 1 乂 ζ 1 乂 ζ 1 ZZ乂 1 1 乂 1 III Κ) IIIIIII 1 to I— ^ 1 κ ο r- ^ -35- ** (Read the precautions on the back before filling in this page)
•衣------1T ♦ 本纸張尺度1¾ ;种關緖_ ( (、NiS ) 規格(210)097公釐) * — - - - -- -1 1 546295 A7 B7 五、發明説明(33 ) HH 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 H-H 1 h-H 1 1—Η 1 H-H 1 HH 1 1 HH 1 HH 1 ΚΗ 1 ΗΗ 1 h-H I ΗΗ 1 ΗΗ 1 Ζ 〇〇 00 U) 00 Κ) 00 00 •ο to Ο 1—^ -0 Ο 〇Ν Ό σ\ 00 σ\ 〇 η Ο ο ο o o Ο o o o o o Ο ο Ο ο ο 〇 ο Ο Ο Ο 〇 o ο o o o o 〇 Ο ο Ο Ο ο 〇 ο Ο Ο ο o o ο o o o o o Ο ο Ο ο ο κ Ε X X K K κ K K K a κ κ a ffi κ 舛 舛 辦 辦 Ul to Κ) Κ) Κ) Κ) 1 K) 1 bO 1 to 1 K) i K) l to 1 b〇 1 Κ) 1 1 1 1 1 I ζ^\ /^s : ψτ Ο ο ο η ο ο Ο ο ο 1 -¾ 1 1 1 -S 1 -¾ 1 1 -s 1 1 1 I 1 ρ p -ρ^ (> 4^ X I κ 1 1 I 1 1 LO ^r U) 1 Ns«^ 1 1 1 1 1 1 1 1 1 Ο o ο ο ο 唞 〇 Ο Ο ο Ο o Ο o 〇 〇 〇 〇 Ο Ο Ο Ο Ο Ο Ν η Ο η ο η o η n o o n o Ο η η Ο η Ο ω (Nj κ hJ X to ffi κ> κ Κ) K to o X to ffi K> ffi hO ffi to to ffi Ki X to κ Κ) κ to ο κ NJ κ to κ to η ο Ο ο ο η o 〇 o o o Ο ο Ο ο Ο X to X to X to κ Κ) Κ Κ) ffi K) to ffi NJ X K) K to ffi to X K) κ to ffi Κ) Ε to Ε Ν) Ε Κ) X NJ ο ο η ο η n η n n n o o ο ο ο Ο ο Ο ffi Κ) κ Κ) X to κ κ> ffi hO ffi K) ffi Κ) ffi K> ffi to K K) ffi to K K) ffi NJ Κ Κ) ffi hJ κ Κ) X Κ) κ Κ) -¾ 1 1 -a -a 1 1 -¾ I Κ) ρ ρ p p p ρ ρ 1 1 -a -¾ 1 -¾ 1 η 1 UJ ο κ Κ) ο κ Ν) X NJ Γ\ X Κ) Γ\ o K κ Κ) /-Ν C J Κ to Ο Κ J to η K) o ffi K) k J ffi Κί η η H2C) Ο κ ο κ 1 1 ffi ΙΌ η 、^〆 o Pi__ 1 P!__ 1 CH κ Κ) ο 1 Ζ ζ 2 1 1 2 1 2 ζ 1 2 1 X Ζ ζ 2 1 1 z 1 1 Ζ Ζ 1 I I I 1 to 'w" 1-^ I 1 1 1 1 I to I I I to Het --------Φ水-- * 一 (讀先閲讀背面之注意事項再填寫本頁) -36- 本紙張尺度適川+國國家標缚(rNS ) Λ4規格(210X 297公釐) 546295 A7 ________j B7 五、發明説明(34 ) 1 HH 1 HH 1 H—( 1 HH 1 HH 1 HH 1 HH 1 HH 祖 1 1—( 1 HH 1 HH 1 HH 1 1—( 1 H—( 1 1—( 1 l-H 1 Z 102 〇 h—i 〇 Ό Ό Ό 00 Ό ON LT\ Ό UJ 1—^ o 00 00 oo OO 00 〇\ 00 〇 n n 〇 o 〇 n n 〇 o o 〇 o n o n o o 〇 o o 〇 o 〇 o o 〇 o o 〇 o o o O o o 〇 o o o o 〇 〇 o o o o 〇 〇 〇 o 〇 o o K K E E X E E K X X E E K X 辦 ψτ ψτ to 1 to 1 to 瞧 to 1 to 1 to 1 1 to 1 to 1 K) 1 to 1 K) 1 o /^s /^s /^N U) ^-N LO U) N U) U) /0^ U) /^s '、 4 n n 〇 o h 〇 o h 〇 〇 ή ή -P^ V 1 V 1 1 V 1 1 4 4 o o o o 〇 o l· l· l· l· l· l· p ρ X X K X ffi X -¾ -9 n λ λ 声t I 1 1 1 1 1 1 1 1 I k 1 1 1 駟 蝌 1 1 1 1 1 1 Ο 〇 〇 〇 〇 〇 o o o o 〇 〇 O 〇 〇 〇 〇 o N 〇 o o o o o o o o o n O o o o o o o d〇 X to X K) to K NJ K K) K K) K to K to K to K K) ro rc K) K h〇 K K) K K> K NJ X to a (Ό η n o 〇 o n o o n n 〇 o n o o n n o X NJ X K> X K> E to X NJ K) X K> E to E K> X K) K NJ E NJ E K) X NJ K NJ E N-) a K) E to η n o o n o o o o 〇 n 〇 O o 〇 O o X to ffi k) K) ro ffi K) X Ki ffi NJ ffi to E K> ffi K) K to K) K) K K) K ro K NJ X K) K NJ 1 1 1 -¾ 1 1 -s n hri 1 1 M pi p pi Ή U> 1 1 1 /^N N -a 1 1 /—N o -¾ -9 1 1 Lh> n E K) O K K) o K K) o K K) 〇 X o ffi K to K> O X K) K) o q ffi K) 〇 o E 1 o 〇 1 1 w O n 1 1 w o n 〇 1 1 K E E K K X 1 z 1 1 2 z 1 1 2 z fl 1 X 1 1 1 Z Z 2 1 1 2 2 1 I bo 1 K) ^^/ 1—^ 1 1 1 1 bo t—^ 1 1 1 D 1 K) H—^ X ft) (請先閱讀背面之注意事項再填寫本頁) •♦衣· 訂 t -37- 本紙張尺度1¾州中國國家標缚((、NS ) Λ4規格(210X 297公釐) 546295 A7 _______B7 五、發明説明(35 )• Clothing ------ 1T ♦ The size of this paper is 1¾; the kind of thread _ ((, NiS) specifications (210) 097 mm) * —-----1 1 546295 A7 B7 V. Description of the invention (33) HH 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 HH 1 hH 1 1—Η 1 HH 1 HH 1 1 HH 1 HH 1 ΚΗ 1 ΗΗ 1 hH I ΗΗ 1 ΗΗ 1 ZZ 〇0000 U) 00 Κ) 00 00 • ο to Ο 1— ^ -0 ΟΝ Ό σ \ 00 σ \ 〇η Ο ο ο oo 〇 ooooo ο ο ο ο ο ο ο Ο Ο 〇 ο oo oo 〇 ο Ο Ο ο ο Ο ο oo ο ooooo Ο ο Ο ο ο κ Ε XXKK κ KKK a κ κ a ffi κ Office Ul to Κ) Κ) Κ) Κ) 1 K) 1 bO 1 to 1 K) i K) l to 1 b〇1 Κ) 1 1 1 1 1 I ζ ^ \ / ^ s: ψτ Ο ο ο η ο ο ο ο 1 -¾ 1 1 1 -S 1 -¾ 1 1 -s 1 1 1 I 1 ρ p -ρ ^ (> 4 ^ XI κ 1 1 I 1 1 LO ^ r U) 1 Ns «^ 1 1 1 1 1 1 1 1 1 Ο o ο ο ο 唞〇〇 〇 ο Ο o 〇 o 〇〇〇〇〇〇 〇 Ο Ο Ο Ο Ν η Ο η ο η o η noono Ο η η Ο η ω (Nj κ hJ X to ffi κ > κ κ) K to o X to ffi K > ffi hO ffi to to ffi Ki X to κ Κ) κ to ο κ NJ κ to κ to η ο Ο ο ο η o 〇ooo 〇 ο Ο ο Ο X to X to X to κ Κ) Κ Κ ) ffi K) to ffi NJ XK) K to ffi to XK) κ to ffi Κ) Ε to Ε Ν) Ε Κ) X NJ ο ο η ο η n η nnnoo ο ο ο Ο ο Ο ffi κ) κ Κ) X to κ κ > ffi hO ffi K) ffi κ) ffi K > ffi to KK) ffi to KK) ffi NJ Κ Κ) ffi hJ κ κ) X κ) κ κ) -¾ 1 1 -a -a 1 1 -¾ I Κ) ρ ρ ppp ρ ρ 1 1 -a -¾ 1 -¾ 1 η 1 UJ ο κ Κ) ο κ Ν) X NJ Γ \ X Κ) Γ \ o K κ Κ) / -Ν CJ Κ to Ο Κ J to η K) o ffi K) k J ffi Κί η η H2C) Ο κ ο κ 1 1 ffi ΙΌ η, ^ 〆o Pi__ 1 P! __ 1 CH κ Κ) ο 1 Zn ζ 2 1 1 2 1 2 ζ 1 2 1 X ZO ζ 2 1 1 z 1 1 ZO Zn 1 III 1 to 'w " 1- ^ I 1 1 1 1 I to III to Het -------- Φ water-* one (read the precautions on the back before filling this page) -36- This paper is suitable for Sichuan + National Standard Binding (rNS) Λ4 specification (210X 297 mm) 546295 A7 ________j B7 V. Description of the invention (34) 1 HH 1 HH 1 H— (1 HH 1 HH 1 HH 1 HH 1 HH Zu 1 1— (1 HH 1 HH 1 HH 1 1— (1 H— (1 1— (1 lH 1 Z 102 〇h-i 〇Ό Ό Ό 00 Ό ON LT \ Ό UJ 1- ^ o 00 00 oo OO 00 〇 \ 00 〇 nn 〇o 〇nn 〇oo 〇ononoo 〇oo 〇o 〇oo 〇oo 〇ooo O oo oooo 〇〇oooo 〇〇〇o 〇oo KKEEXEEKXXEEKX Office ψτ ψτ to 1 to 1 to 1 1 to 1 to 1 K) 1 to 1 K) 1 o / ^ s / ^ s / ^ NU) ^ -N LO U) NU) U) / 0 ^ U) / ^ s', 4 nn 〇oh 〇oh 〇〇价 ή -P ^ V 1 V 1 1 V 1 1 4 4 oooo 〇ol · l · l · l · l · l · p ρ XXKX ffi X -¾ -9 n λ λ sound t I 1 1 1 1 1 1 1 1 I k 1 1 1 驷 蝌 1 1 1 1 1 1 1 〇 〇〇〇〇〇〇〇oooo 〇〇O 〇〇〇〇〇 〇oooooooooon O ooooood (X to XK) to K NJ KK ) KK) K to K to K to KK) ro rc K) K h〇KK) K K > K NJ X to a (Ό η no 〇onoonn 〇onoonno X NJ X K > X K > E to X NJ K) X K > E to E K > XK) K NJ E NJ EK) X NJ K NJ E N-) a K) E to η noonoooo 〇n 〇O o 〇O o X to ffi k) K) ro ffi K) X Ki ffi NJ ffi to E K > ffi K) K to K) K) KK) K ro K NJ XK) K NJ 1 1 1 -¾ 1 1 -sn hri 1 1 M pi p pi Ή U > 1 1 1 / ^ NN -a 1 1 /-N o -¾ -9 1 1 Lh > n EK) OKK) o KK) o KK) 〇X o ffi K to K > OXK) K) oq ffi K) 〇o E 1 o 〇1 1 w O n 1 1 won 〇1 1 KEEKKX 1 z 1 1 2 z 1 1 2 z fl 1 X 1 1 1 ZZ 2 1 1 2 2 1 I bo 1 K) ^^ / 1— ^ 1 1 1 1 bo t— ^ 1 1 D 1 K) H— ^ X ft) (Please read the precautions on the back before filling out this page) -37- Size of this paper 1¾ State China National Standard ((, NS) Λ4 specification (210X 297mm) 546295 A7 _______B7 V. Description of the invention (35)
HH 1 1—Η 1 ΗΗ 1 HH 1 H-H 1 HH 1 ΗΗ 1 HH 1 HH 1 HH 1 HH 1 HH 1 ΗΗ 1 H-H 1 Η—1 1 κ—( j 1 1—^ 1—^ 〇〇 Η- Η—* h—* 1—^ OS H-h—^ H—* h-^ 1—i H—^ Lk) Η—^ Η—^ Κ) 1—-k H—* 1—^ o H—^ <〇 00 H—* o Η—^ H—^ s Η—^ Ο h—1 ' Ο U) η η Ο n 〇 n ο 〇 o n o n η n η ο 〇 ο Ο 〇 o 〇 ο o 〇 〇 o 〇 ο 〇 ο 〇 〇 ο Ο o o o ο o o o o o ο o ο ο κ ffi m ffi K κ ffi a E ffi K κ K κ Ε 舛 舛 辦 辦 树 ^ 1 u> 1 U) 1 U) I to 1 b〇 1 K) I to I K) 1 Κ) I Κ) I Os 1 t〇 LO 1 t〇 LO 1 ^ to UJ 树 w ^ 1 払 w ^ 1 ^ /—V U) ? /^S w v ψ V w v π ή p ή ^ ή V V V m 莓 ^ |n -¾ 審V In ~S u ^ In -9 a a a _ ο ο κ I LO I _ o 0 ffi 1 U) 1 _ o 0 ffi 1 u> i丨 声t 卜 声r k 卜 声r k 声t k L· ^0/ 1 C 1 I pi -a Ο ρ p Nw^ 1 1 1 1 O Ο C^ Ο ο O o o Ο Ο o o o o Ο o Ο Ο ο Ν 〇 ο o o o ο Ο o o o o ο o Ο Ο ο W X κ> κ Κ) X KJ ffi K) ffi K) ffi bJ Ε Κ) tc KJ ffi K) E to K to κ to ffi to m to ffi Κ) Ε κ> η Ο o o 〇 η ο o o o o ο o ο ο ο κ Κ) κ ίο K to ro K ro κ Μ DC to K K) K to K to E N) κ κ> E N> κ Ν-> κ to Ν> η ο o O o Ο Ο o o n 〇 ο 〇 Ο ο X to X ίο ffi K) K K> E K) Ε Κ) ffi to ill ffi to ffi to X to κ Μ ffi N) X Ν> κ Κ) Ε ί〇 1 1 1 1 -¾ 1 -¾ Κ) p p p ρ , 1 1 -¾ 1 -s 1 ^•N -a 1 u> o ffi to o K K) o 1 ο n 1 o ο 1 o n 1 ο O 1 ο η κ X K X K ffi κ ffi ίϋ X 1 2 z 1 1 1 乂 ζ 2 1 X 1 2 z 1 D z i ζ Z 1 弋 I 1 1 層 1 1 應 I 1 1 I Κ CD (請先閱讀背面之注意事項再填寫本頁)HH 1 1—Η 1 ΗΗ 1 HH 1 HH 1 HH 1 ΗΗ 1 HH 1 HH 1 HH 1 HH 1 HH 1 ΗΗ 1 HH 1 Η—1 1 κ— (j 1 1— ^ 1— ^ 〇〇Η- Η — * H— * 1— ^ OS Hh— ^ H— * h- ^ 1—i H— ^ Lk) Η— ^ Η— ^ Κ) 1—-k H— * 1— ^ o H— ^ < 〇00 H— * o Η— ^ H— ^ s Η— ^ 〇 h—1 '〇 U) η η Ο n 〇 n ο 〇onon η n η ο 〇ο 〇 〇o 〇ο o 〇〇o 〇ο 〇ο 〇〇ο Ο ooo ο ooooo ο o ο ο κ ffi m ffi K κ ffi a E ffi K κ K κ Ε 舛 舛 办 ^^^ u > 1 U) 1 U) I to 1 b〇1 K ) I to IK) 1 Κ) I Κ) I Os 1 t〇LO 1 t〇LO 1 ^ to UJ tree w ^ 1 払 w ^ 1 ^ /-VU)? / ^ S wv ψ V wv π price p price ^ ή VVV m berry ^ | n -¾ Review V In ~ S u ^ In -9 aaa _ ο ο κ I LO I _ o 0 ffi 1 U) 1 _ o 0 ffi 1 u > i 丨 声 t 博 声 rk声声 rk sound tk L · ^ 0/1 C 1 I pi -a Ο ρ p Nw ^ 1 1 1 1 O Ο C ^ Ο ο O oo Ο Ο oo oo Ο o Ο Ο ο Ν 〇ο ooo ο Ο oooo ο o Ο Ο ο WX κ > κ Κ) X KJ ffi K) ffi K) ffi bJ Ε Κ) tc KJ ffi K) E to K to κ to ffi to m to ffi Κ) Ε κ > η Ο oo 〇η ο oooo ο o ο ο ο κ Κ) κ ίο K to ro K ro κ Μ DC to KK) K to K to EN) κ κ > E N > κ Ν -> κ to Ν > η ο o O o Ο oon 〇ο 〇〇 ο X to X ίο ffi K) K K > EK) Ε Κ) ffi to ill ffi to ffi to X to κ Μ ffi N) X Ν > κ Κ) Ε 〇〇 1 1 1 1 -¾ 1 -¾ Κ) ppp ρ, 1 1 -¾ 1 -s 1 ^ • N -a 1 u > o ffi to o KK) o 1 ο n 1 o ο 1 on 1 ο O 1 ο η κ XKXK ffi κ ffi ίϋ X 1 2 z 1 1 1 乂 ζ 2 1 X 1 2 z 1 D zi ζ Z 1 弋 I 1 1 layer 1 1 shall I 1 1 I Κ CD (Please read the notes on the back before filling this page)
、1T -38- 本紙張尺度適用中國國家標峰((、NS ) Λ4規格(2I0X297公釐) 546295、 1T -38- This paper size applies to China National Standard Peak ((, NS) Λ4 specification (2I0X297 mm) 546295
AA
7 B 五、發明説明(36 ) 1-132 1-131 1-130 1-129 1-128 11-127 [1-126 1-125 1-124 1-1231 I 1-122 j _1 1-121 1-120 1-119 2 COOH COOH COOH COOH COOH COOH COOH COOH ] COOH ! _ ______1 COOH COOH COOH COOH COOH 苯基 苯基 苯基 苯基 苯基 1苯基1 1苯基| |苯基 苯基 苯基 I 1 苯基 1 _1 苯基 苯基 苯基 苯基 苯基 苯基 苯基 苯基 苯基 丨苯基J 序基」 苯基 苯基 1 _______ J 苯基 苯基 苯基 苯基1 ! 2-(4-羥基-3-甲氧基-苯 基)-乙基 2-(4-羥基-3-甲氧基-苯 基)-乙基 2-(4-羥基-3-甲氧基-苯 基)-乙基 2-(4-羥基-3-甲氧基-苯 基)-乙基 2-(4-羥基-3-甲氧基-苯 基)-乙基 2-(4-羥基-苯基)-乙基 2-(4-羥基-苯基)-乙基 2-(4-羥基-苯基)-乙基 2-(4-二甲基-胺基-苯基)-乙基 2-(4-二甲基-胺基-苯基)-| 乙基 | 2-(4-二曱基-胺基-苯基)-乙基 2-(3,4-伸甲基二氧基-苯 基)-乙基 2-(3,4-伸曱基二氧基-苯 基乙基 2-(3,4-伸甲基二氧基-苯| 基;)-乙基 丨 σ\ Ο 〇 〇 〇 〇 〇 〇 〇 〇 〇 〇 〇 〇 〇 Ν ch2ch2ch2 η X 〇 to ο 〇 X 〇 κ> ο κ Κ) ch2ch2ch2 ch2ch2ch2 ch2ch2ch2 ch2ch2ch2 〇 K) 〇 to ο to 〇 to 〇 K) η to 〇 to 〇 K) 〇 K) 〇 X to η to ο κ ch2ch2ch2 ch2ch2ch2 〇 K Μ 〇 X to ο κ Κ) do 甲氧基 甲基 1 甲氧基 甲基 1 甲氧基 1甲基_1 1 甲氧基 甲基 1 甲氧基 曱基 to 甲基 i ! 甲基 1 1 _1 1 甲基 甲基 1 甲基 甲基 1 甲基 甲基 1 甲基 甲基 OJ CH CH CH CH 1 1CH 1 1CH J 1 CH CH 1 t' CH CH 2 層 2 1 1 1 X 1 2 1 1 1 1 1 1 1 1 1 1 1 K) 1 1 |Het -39- (請先閱讀背面之注意事項再填寫本頁) .參衣_ 訂 標 家 國 i 及 尺 紙 本 枱 規 4 Λ 5 Ν7 B V. Description of the invention (36) 1-132 1-131 1-130 1-129 1-128 11-127 [1-126 1-125 1-124 1-1231 I 1-122 j _1 1-121 1 -120 1-119 2 COOH COOH COOH COOH COOH COOH COOH COOH COOH] COOH! _ ______1 COOH COOH COOH COOH COOH COOH phenylphenylphenylphenylphenyl 1phenyl 1 1phenyl | | phenylphenylphenyl I 1 phenyl 1 _1 phenyl phenyl phenyl phenyl phenyl phenyl phenyl phenyl 丨 phenyl J motif "phenyl phenyl 1 _______ J phenyl phenyl phenyl phenyl 1! 2- ( 4-hydroxy-3-methoxy-phenyl) -ethyl 2- (4-hydroxy-3-methoxy-phenyl) -ethyl 2- (4-hydroxy-3-methoxy-phenyl) ) -Ethyl 2- (4-hydroxy-3-methoxy-phenyl) -ethyl 2- (4-hydroxy-3-methoxy-phenyl) -ethyl 2- (4-hydroxy-benzene ) -Ethyl 2- (4-hydroxy-phenyl) -ethyl 2- (4-hydroxy-phenyl) -ethyl 2- (4-dimethyl-amino-phenyl) -ethyl 2 -(4-dimethyl-amino-phenyl)-| ethyl | 2- (4-diamidino-amino-phenyl) -ethyl 2- (3,4-methyldioxy -Phenyl) -ethyl 2- (3,4-methylenedioxy-phenylethyl 2- (3,4-methylenedioxy-phenyl | yl;)-ethyl 丨 σ \ 〇 〇〇 〇〇〇〇〇〇〇〇〇〇Ν ch2ch2ch2 η X 〇to ο 〇X 〇κ > ο κ K) ch2ch2ch2 ch2ch2ch2 ch2ch2ch2 ch2ch2ch2 〇K) 〇to ο to 〇to 〇K) η to 〇to 〇K K) 〇X to η to κ ch2ch2ch2 ch2ch2ch2 〇K Μ 〇X to ο κ K) do methoxymethyl1 methoxymethyl1 methoxy1methyl_1 1 methoxymethyl1 methyl Oxymethyl to methyl i! Methyl 1 1 _1 1 methyl methyl 1 methyl methyl 1 methyl methyl 1 methyl methyl OJ CH CH CH CH 1 1CH 1 1CH J 1 CH CH 1 t ' CH CH 2 Layer 2 1 1 1 X 1 2 1 1 1 1 1 1 1 1 1 1 1 K) 1 1 | Het -39- (Please read the precautions on the back before filling this page).家 国 i and ruler paper rule 4 Λ 5 Ν
釐 公 7 9 2 X 546295 A7 B7 五、發明説明 37 部 ii 卑 局 消 竹 印Centimeter 7 9 2 X 546 295 A7 B7 V. Description of the invention Part 37 ii.
ΗΗ 1 HH 1 H—^ HH I 1-147 1 1 HH 1 HH 1 HH 1 h-H 1 ΗΗ 1 )-Η 祖 )—1 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 Η-Η 1 ΗΗ 1 Κ-Η 1 00 On 払 S 4^ Η—^ Ο U) Ό UJ ΟΟ LO Ον UJ LT\ LO 4^ UJ LO η n n 〇 n o n 〇 ο Ο ο ο η Ο η η η ο 方 ο o o o o o o o ο ο ο ο ο ο ο ο ο ο ο o o o o o o o ο ο ο ο ο ο ο ο ο ο X :E K K E Ε X X κ X κ X X X X 辦 η 树 辦 η , LO V 1 It LO 1 il U) V 1 |i U) 瞧 it U) V 1 |i LO 1 h u> 1 II LO 1 II U) I |ι U) V I |ι UJ I Ιι U) 1 Ιι LO V I h LO V 1 It 1 ) -¾ 1 1 1 -¾ 1 -¾ 1 -¾ 1 1 -¾ 1 -¾ 1 -S 1 1 1 -a p pi p ρ ρ λ LO 4^ 1 1 1 4^ 1 1 1 -¾ -a -a V ^ 1 to ' Κ) 舛人 _ f v On 1 -a V ^ /—ν LO l· p p p π _ ;丨 l· p p 瑚 1 ρ ρ 1 LO r I 1 1 濁 p 舛 o o o o O o o ο Ο Ο ο Ο Ο ο Ο ο Ο 〇 N n o o o o n n ο η Ο η Ο ο ο η ο ο 〇 tjd X K) K K) K N·) ffi K) X NJ X h〇 X K) X Κ) ffi ΪΌ X KJ κ Κ) κ Κ) κ Κ) κ Κ) X Κ) X to ffi Κ) ffi to n o o o 〇 o O ο Ο ο η Ο Ο Ο η ο ο n X K) ffi NJ E K) ffi X ffi NJ ffi K) X Κ) X Κ) κ Κ) X Κ) ffi to ffi Κ) X Κ) ffi to ffi Κ) X Κ) ffi K) O o o o o 〇 n ο η ο η ο η ο ο ο ο o ffi K) K t^) K K) X to ffi ro E to ffi to ffi Κ) κ) ffi to X Κ) ffi to κ NJ X to Κ) to κ NJ ffi K) 1 -9 1 1 1 ~0 ο ΗγΗ 1 1 hO p p ρ U) ρ ρ , 5 n 1 -¾ 1 1 1 /—Ν 5 Ο -θ 1 -a -a 1 U) o K ο κ X Ki o κ to ο n O X 1 〇 o 1 I 1 ο Ε ο ο η 1 η η 1 ffi ffi K) O K ffi ffi Κί Ο ffi κ X κ ffi o ffi to η ffi to z 2 1 1 1 1 Ζ ζ ζ 1 2 1 X Z 1 1 I 1 Ζ 2 ζ 1 Ζ 1 < 1 1 1 to to * 1 1 H—1 1—^ * to * Η—^ 1 1 1 I I to I I vw^ K a> r-K (讀先閱讀背面之注意事項再填寫本頁)ΗΗ 1 HH 1 H— ^ HH I 1-147 1 1 HH 1 HH 1 HH 1 hH 1 ΗΗ 1) -Η)) — 1 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 Η-Η 1 ΗΗ 1 Κ-Η 1 00 On払 S 4 ^ Η— ^ Ο U) Ό UJ ΟΟ LO Ον UJ LT \ LO 4 ^ UJ LO η nn 〇non 〇ο Ο ο ο η Ο η η η ο square ο ooooooo ο ο ο ο ο ο ο ο ο ο ο ο ooooooo ο ο ο ο ο ο ο ο ο X: EKKE Ε XX κ X κ XXXX 办 办 LO, LO V 1 It LO 1 il U) V 1 | i U) See it U) V 1 | i LO 1 h u > 1 II LO 1 II U) I | ι U) VI | ι UJ I Ιι U) 1 Ιι LO VI h LO V 1 It 1) -¾ 1 1 1 -¾ 1 -¾ 1 -¾ 1 1 -¾ 1 -¾ 1 -S 1 1 1 -ap pi p ρ ρ λ LO 4 ^ 1 1 1 4 ^ 1 1 -¾ -a -a V ^ 1 to 'Κ) 舛 人 _ fv On 1 -a V ^ /-ν LO l · ppp π _; 丨 l · pp 1 1 ρ ρ 1 LO r I 1 1 p 舛 oooo O oo ο Ο Ο ο Ο Ο ο Ο ο Ο 〇N noooonn ο η Ο η Ο ο ο η ο ο 〇tjd XK) KK) KN ·) ffi K) X NJ X h〇XK) X Κ) ffi ΪΌ X KJ κ Κ) κ Κ) κ Κ) κ Κ) X Κ) X to ffi κ) ffi to nooo 〇o O ο Ο ο η Ο Ο Ο η ο ο n X EK) ffi X ffi NJ ffi K) X Κ) X Κ) κ KK) X Κ) ffi to ffi KK) X Κ) ffi to ffi κ) X Κ) ffi K) O oooo 〇n ο η ο η ο η ο ο ο o ffi K) K t ^) KK) X to ffi ro E to ffi to ffi κ) κ) ffi to X Κ) ffi to κ NJ X to Κ) to κ NJ ffi K) 1 -9 1 1 1 ~ 0 ο ΗγΗ 1 1 hO pp ρ U) ρ ρ, 5 n 1 -¾ 1 1 1 / —Ν 5 Ο -θ 1 -a -a 1 U) o K ο κ X Ki o κ to ο n OX 1 〇o 1 I 1 ο Ε ο ο η 1 η η 1 ffi ffi K) OK ffi ffi Κί Ο ffi κ X κ ffi o ffi to η ffi to z 2 1 1 1 1 Z ζ ζ 1 2 1 XZ 1 1 I 1 Zn 2 ζ 1 ZZ 1 & l t; 1 1 1 to to * 1 1 H—1 1— ^ * to * Η— ^ 1 1 1 I I to I I vw ^ K a > r-K (Read the precautions on the back before filling this page)
、1T -40- 本紙張尺度適川中國國家標缚(rNS ) Λ4規格(210X 297公釐) 546295 A7 _______ B7 五、發明説明(38 ) HH 1 1—Η 1 ΗΗ I Η-Η 麵 ΗΗ 1 Η-Η 1 h-H 1 h—1 1 )—H 1 HH 1 h-H 1 HH 1 H-< 1 KH 1 HH 1 h-H 量 ΗΗ 1 2 Η—^ -<1 os Os ι—^ Ον 1—* 〇\ 払 〇\ LO Η—» 〇\ to Η—^ 〇\ 1—^ ON ^t\ oo (-^ H—* U\ 〇\ t—^ H-* ΟΊ (—* LO h—* to Η—» ^Τ\ ι—^ η Ο Ο η Ο ο o n n o n n n n O ο Ο 〇 Ο Ο ο Ο Ο 〇 〇 〇 o 〇 O o 〇 o ο ο 〇 Ο ο ο ο ο o o o o o O o o o ο ο X X X X ffi K a a X K E E a E X X 舛 U) V I 1 , V I \ . Lk) I U) V Β \ . LO V I 1 . U) V 1 1 . LO V 1 1 . LO 1 1 , LO V 1 \ . 1 | , LO 1 \ . UJ V 1 \ . LO 1 1 . LO V 1 t . LO V 1 LO V 1 1 . LO V 1 1 . LT\ Ρ Ρ -¾ Ρ Ρ Ρ Ρ -a P -a P -a P P -¾ P P -9 P -¾ P l· -9 Ρ Ρ -a ρ ρ\ ρ ρ p p p p p p ρ k η k k 1 I 1 1 1 1 1 1 4^ 1 1 1 -P^ 1 1 1 U) UJ UJ Ο -¾ -a 声T 声T 声r 1 1 -Ρ^ I ,Vj . ,Vj , ρ ,Vj , 1 1 1 1 1 1 l· 1 l· I l· 1 1 ψ- 1 ψ· 1 -a -¾ -9 p p ρ 1 ι ι ο Ο Ο Ο 〇 Ο O Ο O o O o o o Ο Ο Ο Ν ο ο ο Ο η Ο o Ο o o o n n o η η Ο ω κ Κ) Κ to Ε h〇 ffi Κ) Κ Κ) Ε Κ) X to KJ ffi K) X to K to K NJ K K) K to X hO Κ) X Κ) Ο η η ο ο ο n η o n o n O o Ο ο X NJ κ NJ Κ X Κ) κ Κ) κ κ> ffi NJ X NJ K to K b〇 K ffi K) K NJ K K) κ to Κ Κ) X Κ) ο η η ο η ο n Ο n n n o n O η ο η X μ κ to κ ΙΌ Ε E to E Κ·) NJ K to NJ X to E to E K> Ε Κ) Ε κ> κ NJ -9 -9 -¾ 1 1 1 1 -9 1 to ρ ρ p p ρ ρ 5 Ο 1 5 Ο 1 /^N o 1 1 -¾ ^2 〇 1 UJ X ο κ NJ Ο Ο a n K to κ Κ) Ο X η ο 1 X ο ffi to i o n O ffi K) 1 1 o 〇 X 1 ο ο X X ο ffi ffi ffi ο κ κ t^J Κ) ο o a Κ) ζ ζ 1 2 1 z Z 1 1 2 Z 1 X 乂 ζ ζ 1 Ζ 2 1 X Z 1 1 2 Ζ 1 2 弋 I I I ^to 1 1 K—k 1 1 1 to 1 1 1 Η—^ I X ι—^ * 〇 (讀先閲讀背面之注意事項再填寫本頁) 訂 -41 - 本纸張尺度边用中國國家標缚((、NS ) Λ4規格(2丨OX 297公釐) 546295 A7 B7 五、發明説明(39 ) 1-185 11-184 11-183 1-182 11-181 I |l-180 |l-179 |l-178 |l-177 |l-176 l1-175 1 1-174 1-173 |Ι-172 1 I1-171 1 |I-170 |I-169 |ΐ-168 乂 *-5 〇 η η η ο η o 〇 o o o n n η n o 〇 η 〇 ο ο ο ο ο o o o o o 〇 〇 ο 〇 o o ο 〇 ο ο ο ο ο o o o o o o o ο o o o ο K X X X Ε ffi ffi ffi X ffi a X a κ a X ffi κ ψτ 辦 V 1 \ { U) V I \ , U) V I \ , LO V I \ . U) V I 1 . LO V 1 l , LO 1 \ , LO 1 1 . UJ V 1 \ . LO 1 \ . LO 1 1 . LO 1 1 , LO V 1 \ . Lk) 1 1 . LO 1 1 . LO V 1 1 . LO V 1 \ . LO V I 1 . P Ρ Ρ Ρ Ρ P P -Θ I1 -9 P P -¾ P P -¾ P -s Ρ -¾ I1 P -9 P -¾ Ρ p ρ ρ ρ ρ p p p p p p p p p p p p ρ k k k k k k 辦 1 1 1 4^ I 1 1 4^ 1 4^ 1 1 U) LO uj LO U) -f^ 1 1 1 〇 ο ο ο ο o -a -s 4^ 1 1 1 1 4^ 1 V 1 -9 -S 〇 〇 ο ο ο ο ο ο ο ο o o l· 1 l· 1 l· 1 l· 1 l· 1 l· 1 p ρ ffi 1 ffi 1 Ε 1 X 1 Ε 1 ffi 1 4十 4今 -a -s -¾ -a 十r p p pi p 4今 辦 啉 駟 4十 4ΐ 〇 Ο Ο ο ο o o o o o o 〇 ο O 〇 o Ο ο Ν 〇 ο Ο ο ο o 〇 O o o 〇 o η o o o Ο ο ω K to ffi to X Κ) X Κ) X Μ K to K) K) K to E to X NJ to X to ffi NJ K K) E to κ Κ) to 〇 η ο ο ο n o o o o n n ο o 〇 o π ο K to Κ) Ε Κ) ffi hJ Ε Κ) ffi K) ffi K) X to ffi K) ffi K) K to ffi K> X Κ) K to X K) K K) κ Κ) X to η η η ο ο o o o n o n o ο o o o ο ο Κ Μ X Κ) X to κ κ> X to K K) X K) KJ K K NJ K to K K) κ Κ) NJ K NJ E to κ Κ) X NJ 1 1 -a -¾ 1 -¾ 1 1 -S -¾ 1 I -¾ Κί ρ pi p pi 1 1 -s 1 -a 1 1 5 η 1 1 u> Ο Ε o X ο X Κ) η X ο X ro 1 1 ο X ο n 1 n o 1 1 o ffi o n 1 1 Ο κ NJ η ffi ffi X a ffi K) ο ffi tr ffi η X Κ) o κ Κ) ο 1 1 Ζ ζ 2 1 z 2 1 1 2 2 2 Z 1 1 X 1 ί 2 1 z 1 1 Z 2 1 i Η—^ 1 I 1 1 1 1 l~* 1 1 1 1 K) 1—^ 1 (請先閱讀背面之注意事項再填寫本頁)、 1T -40- This paper is suitable for Sichuan National Standard (rNS) Λ4 specification (210X 297 mm) 546295 A7 _______ B7 V. Description of the invention (38) HH 1 1—Η 1 ΗΗ I Η-Η ΗΗ ΗΗ 1 Η-Η 1 hH 1 h—1 1) —H 1 HH 1 hH 1 HH 1 H- < 1 KH 1 HH 1 hH ΗΗ 1 2 Η— ^-< 1 os Os ι— ^ Ον 1— * 〇 \ 払 〇 \ LO Η— »〇 \ to Η— ^ 〇 \ 1— ^ ON ^ t \ oo (-^ H— * U \ 〇 \ t— ^ H- * ΟΊ (— * LO h— * to Η— »^ Τ \ ι— ^ η Ο Ο η Ο ο onnonnnn O ο Ο 〇〇 〇 ο Ο 〇 〇〇〇〇o 〇O o 〇o ο ο 〇〇 ο ο ο oo ooo O ooo ο ο XXXX ffi K aa XKEE a EXX 舛 U) VI 1, VI \. Lk) IU) V Β \. LO VI 1. U) V 1 1. LO V 1 1. LO 1 1, LO V 1 \. 1 |, LO 1 \. UJ V 1 \. LO 1 1. LO V 1 t. LO V 1 LO V 1 1. LO V 1 1. LT \ Ρ Ρ -¾ Ρ Ρ Ρ Ρ -a P -a P -a PP -¾ PP -9 P -¾ P l · -9 Ρ Ρ -a ρ ρ \ ρ ρ pppppp ρ k η kk 1 I 1 1 1 1 1 1 4 ^ 1 1 1 -P ^ 1 1 1 U) UJ UJ 〇 -¾ -a sound T sound T sound r sound 1 1 -P ^ I, Vj., Vj, ρ, Vj, 1 1 1 1 1 1 l · 1 l · I l · 1 1 ψ- 1 ψ · 1 -a -¾ -9 pp ρ 1 ι ι ο Ο Ο Ο 〇Ο O 〇 O o O ooo Ο Ο Ο Ν ο ο ο Ο η Ο o Ο ooonno η η Ο ω κ κ) Κ to Ε h〇ffi Κ) Κ Κ) Ε Κ) X to KJ ffi K) X to K to K NJ KK) K to X hO Κ) X Κ) Ο η η ο ο ο n η onon O o Ο ο X NJ κ NJ Κ X Κ) κ κ) κ κ > ffi NJ X NJ K to K b〇K ffi K) K NJ KK) κ to Κ Κ) X Κ) ο η η ο η ο n Ο nnnon O η ο η X μ κ to κ ΙΌ Ε E to E Κ ·) NJ K to NJ X to E to E K > Ε Κ) Ε κ > κ NJ -9- 9 -¾ 1 1 1 1 -9 1 to ρ ρ pp ρ ρ 5 Ο 1 5 Ο 1 / ^ N o 1 1 -¾ ^ 2 〇1 UJ X ο κ NJ Ο 〇 an K to κ Κ) 〇 X η ο 1 X ο ffi to ion O ffi K) 1 1 o 〇X 1 ο ο XX ο ffi ffi ffi κ κ t ^ J KK) ο oa KK) ζ ζ 1 2 1 z Z 1 1 2 Z 1 X 乂 ζ ζ 1 ZZ 2 1 XZ 1 1 2 Zn 1 2 弋 III ^ to 1 1 K—k 1 1 1 to 1 1 1 Η— ^ IX ι— ^ * 〇 (Read the precautions on the back before filling in this page) Order -41-This paper uses the Chinese national standard ((, NS) Λ4 specifications (2 丨 OX 297 mm) 546295 A7 B7 V. Description of the invention (39) 1-185 11-184 11-183 1-182 11-181 I | l-180 | l-179 | l-178 | l-177 | l-176 l1-175 1 1-174 1-173 | 1-172 1 I1-171 1 | I-170 | I-169 | ΐ-168 乂 * -5 〇η η ο η o 〇ooonn η no 〇η 〇ο ο ο ο ο ooooo 〇〇ο 〇oo ο ο ο ο ο ο ooooooo ο ooo ο KXXX Ε ffi ffi ffi X ffi a X a κ a X ffi κ ψτ Office V 1 \ {U) VI \ , U) VI \, LO VI \. U) VI 1. LO V 1 l, LO 1 \, LO 1 1. UJ V 1 \. LO 1 \. LO 1 1. LO 1 1, LO V 1 \. Lk) 1 1. LO 1 1. LO V 1 1. LO V 1 \. LO VI 1. P Ρ Ρ Ρ PP PP -Θ I1 -9 PP -¾ PP -¾ P -s Ρ -¾ I1 P -9 P -¾ ρ p ρ ρ ρ ρ pppppppppppp ρ kkkkkk Office 1 1 1 4 ^ I 1 1 4 ^ 1 4 ^ 1 1 U) LO uj LO U) -f ^ 1 1 1 〇ο ο ο ο o -a -s 4 ^ 1 1 1 1 4 ^ 1 V 1 -9 -S 〇〇ο ο ο ο ο ο ool · 1 l · 1 l · 1 l · 1 l · 1 l · 1 p ρ ffi 1 ffi 1 Ε 1 X 1 Ε 1 ffi 1 4 ten -a -s -¾ -a ten rpp pi p 4 ο ο oooooo 〇ο O 〇o Ο ο Ν 〇ο Ο ο ο o 〇O oo 〇o η ooo Ο ο ω K to ffi to X Κ) X Κ) X Μ K to K) K) K to E to X NJ to X to ffi NJ KK) E to κ Κ) to 〇η ο ο ο noooonn ο o 〇o π ο K to Κ) Ε Κ) ffi hJ Ε Κ) ffi K) ffi K) X to ffi K) ffi K) K to ffi K > X Κ) K to XK) KK) κ Κ) X to η η η ο ο ooonono ο ooo ο ο Κ Μ X Κ) X to κ κ > X to KK) XK) KJ KK NJ K to KK) κ Κ) NJ K NJ E to κ Κ) X NJ 1 1 -a -¾ 1 -¾ 1 1 -S -¾ 1 I -¾ Κί ρ pi p pi 1 1 -s 1 -a 1 1 5 η 1 1 u > Ο Ε o X ο X Κ) η X ο X ro 1 1 ο X ο n 1 no 1 1 o ffi on 1 1 Ο κ NJ η ffi ffi X a ffi K) ο ffi tr ffi η X Κ) o κ Κ) ο 1 1 Z ζ 2 1 z 2 1 1 2 2 2 Z 1 1 X 1 ί 2 1 z 1 1 Z 2 1 i Η— ^ 1 I 1 1 1 1 l ~ * 1 1 1 1 K) 1-^ 1 ( (Please read the notes on the back before filling out this page)
、1T -42- 本紙張尺度適川中國國家標缚((、NS ) Λ4規格(21 OX 297公釐) 546295 A7 B7 部屮次杈卑局17,,/nfr合仍衫印^ 五、發明説明(4〇 ) HH 1 to 〇 Ι-Η 1 Κ) ο 私 h-H to ο LO ΗΗ 1 Κ) g ΗΗ 1 Μ Η-^ ►—1 1 Κ) ο ο h-H 1 ΗΗ 1 Η—1 00 ΗΗ 1 )—^ ΗΗ 1 h—k σ\ ΗΗ 1 Η—1 Lh HH 1 Η—λ Ό 仁 ΗΗ 1 μ—* MD LO t-H 1 h— to ΗΗ 嘗 Η—* ΗΗ 1 ο ΗΗ 1 h—^ 00 ΗΗ 1 Η—^ 00 00 ΗΗ 1 1—^ ΟΟ ΗΗ 1 Ον 2 η ο η ο Ο ο ο η ο ο ο ο ο ο η η η ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο Ο Ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο Ο ο ο κ X κ X κ X X κ X κ κ κ κ Ε κ κ X Ε κ κ 舛 η 树 辦 η 辦 辦 舛 辦 辦 舛 LO Lh) U) U) LO Lk> U) V 1 1 , U) V 1 1 , LO V 1 I . LO LO U) LO U) V 1 \ , U) LO LO LO LO u> U\ I 1 , V 1 1 , 1 1 , 1 1 , 1 1 , 1 \ , 1 1 . 1 1 . 1 1 . I I 1 , I 1 , I I 1 I . V 1 1 . Ρ Ρ Ρ Ρ -a Ρ -S Ρ Ρ Ρ I1 -¾ Ρ Ρ -a Ρ -a I1 -a Ρ Ρ Ρ -¾ I1 -8 Ρ Ρ I1 pi pi ρ ρ ρ ρ ρ ρ ρ ρ\ ρ k η ο ό ο η ο ό ο ή ο ό ο h ο -Ρ^ η ο ό ο ό ο LO 1 ο ο ο κ 1 LO I η ο ο Ε 1 U) I Ο ο ο Ε 1 4^ -a -Ρ^ I 1 4^ 1 声τ ON ο X UJ ο ffi ΰ) ο κ U) ο X U) ο ffi 心 ο X ΰ) ο κ ΰ) ο κ UJ ο ffi L*J ο X ΰ) 1 1 1 4^ 忌 ρ ρ ρ ρ ρ ♦ Mr 蝌 蝌 ο Ο Ο Ο ο ο ο ο ο ο ο ο Ο ο ο Ο Ο ο ο ο N ο Ο Ο Ο ο ο η ο ο ο η η η η ο η η η ο η dd κ κ X ffi ffi ffi X X X X X X X X ffi X X X X κ ο η η Ο ο ο ο η ο ο η ο ο ο η η ο ο ο ο Ε Κ) Κ Κ) X to Κ Κ) X ho κ to κ Κ) κ Κ) Ε NJ ffi to Ε NJ Ε tsJ ffi to Ε to κ NJ Κί X Κ) κ κ) X to X to ο Ο η ο ο η ο ο ο ο η η η ο η η Ο η ο η κ Κ) κ NJ κ Κ) Ε Κ) κ Κ) κ κ> ffi Κ) X Κ) κ Κ) X to X ίο κ to X Κ) X κ> κ Κ) Κ) κ to X to to to 1 1 ο ΗτΗ ο 1 -¾ 1 -a 1 ~a 1 K) ρ ρ U) ρ ρ ρ pi 5 η 1 1 1 -a 1 I -S 1 X ο ο κ 1 Ο ο 1 ο ο 1 ο ο 1 ο ο 1 η η 1 ο n κ ο ffi ffi Μ κ ffi κ κ \ κ κ ffi K X NJ 1 1 1 乂 1 1 2 1 ζ z X 乂 1 Ζ 1 ζ 1 1 1 乂 1 z 弋 1 0 Κ) I 1 h—k 1 1 Κ) 1 1 Κ) I 1 I I to 1 1 (讀先閲讀背面之注意事項再填寫本頁) -43- 本紙張尺度適用+國國家標埤(rNS ) Λ4規格(210X 297公釐) 546295 A7 B7 五、發明説明(41 ) HH 1 ΗΗ HH HH HH 1 Η—1 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 Η-Η 1 ΗΗ 1 HH 1 h-H 1 HH 1 HH 1 HH 1 HH 1 2 K) K) LO Κ) Κ) Κ) K) bO 1-^ bO K) o K) VO to oo Κ) Κ) 〇\ Κ) h—k Κ) 払 Κ) LO Κ) to to 1—i to »—* o to s K) % K) o K) 〇 η n o 〇 n η ο ο η η ο 〇 o n n o n 〇 ο o o 〇 〇 ο ο ο ο ο ο 〇 o o o O 〇 〇 ο o o 〇 〇 ο ο ο ο ο ο 〇 o o o o o X X X X X ffi X SC X κ X PC E K X K X η 辦 UJ UJ UJ U) U) U) 1 I . U) I \ . LO I \ , U) LO LO UJ U) 1 Lk) 1 1 . U) 1 \ . LO LO LO 1 \ , 1 1 . V 1 t . 1 1 . 1 | . 1 1 . I 1 . I 1 . 1 1 1 \ . V 1 1 . P 瑚 Ρ I1 -« I1 I1 P -a Ρ -¾ Ρ Ρ -¾ Ρ Ρ I1 I1 l· -s P -¾ l· P P -9 p ρ p k k k K) to K) K) to to Κ) to y^\ Κ) to to to to to K) to On 4^ 1 "ί^ k k C> 七 -¾ -€ -¾ p p p ρ 1 瞧 1 1 1 1 h k vw 1 vw/ ΐ C> C> ο o o o o ο Ο Ο Ο Ο Ο 〇 o O o o o o N ο o o o n ο ο Ο ο η ο 〇 n o o o o n w Ε Κί X r-j X K) X N) X K) κ Κ) κ Κ) κ Κ) X κ> ffi Κ) ffi Κ) X bJ X KJ E K) ffi K) E N) ffi r〇 X K) ο o o n O η ο η ο η ο η o o o n o O X μ to X to ffi K) X NJ Κ Κ) X Κ) Κ) κ Κ) PC to X Μ Κ) K to to E K) X K) K NJ K K) ο o o n o ο ο ο ο ο Ο ο o n o n 〇 o κ Κ) ffi K) E to E to X K> ffi NJ ffi to X Κ) κ Κ) X Κ) ffi to ffi to K K) K K) X to X NJ K to X to η μ-Η 1 1 -a 1 1 -a -a 1 -s 1 K) U) p ρ ρ p p -a 1 1 5 o I 1 5 ο 1 -9 1 LO 〇 E to E K) n κ Κ) ο Ο ffi Ν> η 1 1 O K K> ffi K) n Ο η I 1 X η NJ O o 1 〇 n 1 n κ Ε ffi ο X 'K K X K n 'w^ X K) Ε to η 1 1 1 1 1 z z 1 z X 1 1 Ζ 1 1 1 z 1 z I to H—* 1 1 I 1 Κ) Η—^ 、* 1 I 1 1 to 1 to I ffi CD r-f· (讀先閲讀背面之注意事項再填寫本頁) -44- 本紙張尺度適川+國國家標缚(rNS ) Λ4規格(210X297公釐) 546295 A7 B7 五、發明説明( s if: 準 局 消 1V A 竹 印 42 1—Η 1 to t—1 ΗΗ 1 to 0 ΗΗ 1 Κ) Lk) ^0 l-H 1 K) OJ 00 I—H 1 K) Lk) *<1 1—1 1 K) OJ ON Η-Η 1 Κ) U) ^Τ\ ΗΗ 1 to LO HH 1 K) LO Lk> h-H 1 K) U) K) HH 1 K) U) 1-^ HH 1 b〇 LO 〇 l-H 1 K) to Ό 1—H 1 to K) 00 l-H 1 to to h-H 1 K) Κ) Η-Η 1 to Κ) )—I 1 K> K> 2 >-s η η 0 n 0 〇 η 0 〇 〇 〇 n 〇 n 〇 η ο n ο ο 0 0 0 O ο Ο O O O 0 O O O ο ο 〇 ο ο 0 〇 0 O ο Ο O O O 0 O O O ο ο 0 ffi X Κ K K ffi X ffi K X ffi K ffi ffi K X κ ffi 辦 舛 ψτ 1 1 . LO I 1 , U) 1 1 , U) V 1 1 . U) 1 \ . U) V I 1 . U) I 1 . U) V 1 1 , U) V 1 1 . U) 1 U) V 1 \ , LO 1 LO 4^ 1 1 . LO V 1 Lk) 4^ 1 1 . LO V I LO V I ι . LO 1 1 . I1 Ρ Ρ -0 P P l· I1 P I1 I1 -9 I1 l· I1 -¾ I1 -¾ I1 I1 I1 -€ I1 p ρ ρ p p p ρ p p p p p p p ρ ρ pi k k k k k 唞 K) 人 to to /^s to to bO Κ) 1 to Q 1 to to 息 K) 1 K) ^ a ^ A On f" -1^ -i^ 4^ 声t -¾ Ο Ο Ο 〇 O O n 0 0 〇 〇 o 〇 O O h 0 0 X 1' 4^ 1' 丨•丨 !' ’ 1' Ss«^ 熟 κ X K X X -¾ -¾ -¾ -¾ -¾ h h k h h h p p c> 1 纏 1 Di 1 (> (S (> 〇 0 0 O O ο ο O 0 0 0 〇 ό 0 6 ό 6 ό N η η 0 〇 〇 ο η n 0 0 0 〇 o 0 ο ο n o ω X Κ) X Κ) K K) X K) ffi to ffi Κ) X ro E to X K) K) ffi to to ffi K) to K) Ε to X ro E to η η 0 〇 0 ο Ο 〇 〇 0 〇 n 0 0 ο 0 0 〇 X Κ) Ε Κί X NJ K Ki ffi K) κ Κ) Κ Κ) K K) ffi to ffi K) K to K ffi to E to X to ffi Κ) X K) X t〇 η η 0 n n ο ο 0 0 0 0 n 0 n 0 ο 〇 〇 κ ίΌ κ Κ) E ro E K) K ro κ to κ Κ) E K) E to E K) X to X K) X to κ ro Ε NJ K> K ro 1 -¾ -¾ 1 1 1 -a -¾ 1 1 -€ -¾ -Q -¾ to ρ p p p 1 -9 -9 1 1 1 5 n I 1 5 Ο u> 〇 ffi NJ 〇 η X to κ to Ο I Ο n 8 n η 1 ί n ffi K> K 0 0 1 1 η ffi n 〇 ffi X K X n a ffi 汛 Ο X K 0 K bO ο κ κ> 1 z 1 ζ 1 1 z 2 1 1 2 z Z X 1 2 1 2 ζ 1 1 Z z 1 1 2 z Z 弋 to 、^^ 1 1 ^0 1 I to )—^· 1 1 1 1 ^0 H—A 1 1 1 1 K 〇 r-f -45 (請先閱讀背面之注意事項再填寫本頁) 、1Τ 本紙張尺度逍用中國國家標碑(CNS ) Λ4規格(21 OX 297公釐) 546295 B7 五、發明説明(43 樣 準 局 J1 消 A 印 H-H 1 Η-Η 1 ΗΗ 1 ΗΗ 匡 Ι-Η 1 )—1 1 1—Η 1 1—H 1 1—H 1 l-H 1 h-H 1 HH 1 )—1 1 Η-Η 1 ι—ι I 2 b〇 ^r\ 〇\ Κ) ΙΜ Κ) Κ) U) Κ) U\ Κ) Κ) Ln 1—^ b〇 Ln ο to K> oo to Os to K) 仁 Κ) hJ NJ 卜t η Ο Ο Ο Ο Ο Ο o 〇 o n o o ο n ο ο Ο Ο Ο Ο Ο O 〇 o o O o ο O ο ο ο ο Ο ο Ο o o o o o o ο O X κ Ε X X X ffi X E E X K η η 舛 u> U) U) U) υο U) Lk) U) U) LO LO υο U) U) U) I « . 私 1 \ . 1 t . 払 1 1 , V 1 1 . V 1 ι . V 1 1 . V 1 I . V 1 t . V 1 \ . V 1 1 . 1 1 . V 1 1 . V 1 ι . V 1 i . Ρ Ρ Ρ -9 Ρ -¾ Ρ -9 Ρ P P P -¾ P P -9 P -¾ Ρ P -9 ρ ρ ρ ρ ρ p p p p p ρ p 1 I 1 1 1 1 1 1 1 1 1 k ¥r Μ 粑A V LO U) yj U) ρ UJ h U) h Lk) h V ^ C^ ή K) p κ> p Κ) ρ to Lk) On > ο > V a 3 > a c^ ό V V V V -¾ to ψ \h ί, to ψ Μ Κ) ψ L· ^Τ\ W a h _ g X _ g X ^ 〇 1 i丨 声t 1 ί丨 1 卜 I ί丨 -9 ~\η -a U) 1 ΰ> l· p l· p ψ p p ρ -½ -¾ I 雇 1 p p Ψ p k k ο ο Ο Ο ο Ο o o o o o o 〇 Ο ο Ν ο ο Ο Ο ο η n O n o o O η ο ο W κ to X to Ε to K Κ) Κ Κ) Ε Κ) K to K K) X K) K K) K K> E to Ε to Ε Κί κ Κ) Ο Ο ο ο ο η o n o o o O η Ο Ο κ κ> X Κ) X κ> Ε Κ) Κ) κ to X NJ K K) K K> to E K) E K) X Κ) Ε Κ) Ε Κ) ο ο η ο ο ο 〇 o o o o o η ο ο X Κ) κ Νί Κ Κ) Κ Κ) κ> κ to K to K K) ffi to K Ki K K> K) X to to Ε to -S 1 -a 1 -9 -s 1 -¾ 1 -¾ NJ ρ ρ p p ρ -S 1 -9 1 -Θ 1 1 ,^\ -¾ -¾ UJ Ο κ to ο ο I Ο ο n n 1 n o 1 η η Ο ffi κ ffi X ffi K X 、ffi X Κ) η X ffi ζ I 2 2 1 Z 2 1 2 1 ζ ζ X 1 2 1 z 2 1 2 Z 1 Ζ 1 I 1 I 1 1 1 1 I ι ι K CD 46 (請先閱讀背面之注意事項再填寫本頁) 、11 本紙張尺度適用中國國家標埤((、阳)/\4規格(210'乂 297公釐) 546295 A7 B7 五、發明説明 44、 1T -42- The paper size is suitable for the Chinese national standard ((, NS) Λ4 specification (21 OX 297 mm) 546295 A7 B7 Ministry of Inferiority Bureau 17 ,, / nfr He still printed shirt ^ V. Invention Explanation (4〇) HH 1 to 〇Ι-Η 1 Κ) ο private hH to ο LO ΗΗ 1 Κ) g ΗΗ 1 Μ Η- ^ ►—1 1 Κ) ο ο hH 1 ΗΗ 1 Η—1 00 ΗΗ 1 ) — ^ ΗΗ 1 h—k σ \ ΗΗ 1 Η—1 Lh HH 1 Η—λ Ό RenΗΗ 1 μ— * MD LO tH 1 h— to ΗΗ Η Η— * ΗΗ 1 ο ΗΗ 1 h— ^ 00 ΗΗ 1 Η— ^ 00 00 ΗΗ 1 1— ^ ΟΟ ΗΗ 1 Ον 2 η ο η ο ο ο ο η ο ο ο ο ο η η η ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο Ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο κ X κ X κ XX κ X κ κ κ κ κ ε κ κ X ε κ κ κ ηη DO Lh) U) U) LO Lk > U) V 1 1, U) V 1 1, LO V 1 I. LO LO U) LO U) V 1 \, U) LO LO LO LO u > U \ I 1, V 1 1, 1 1, 1 1, 1 1, 1 \, 1 1. 1 1. 1 1. II 1, I 1, II 1 I. V 1 1. Ρ Ρ Ρ Ρ -a Ρ -S Ρ Ρ Ρ I1 -¾ Ρ Ρ -a Ρ -a I1 -a Ρ Ρ Ρ -¾ I1 -8 Ρ Ρ I1 pi pi ρ ρ ρ ρ ρ ρ ρ ρ ρ ρ k η ο ό ο η ο ό ο ή ο ό ο h ο -Ρ ^ η ο ό ο ο LO 1 ο ο κ 1 LO I η ο ο Ε 1 U) I Ο ο ο Ε 1 4 ^ -a -Ρ ^ I 1 4 ^ 1 sound τ ON ο X UJ ο ffi ΰ) ο κ U) ο XU) ο ffi heart ο X ΰ) ο κ ΰ) ο κ UJ ο ffi L * J ο X ΰ) 1 1 1 4 ^ Avoid ρ ρ ρ ρ ρ ♦ Mr 蝌 蝌 ο Ο Ο ο ο ο ο ο ο ο ο ο ο Ο Ο ο ο ο N ο Ο Ο Ο ο ο ο ο ο ο η η η η ο η η ο ο η dd κ κ X ffi ffi ffi XXXXXXXX ffi XXXX κ ο η η Ο ο ο ο η ο ο η ο ο ο η η ο ο ο ο ο Ε Κ) Κ Κ) X to Κ Κ) X ho κ to κ Κ) κ Κ) Ε NJ ffi to Ε NJ Ε tsJ ffi to Ε to κ NJ Κί X Κ) κ κ) X to X to ο Ο η ο ο η ο ο ο ο η η η ο η η Ο η ο η κ κ) κ NJ κ Κ) Ε Κ) κ κ) κ κ > ffi κ) X Κ) κ κ) X to X ίο κ to X κ) X κ > κ) κ) κ to X to to 1 1 ο ΗτΗ ο 1 -¾ 1 -a 1 ~ a 1 K) ρ ρ U) ρ ρ ρ pi 5 η 1 1 1 -a 1 I -S 1 X ο ο κ 1 Ο ο 1 ο ο 1 ο ο 1 ο ο 1 η η 1 ο n κ ο ffi ffi Μ κ ffi κ κ \ κ κ ffi KX NJ 1 1 1 乂 1 1 2 1 ζ z X 乂 1 ZZ 1 ζ 1 1 1 乂 1 z 弋 1 0 Κ) I 1 h—k 1 1 KK) 1 1 Κ) I 1 II to 1 1 (read the precautions on the back before filling this page) -43- This paper is applicable to the standard + national standard 埤(RNS) Λ4 specification (210X 297 mm) 546295 A7 B7 V. Description of the invention (41) HH 1 ΗΗ HH HH HH 1 Η—1 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 ΗΗ 1 Η-Η 1 ΗΗ 1 HH 1 hH 1 HH 1 HH 1 HH 1 HH 1 2 K) K) LO Κ) Κ) Κ) K) bO 1- ^ bO K) o K) VO to oo Κ) Κ) 〇 \ Κ) h—k Κ) 払 Κ ) LO Κ) to to 1—i to »— * o to s K)% K) o K) 〇η n o 〇 η ο ο η η ο 〇onnon 〇ο oo 〇〇ο ο ο ο ο ο οooo O 〇〇ο oo 〇〇ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο UJ UJ UJ U) U) U) 1 I. U) I \. LO I \, U) LO LO UJ U) 1 Lk) 1 1. U) 1 \. LO LO LO 1 \, 1 1. V 1 t. 1 1. 1 |. 1 1. I 1. I 1. 1 1 1 \. V 1 1. P Ip I1-«I1 I1 P -a P -¾ P P -¾ P P I1 I1 l · -s P -¾ l · PP -9 p ρ pkkk K) to K) K) to to Κ) to y ^ \ Κ) to to to K) to On 4 ^ 1 " ί ^ kk C > VII -¾-€ -¾ ppp ρ 1 See 1 1 1 1 hk vw 1 vw / ΐ C > C > ο oooo ο Ο Ο Ο Ο 〇 〇o O oooo N ο ooon ο ο Ο ο η ο 〇noooonw Ε Κί X rj XK) XN) XK) κ Κ) κ κ) κ Κ) X > ffi Κ) ffi Κ) X bJ X KJ EK) ffi K) EN) ffi r〇XK) ο oon O η ο η ο η ο η ooono OX μ to X to ffi K) X NJ Κ Κ) X Κ ) Κ) κ Κ) PC to X Μ Κ) K to to EK) XK) K NJ KK) ο oono ο ο ο ο ο ο ο onon 〇o κ Κ) ffi K) E to E to X K > ffi NJ ffi to X Κ) κ Κ) X Κ) ffi to ffi to KK) KK) X to X NJ K to X to η μ-Η 1 1 -a 1 1 -a -a 1 -s 1 K) U) p ρ ρ pp -a 1 1 5 o I 1 5 ο 1 -9 1 LO 〇E to EK) n κ Κ) ο 〇 ffi Ν > η 1 1 OK K > ffi K) n Ο η I 1 X η NJ O o 1 〇n 1 n κ Ε ffi ο X 'KKXK n' w ^ XK) Ε to η 1 1 1 1 1 zz 1 z X 1 1 Zn 1 1 1 z 1 z I to H— * 1 1 I 1 Κ ) Η— ^, * 1 I 1 1 to 1 to I ffi CD rf · (Read the precautions on the back before filling this page) -44- This paper is suitable for Sichuan + National Standard Binding (rNS) Λ4 specifications ( 210X297 mm) 546295 A7 B7 V. Description of invention (s if: quasi-offset 1V A bamboo Imprint 42 1—Η 1 to t—1 ΗΗ 1 to 0 ΗΗ 1 Κ) Lk) ^ 0 lH 1 K) OJ 00 I—H 1 K) Lk) * < 1 1-1 1 K) OJ ON Η- Η 1 Κ) U) ^ Τ \ ΗΗ 1 to LO HH 1 K) LO Lk > hH 1 K) U) K) HH 1 K) U) 1- ^ HH 1 b〇LO 〇lH 1 K) to Ό 1 --H 1 to K) 00 lH 1 to to HH 1 K) Κ) Η-Η 1 to Κ)) -I 1 K > K > 2 > -s η η 0 n 0 〇η 0 〇〇〇〇〇 n 〇η ο n ο ο 0 0 0 O ο Ο OOO 0 OOO ο ο 〇ο ο 0 〇0 O ο Ο OOO 0 OOO ο ο 0 ffi X KK KK ffi X ffi KX ffi K ffi ffi KX κ ffi ψτ 1 1. LO I 1, U) 1 1, U) V 1 1. U) 1 \. U) VI 1. U) I 1. U) V 1 1, U) V 1 1. U) 1 U ) V 1 \, LO 1 LO 4 ^ 1 1. LO V 1 Lk) 4 ^ 1 1. LO VI LO VI ι. LO 1 1. I1 Ρ Ρ -0 PP l · I1 P I1 I1 -9 I1 l · I1 -¾ I1 -¾ I1 I1 I1-€ I1 p ρ ρ ppp ρ ppppppp ρ pi kkkkk 唞 K) person to to / ^ s to to bO Κ) 1 to Q 1 to to interest K) 1 K) ^ a ^ A On f " -1 ^ -i ^ 4 ^ sound t -¾ Ο Ο Ο 〇OO n 0 0 〇〇o 〇OO h 0 0 X 1 '4 ^ 1' 丨 • 丨! '' 1 'Ss «^ cooked κ XKXX- ¾ -¾ -¾ -¾ -¾ hhkhhhpp c > 1 wrapped 1 Di 1 (> (S (> 〇0 0 OO ο ο O 0 0 0 〇ό 0 6 ό 6 ό N η η 0 〇〇ο η n 0 0 0 〇o 0 ο ο no ω X Κ) X Κ) KK) XK) ffi to ffi KK) X ro E to XK) K) ffi to to ffi K) to K) Ε to X ro E to η η 0 〇0 ο 〇 〇〇00 〇n 0 0 ο 0 0 〇X Κ) Ε Κί X NJ K Ki ffi K) κ Κ) Κ KK) KK) ffi to ffi K) K to K ffi to E to X to ffi Κ) XK) X t〇η η 0 nn ο ο 0 0 0 0 n 0 n 0 ο 〇〇κ ίΌ κ Κ) E ro EK) K ro κ to κ κ) EK) E to EK) X to XK) X to κ ro Ε NJ K > K ro 1 -¾ -¾ 1 1 1 -a -¾ 1 1-€ -¾ -Q -¾ to ρ ppp 1 -9 -9 1 1 1 5 n I 1 5 〇 u > 〇ffi NJ 〇η X to κ to 〇 I Ο n 8 n η 1 ί n ffi K > K 0 0 1 1 η ffi n 〇ffi XKX na ffi flood 0 XK 0 K bO ο κ κ > 1 z 1 ζ 1 1 z 2 1 1 2 z ZX 1 2 1 2 ζ 1 1 Z z 1 1 2 z Z 弋 to, ^^ 1 1 ^ 0 1 I to) — ^ · 1 1 1 1 ^ 0 H—A 1 1 1 1 K 〇rf -45 (Please read the precautions on the back before filling out this page) 、 1Τ This paper is not used in China National Monument (CNS) Λ4 specification (21 OX 297 mm) 546295 B7 V. Description of the invention (43 sample standard bureau J1 Consumer A India HH 1 Η-Η 1 ΗΗ 1 ΗΗ ΙΙ-Η 1) —1 1 1— Η 1 1—H 1 1—H 1 lH 1 hH 1 HH 1) —1 1 Η-Η 1 ι—ι I 2 b〇 ^ r \ 〇 \ Κ) ΙΜ Κ) Κ) U) Κ) U \ Κ ) Κ) Ln 1— ^ b〇Ln ο to K > oo to Os to K) Ren KK) hJ NJ BU t η Ο Ο Ο Ο Ο Ο Ο o 〇onoo ο n ο ο Ο Ο Ο Ο Ο O 〇oo O 〇oo O o ο O ο ο ο ο Ο ο Ο oooooo ο OX κ Ε XXX ffi XEEXK η η 舛 u > U) U) U) U) υο U) Lk) U) U) LO LO υο U) U) I) «. Private 1 \. 1 t. 払 1 1, V 1 1. V 1 ι. V 1 1. V 1 I. V 1 t. V 1 \. V 1 1. 1 1. V 1 1. V 1 ι. V 1 i. Ρ Ρ Ρ -9 Ρ -¾ Ρ -9 PPP PPP-¾ PP -9 P- ¾ Ρ P -9 ρ ρ ρ ρ ρ ppppp ρ p 1 I 1 1 1 1 1 1 1 1 1 k ¥ r Μ 粑 AV LO U) yj U) ρ UJ h U) h Lk) h V ^ C ^ Price K) p κ > p Κ) ρ to Lk) On > ο > V a 3 > ac ^ ό VVVV -¾ to ψ \ h ί, to ψ Μ Κ) ψ L · ^ Τ \ W ah _ g X _ g X ^ 〇1 i 丨 声 t 1 ί 丨 1 卜 I ί 丨 -9 ~ \ η -a U) 1 ΰ > l · pl · p ψ pp ρ -½ -¾ I hire 1 pp Ψ pkk ο ο Ο Ο ο Ο oooooo 〇Ο ο Ν ο ο Ο Ο ο η n O noo O η ο ο W κ to X to Ε to K Κ) Κ Κ) Ε Κ) K to KK) XK) KK) K K > E to Ε to Ε Κί κ Κ) Ο Ο ο ο ο η onooo O η Ο Ο κ κ > X κ) X κ > Ε) Κ) κ to X NJ KK) K K > to EK) X EK ) Ε Κ) Ε Κ) ο ο η ο ο ο 〇ooooo η ο ο X Κ) κ Νί Κ Κ) Κ Κ ) κ > κ to K to KK) ffi to K Ki K K > K) X to to Ε to -S 1 -a 1 -9 -s 1 -¾ 1 -¾ NJ ρ ρ pp ρ -S 1 -9 1 -Θ 1 1 ^ \ -¾ -¾ UJ Ο κ to ο ο I Ο ο nn 1 no 1 η η Ο ffi κ ffi X ffi KX, ffi X κ) η X ffi ζ I 2 2 1 Z 2 1 2 1 ζ ζ X 1 2 1 z 2 1 2 Z 1 ZZ 1 I 1 I 1 1 1 1 I ι K CD 46 (Please read the precautions on the back before filling this page) 、 11 This paper size applies to Chinese national standards埤 ((、 阳) / \ 4) (210 '乂 297mm) 546295 A7 B7 V. Description of Invention 44
I 準I quasi
消 fc合印 VCancel fc joint V
ΗΗ 1 HH 1 l-H 1 HH 1 h-H 1 Η-Η 1 1—1 1 ΗΗ 1 HH 1 HH 1 l-H 1 Η-H 1 ΗΗ 1 Η-Η 1 z to 〇 to Ov K> G\ 00 K) 266 Κ) ΟΝ Lh to Os Κ) 〇\ UJ 262 K) ON H- K> On 〇 to U\ o Κ) U\ 00 to KJ\ 〇 Π 〇 〇 〇 η n η 〇 o 〇 n ο ο Ο o o o o ο 〇 ο o o 〇 〇 Ο ο Ο 〇 o o o ο o ο o o o 〇 ο ο K K K K X K X a X X ffi κ a η 1 U) 1 U) V 1 LO 1 U) 4^ 1 LO I V 1 LO I LO V 1 LO 1 LO V 1 U) 1 LO V 1 Lk> V 1 Ul l· l· -¾ l· l· -¾ l· -¾ l· l· l· -¾ l· l· l· l· l· l· p p p p ρ p ρ p p p p ρ p 1 I 1 1 1 I k k k k ^ A Al+ K) Γ \.+ to Γ As Al+ K) ^ As 粑A 您A to to K) ^ a ^ A On ^ f" 〜 χ -h Q l· l· 丫⑺ > γ\ x X o L·雜 i^r \liji m siu^ siii* m l· i丨 ~9 ^ p\ ΰ> U) ΰ> k k -¾ ψ ψ -9 1 I 4 4 im 咐 裙 ρ p ρ (> (> ψ P p I p 1 p 1 h 1 1 6 〇 o o Ο o ο 〇 o o 〇 Ο 6 o N n o n o ο o Ο n o n o Ο η o dd X K> X to X K> X K) Ε Κί ffi K) X to K K) X NJ ffi K) K to ffi Κ) X Κ) X K> n o O n η o η O 〇 o O ο η o X NJ X to ffi K) ffi K) X ίΌ K to X to K to E NJ K K) K K) ffi to ffi Κ) ffi to n o o o ο n Ο n n o o ο η o X ro X K> X ro K ro κ to X NJ κ NJ X ro X ro K K> E NJ κ NJ κ Κ) K NJ 1 -9 1 1 1 -a 1 p p p ρ 1 -¾ 1 1 1 -a 1 U) 〇 1 o 〇 1 n Ο 1 n o 1 ο ο 1 X a ffi K a ffi ffi 、κ X z 1 z 1 2 乂 1 1 1 X z 1 1 1 1 2 1 κ; 1 H—fc I 1 1 1 1 1 bo 1 I to X CD (讀先閱讀背面之注意事項再填寫本頁) .眷衣_ΗΗ 1 HH 1 lH 1 HH 1 hH 1 Η-Η 1 1—1 1 ΗΗ 1 HH 1 HH 1 lH 1 Η-H 1 ΗΗ 1 Η-Η 1 z to 〇to Ov K > G \ 00 K) 266 Κ ) ΟΝ Lh to Os Κ) 〇 \ UJ 262 K) ON H- K > On 〇to U \ o Κ) U \ 00 to KJ \ 〇Π 〇〇〇η n η 〇o 〇n ο ο OO oooo ο 〇 ο oo 〇〇〇 ο Ο 〇ooo ο o ο ooo 〇ο ο KKKKXKX a XX ffi κ a η 1 U) 1 U) V 1 LO 1 U) 4 ^ 1 LO IV 1 LO I LO V 1 LO 1 LO V 1 U) 1 LO V 1 Lk > V 1 Ul l · l · -¾ l · l · -¾ l · -¾ l · l · l · -¾ l · l · l · l · l · pppp ρ p ρ pppp ρ p 1 I 1 1 1 I kkkk ^ A Al + K) Γ \. + to Γ As Al + K) ^ As 粑 A you A to to K) ^ a ^ A On ^ f " ~ χ -h Q l · l · yah > γ \ x X o L · i i ^ r \ liji m siu ^ siii * ml · i 丨 ~ 9 ^ p \ ΰ > U) ΰ > kk -¾ ψ ψ -9 1 I 4 4 im command skirt ρ p ρ (> (> ψ P p I p 1 p 1 h 1 1 6 〇oo 〇 o ο OOoo 〇 Ο 6 o N nono ο o Ο nono Ο η o dd X K > X to X K > XK) Ε Κί ffi K) X to KK) X NJ ffi K) K to ffi κ) X Κ) X K > no O n η o η O 〇o O ο η o X NJ X to ffi K) ffi K) X ίΌ K to X to K to E NJ KK) KK) ffi to ffi Κ) ffi to nooo ο n Ο nnoo ο η o X ro X K > X ro K ro κ to X NJ κ NJ X ro X ro K K > E NJ κ NJ κ KK) K NJ 1 -9 1 1 1 -a 1 ppp ρ 1 -¾ 1 1 1 -a 1 U) 〇1 o 〇1 n Ο 1 no 1 ο ο 1 X a ffi K a ffi ffi, κ X z 1 z 1 2 乂 1 1 1 X z 1 1 1 1 2 1 κ; 1 H—fc I 1 1 1 1 1 bo 1 I to X CD (Read the precautions on the back before filling this page).
、1T 47- 本紙張尺度適用中國國家標蟑((’NS ) Λ4規格(210X29*7公釐) 546295 A7 B7 五、發明説明( 45 部 標 局 j 消 f: 合 印、 1T 47- This paper size applies to the Chinese national standard cockroach ((’NS) Λ4 size (210X29 * 7mm) 546295 A7 B7 V. Description of the invention (45 Ministry of Standards Bureau j Consumer f: Joint printing)
Ι-Η 1 HH 1 HH 1 HH 1 h-H 1 h-H 1 1—H 1 ΗΗ 1 HH 1 ΗΗ 1 ΗΗ 1 h-H 1 ΗΗ 1 ΗΗ 1 HH 1 Z to 00 U\ to 00 Μ 00 OJ κ> 〇〇 to K> 00 H—^ to oo o to Κ) K) Κ) to to to LO INJ to to ►—k Ο 〇 〇 〇 〇 〇 o ο Ο ο ο ο ο ο o Ο 〇 〇 Ο o 〇 o ο ο ο ο Ο ο Ο 〇 Ο ;〇 〇 Ο o O o ο ο ο ο Ο ο Ο 〇 κ K X ffi X X a ffi ffi κ a κ a X a SsLA- -ί^ γ^Ύ ι y^y ι 辦~9 辦~9 -¾ 辦~9 ρ p ρ U) U) -Ρ^ I l· 1 l· ρ p 1 -a -9 -¾ -a -s -3 CS欠 ON ψτ ^ γι 1' (丨 Ο 〇 〇 o o O ο ο ο Ο ο ο ο ο o N η 〇 〇 o o 〇 η ο ο Ο η ο ο ο O ω X Κί K K) ro K N-) X K) K to κ ro κ to Ε to X to X to κ to κ NJ X Κί E to ο 〇 〇 o n n ο ο ο Ο η ο ο η o X Κ) ΪΌ E K) X to X K) X to ffi Κ) E Κ) X Κ) X to X Κ) Ε Κ) X Κ) X ro X ro ο 〇 〇 η n ffi to ffi bO K to X to ffi to 1 I -s 1 1 -¾ I NJ pi ρ ρ 1 1 1 1 5 η -9 1 LO η κ ffi Κ) η 1 〇 〇 1 n o 1 1 η ο κ ο η 1 n X X X E X Ε to ο 'Κ X X η κ to f 2 Z 1 z 1 1 Ζ ζ 2 1 z X 届 Z 1 1 雇 2 1 1—^ 1 1 1 1 to ι 睡 ι ι ι 1 K CD (讀先閱讀背面之注意事項再填寫本頁) 春衣_Ι-Η 1 HH 1 HH 1 HH 1 hH 1 hH 1 1—H 1 ΗΗ 1 HH 1 ΗΗ 1 ΗΗ 1 hH 1 ΗΗ 1 ΗΗ 1 HH 1 Z to 00 U \ to 00 Μ 00 OJ κ > 〇〇to K > 00 H— ^ to oo o to Κ) K) Κ) to to LO INJ to to ►—k 〇 〇〇〇〇〇〇〇o ο Ο ο ο ο ο ο o Ο 〇〇〇〇 o ο ο ο ο Ο ο Ο 〇〇; 〇〇Ο o O o ο ο ο ο Ο ο 〇 〇κKX ffi XX a ffi ffi κ a κ a X a SsLA- -ί ^ γ ^ Ύ ι y ^ y ι Office ~ 9 Office ~ 9 -¾ Office ~ 9 ρ p ρ U) U) -P ^ I l · 1 l · ρ p 1 -a -9 -¾ -a -s -3 CSUnON ψτ ^ γι 1 '(丨 〇 〇〇oo ο ο ο Ο ο ο ο ο o N η 〇〇oo 〇η ο ο Ο η ο ο O ω X Κί KK) ro K N-) XK) K to κ ro κ to Ε to X to X to κ to κ NJ X Κί E to ο 〇〇onn ο ο ο Ο ο ο η o X Κ) ΪΌ EK) X to XK) X to ffi Κ) E Κ) X Κ) X to X Κ) Ε Κ) X Κ) X ro X ro ο 〇〇η n ffi to ffi bO K to X to ffi to 1 I -s 1 1 -¾ I NJ pi ρ ρ 1 1 1 1 5 η -9 1 LO η κ ffi κ) η 1 〇〇1 no 1 1 η ο κ ο η 1 n XXXEX Ε to ο 'Κ XX η κ to f 2 Z 1 z 1 1 ζ ζ 2 1 z X Session Z 1 1 Hire 2 1 1- ^ 1 1 1 1 to ι sleep ι ι ι 1 K CD (read first read the back of the (Please fill in this page again)
、1T 48- 本紙張尺度適用中國國家標缚((、NS ) Λ4規枱(2】0X 297公釐) 546295 A7 B7 五、發明説明( 部 it 卑 局 消 合 印 46 ΗΗ 1 HH 1 HH 1 Η—H 1 HH 1 h—( 1 1—( 1 l-H 1 HH 1 Ι-Η 1 1—( 1 Ι-Η 1 Η—( 1 »—( 1 2 Κ) Ό K) 00 to K) Ό ON to Ό Lh to K) uo K) K) to i—k Κ) Ό ο Κ> οο to οο οο Κ) οο Κ) 00 η 〇 〇 n o 〇 〇 〇 o η η ο Ο η 〇 〇 O o o o o 〇 o Ο ο ο Ο ο 〇 〇 O o o o o 〇 o ο ο ο ο ο X X ffi E K ffi ffi κ κ X κ a 辦 辦 辦 _ -a 辦-0 pi L/ϊ 1 LO 1 U) 1 U) 1 LO 1 U) V Q r ^ r Q K) 1 Κ) 1 /—Ν Is) 1 2(3,‘ 乙基 σ\ W W w w w V C^ V ^ V 1 4^ ! 1 專 尊 尊 _ γι γι l· l· l· w w W -Θ -¾ -9 1 ο 1 1 ο p 1 1 1 1 1 (/) 1 1 (Λ) l "'"Ί ⑺ h-* 1 1 1 Ο ι_^ ο 1—J Ο l_J 1 1 1 〇 〇 o o o o o 〇 Ο ο Ο Ο 〇 〇 N 〇 〇 n o o o n n Ο ο Ο Ο η 〇 dd PC K) X to X K) K K) K K) EC to X K> X NJ κ Κ) Ε κ> κ Κ) κ ΙΌ Κ) E to 〇 〇 O o n o n n Ο ο ο ο ο 〇 X X ffi K X ffi ffi ffi X X X X ffi ffi 〇 〇 o o o o o n ο ο ο ο ο η K NJ to ffi K) a K) K K) K) K t〇 K K) κ Κ) κ ί〇 NJ κ ίο Κ) ffi to -¾ -¾ -¾ 1 -0 I -a I -s NJ p p ρ -¾ -9 1 I -¾ 1 -¾ u> n ffi K K> o 〇 X 〇 ffi t^T n o B o O I η ο 1 η o X K) o o ffi X ffi ffi K κ a κ E NJ o Z z z 1 z 1 ζ ζ 1 ζ X Z 2: 1 z 1 ζ 1 ζ 弋 1 1 1 I 1 1 1 ^κ> I 1 to I 1 X a r-K 49 (請先閱讀背面之注意事項再填寫本頁) 、1Τ 本紙張尺度適川中國國家標缚(CNS ) Λ4規格(210X 297公釐) 546295 A7 B7 五、發明説明( 47^ 部 中 準 消 t: 合 印 本紙張尺度適用中國國家標缚(rNS ) Λ4規桔(210X 297公釐)、 1T 48- This paper size is applicable to China's national standard ((, NS) 规 4 gauge (2) 0X 297 mm) 546295 A7 B7 V. Description of the invention (Ministry of Inferiority and Convergence 46 ΗΗ 1 HH 1 HH 1 Η—H 1 HH 1 h— (1 1— (1 lH 1 HH 1 Ι-Η 1 1— (1 Ι-Η 1 Η— (1 »— (1 2 Κ) Ό K) 00 to K) Ό ON to Ό Lh to K) uo K) K) to i—k Κ) Ό ο Κ > οο to οο οο Κ) οο Κ) 00 η 〇〇no 〇〇〇o η η ο ο η 〇〇O oooo 〇o Ο ο ο Ο ο 〇〇O oooo 〇o ο ο ο ο ο XX ffi EK ffi ffi κ κ X κ a Office Office Office--a Office Office-0 pi L / ϊ 1 LO 1 U) 1 U) 1 LO 1 U) VQ r ^ r QK) 1 Κ) 1 / —Ν Is) 1 2 (3, 'ethylσ \ WW www VC ^ V ^ V 1 4 ^! 1 exclusive respect_ γι γι l · l · l · Ww W -Θ -¾ -9 1 ο 1 1 ο p 1 1 1 1 1 (/) 1 1 (Λ) l " '" Ί ⑺ h- * 1 1 1 Ο ι_ ^ ο 1—J Ο l_J 1 1 1 〇〇ooooo 〇〇 ο Ο Ο 〇〇N 〇〇nooonn Ο ο Ο Ο η 〇dd PC K) X to XK) KK) KK) EC to X K > X NJ κ κ) Ε κ > κ κ ) κ ΙΌ Κ) E to 〇〇O ononn Ο ο ο ο ο 〇XX ffi KX ffi ffi ffi XXXX ffi ffi 〇〇ooooon ο ο ο ο ο η K NJ to ffi K) a K) K) K t 〇KK) κ Κ) κ ί〇NJ κ ίο Κ) ffi to -¾ -¾ -¾ 1 -0 I -a I -s NJ pp ρ -¾ -9 1 I -¾ 1 -¾ u > n ffi K K > o 〇X 〇ffi t ^ T no B o OI η ο 1 η o XK) oo ffi X ffi ffi K κ a κ E NJ o Z zz 1 z 1 ζ ζ 1 ζ XZ 2: 1 z 1 ζ 1 ζ 弋 1 1 1 I 1 1 1 ^ κ > I 1 to I 1 X a rK 49 (Please read the precautions on the back before filling out this page), 1T This paper is suitable for Sichuan China National Standards (CNS) Λ4 specifications (210X 297 mm) 546295 A7 B7 V. Description of the invention (47 ^ Partial quasi-consumption t: The size of the joint paper is applicable to China House Standard Binding (rNS) Λ4 gauge orange (210X 297 mm)
1*Η2Λ4,5 丨hf 2*"2-(4,5-卜瑚^無^;10 H—( 1 U) 〇 K) ΗΗ 1 UJ Η—^ ΗΉ 1 UJ Ο 2 Π 〇 〇 Ο ο ο κ η ο ο ϊ: π ψτ 1 1丨 ^ |\ ψτ 1 U) W I LO m Os 〇 ο ο Ν 〇 Κ) 〇 ffi hJ η Ε ίΌ η κ ί〇 ο ffi Κ) η X Ν·) ο X Κ) η ffi to η κ NJ ω 1 1 hj -a 1 1 u> η κ 1 1 1 1 X 1 1 弋 I Κ) Ν^^ K CD (請先閱讀背面之注意事項再填寫本頁) 546295 A7 B7 五、發明説明(48) 範例1 2 以前述的键結分析方法測定化合物所得之受體键結數據 如下表所列,結果列於2中。 表2 受體鍵結數據(I數値) 化合物 ETa Ki[nM] ETb Ki[nM] 1-2 一種鏡像異構物 43 345 1-224 一種鏡像異構物 33 6.8 1-171 一種鏡像異構物 15.7 26.4 1-145 一種鏡像異構物 1100 13.6 1-137 一種鏡像異構物 60 11 1-1 一種鏡像異構物 190 495 1-88 一種鏡像異構物 50 10 1-89 一種鏡像異構物 25 17 1-35 一種鏡像異構物 400 250 1-36 一種鏡像異構物 300 250 1-128 一種鏡像異構物 46 9 1-129 一種鏡像異構物 23 10 1-44 一種鏡像異構物 205 365 1-45 一種鏡像異構物 40 255 1-89 一種鏡像異構物 35 93 1_10 一種鏡像異構物 65 190 1-116 一種鏡像異構物 9 43 1-290 一種鏡像異構物 22 700 1-292 一種鏡像異構物 1.8 170 1-293 一種鏡像異構物 13 15 1-295 一種鏡像異構物 215 1400 -51 - 本紙張尺度適用中國國家標摩((、NS ) Λ4規格(2]OX 297公釐) (請先閱讀背面之注意事項再填寫本頁)1 * Η2Λ4,5 丨 hf 2 * " 2- (4,5-Buhu ^ None ^; 10 H— (1 U) 〇K) ΗΗ 1 UJ Η— ^ ΗΉ 1 UJ 〇 2 Π 〇〇〇〇 ο ο κ η ο ο ϊ: π ψτ 1 1 丨 ^ | \ ψτ 1 U) WI LO m Os 〇ο ο Ν 〇Κ) 〇ffi hJ η Ε ίΌ η κ ί〇ο ffi κ) η X Ν ·) ο X Κ) η ffi to η κ NJ ω 1 1 hj -a 1 1 u > η κ 1 1 1 1 X 1 1 1I Κ) Ν ^^ K CD (Please read the precautions on the back before filling this page) 546295 A7 B7 V. Explanation of the Invention (48) Example 1 2 The receptor binding data obtained by the above method for the determination of compounds by the above-mentioned method of binding analysis are listed in the following table, and the results are listed in 2. Table 2 Acceptor bonding data (I number 値) Compound ETa Ki [nM] ETb Ki [nM] 1-2 a mirror isomer 43 345 1-224 a mirror isomer 33 6.8 1-171 a mirror isomer 15.7 26.4 1-145 A mirror isomer 1100 13.6 1-137 A mirror isomer 60 11 1-1 A mirror isomer 190 495 1-88 A mirror isomer 50 10 1-89 A mirror isomer 25 17 1-35 one enantiomer 400 250 1-36 one enantiomer 300 250 1-128 one enantiomer 46 9 1-129 one enantiomer 23 10 1-44 one enantiomer 205 365 1-45 an enantiomer 40 255 1-89 an enantiomer 35 93 1_10 an enantiomer 65 190 1-116 an enantiomer 9 43 1-290 an enantiomer 22 700 1-292 A mirror image isomer 1.8 170 1-293 A mirror image isomer 13 15 1-295 A mirror image isomer 215 1400 -51-This paper is applicable to China National Standard ((, NS) Λ4 specifications ( 2] OX 297 mm) (Please read the notes on the back before filling this page)
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19738578A DE19738578A1 (en) | 1997-09-04 | 1997-09-04 | Carboxylic acid derivatives useful as endothelin A and B antagonists also active as renin and angiotensin inhibitors |
DE1998111915 DE19811915A1 (en) | 1998-03-18 | 1998-03-18 | New carboxylic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
TW546295B true TW546295B (en) | 2003-08-11 |
Family
ID=26039663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087114595A TW546295B (en) | 1997-09-04 | 1998-09-03 | Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1009741A1 (en) |
JP (1) | JP2001514254A (en) |
KR (1) | KR20010023615A (en) |
CN (1) | CN1269792A (en) |
AR (1) | AR017052A1 (en) |
AU (1) | AU748610B2 (en) |
BG (1) | BG104222A (en) |
BR (1) | BR9811631A (en) |
CA (1) | CA2302350A1 (en) |
CO (1) | CO4970738A1 (en) |
HR (1) | HRP980484A2 (en) |
HU (1) | HUP0004935A3 (en) |
ID (1) | ID25620A (en) |
IL (1) | IL134276A0 (en) |
NO (1) | NO20001077L (en) |
NZ (1) | NZ502660A (en) |
PL (1) | PL338954A1 (en) |
SK (1) | SK1522000A3 (en) |
TR (1) | TR200000602T2 (en) |
TW (1) | TW546295B (en) |
WO (1) | WO1999011629A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19924892A1 (en) * | 1999-06-01 | 2000-12-07 | Basf Ag | New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists |
KR20090020559A (en) * | 2006-05-29 | 2009-02-26 | 니콕스 에스. 에이. | Nitrated heterocyclic compounds as endothelin receptor antagonists |
WO2009109549A1 (en) | 2008-03-05 | 2009-09-11 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
EP2712865B1 (en) * | 2009-07-10 | 2016-03-16 | Cadila Healthcare Limited | Improved process for the preparation of ambrisentan |
MX2012009149A (en) | 2010-02-19 | 2012-09-28 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation. |
EP2760868B1 (en) | 2011-08-17 | 2018-04-25 | Boehringer Ingelheim International GmbH | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4411225A1 (en) * | 1994-03-31 | 1995-10-05 | Basf Ag | Use of carboxylic acid derivatives as a drug |
DE19533023B4 (en) * | 1994-10-14 | 2007-05-16 | Basf Ag | New carboxylic acid derivatives, their preparation and use |
JP2000504013A (en) * | 1996-02-01 | 2000-04-04 | スミスクライン・ビーチャム・コーポレイション | Endothelin receptor antagonist |
DE19614542A1 (en) * | 1996-04-12 | 1997-10-16 | Basf Ag | New carboxylic acid derivatives, their production and use |
DE19636046A1 (en) * | 1996-09-05 | 1998-03-12 | Basf Ag | New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists |
-
1998
- 1998-08-24 ID IDW20000386D patent/ID25620A/en unknown
- 1998-08-24 BR BR9811631-2A patent/BR9811631A/en not_active IP Right Cessation
- 1998-08-24 KR KR1020007002264A patent/KR20010023615A/en not_active Application Discontinuation
- 1998-08-24 HU HU0004935A patent/HUP0004935A3/en unknown
- 1998-08-24 AU AU95333/98A patent/AU748610B2/en not_active Ceased
- 1998-08-24 TR TR2000/00602T patent/TR200000602T2/en unknown
- 1998-08-24 EP EP98948859A patent/EP1009741A1/en not_active Withdrawn
- 1998-08-24 IL IL13427698A patent/IL134276A0/en unknown
- 1998-08-24 CA CA002302350A patent/CA2302350A1/en not_active Abandoned
- 1998-08-24 WO PCT/EP1998/005354 patent/WO1999011629A1/en not_active Application Discontinuation
- 1998-08-24 SK SK152-2000A patent/SK1522000A3/en unknown
- 1998-08-24 PL PL98338954A patent/PL338954A1/en unknown
- 1998-08-24 NZ NZ502660A patent/NZ502660A/en unknown
- 1998-08-24 JP JP2000508669A patent/JP2001514254A/en active Pending
- 1998-08-24 CN CN98808862A patent/CN1269792A/en active Pending
- 1998-09-02 HR HR19811915.1A patent/HRP980484A2/en not_active Application Discontinuation
- 1998-09-03 TW TW087114595A patent/TW546295B/en active
- 1998-09-03 CO CO98050561A patent/CO4970738A1/en unknown
- 1998-09-03 AR ARP980104402A patent/AR017052A1/en not_active Application Discontinuation
-
2000
- 2000-03-02 NO NO20001077A patent/NO20001077L/en not_active Application Discontinuation
- 2000-03-06 BG BG104222A patent/BG104222A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR9811631A (en) | 2000-09-26 |
CN1269792A (en) | 2000-10-11 |
AR017052A1 (en) | 2001-08-22 |
CA2302350A1 (en) | 1999-03-11 |
NO20001077D0 (en) | 2000-03-02 |
TR200000602T2 (en) | 2000-12-21 |
HUP0004935A3 (en) | 2001-12-28 |
SK1522000A3 (en) | 2000-08-14 |
EP1009741A1 (en) | 2000-06-21 |
PL338954A1 (en) | 2000-12-04 |
WO1999011629A1 (en) | 1999-03-11 |
AU9533398A (en) | 1999-03-22 |
HUP0004935A2 (en) | 2001-10-28 |
BG104222A (en) | 2001-02-28 |
IL134276A0 (en) | 2001-04-30 |
ID25620A (en) | 2000-10-19 |
CO4970738A1 (en) | 2000-11-07 |
HRP980484A2 (en) | 1999-06-30 |
JP2001514254A (en) | 2001-09-11 |
AU748610B2 (en) | 2002-06-06 |
NZ502660A (en) | 2002-02-01 |
KR20010023615A (en) | 2001-03-26 |
NO20001077L (en) | 2000-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2265504A1 (en) | Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed eta/etb endothelin receptor antagonists | |
BG63389B1 (en) | New derivatives of amino acids, their preparation and application | |
NO310497B1 (en) | Pyrimidine or triazine carboxylic acid derivatives which can be used as drugs | |
SK134498A3 (en) | Novel 'alpha'-hydroxylic acid derivatives, their production and use | |
TW546295B (en) | Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists | |
NO311802B1 (en) | New carboxylic acid derivatives and their use | |
HRP980560A2 (en) | New carboxylic acid derivatives, carrying amido side-chains, their production and use as endothelin receptor antagonists | |
CA2294050A1 (en) | New .beta.-amino and .beta.-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists | |
KR20000057642A (en) | Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists | |
TW579376B (en) | Novel carboxylic acid derivatives having a 5-substituted pyrimidine ring, their preparation and use | |
SK11752000A3 (en) | Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists | |
AU765345B2 (en) | Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists | |
HRP980591A2 (en) | Novel heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists | |
SK8682001A3 (en) | New beta-amide and beta-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists | |
MXPA00007417A (en) | Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta | |
CA2340167A1 (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists | |
CZ2000743A3 (en) | Derivatives of carboxylic acid and their use | |
MXPA00006463A (en) | 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists | |
CZ20002963A3 (en) | Novel derivatives of carboxylic acid containing 5-substituted pyrimidine ring, process of their preparation and use | |
CZ2001437A3 (en) | Derivatives of carboxylic acid and their use | |
HRP970503A2 (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb receptor antagonists | |
CZ454399A3 (en) | Derivatives of ›-amino a ›-acidocarboxylic acid, process of their preparation and their use | |
MXPA99001995A (en) | New derivatives of oxilic acid, its obtaining and use in quality of mixed antagonists of receivers eta / | |
MXPA00001479A (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta | |
MXPA01001246A (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists |